AU2016202040A1 - Certain medical entities, compositions, and methods - Google Patents
Certain medical entities, compositions, and methods Download PDFInfo
- Publication number
- AU2016202040A1 AU2016202040A1 AU2016202040A AU2016202040A AU2016202040A1 AU 2016202040 A1 AU2016202040 A1 AU 2016202040A1 AU 2016202040 A AU2016202040 A AU 2016202040A AU 2016202040 A AU2016202040 A AU 2016202040A AU 2016202040 A1 AU2016202040 A1 AU 2016202040A1
- Authority
- AU
- Australia
- Prior art keywords
- imidazo
- pyrazin
- phenylethyl
- bromo
- pentan
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 title claims abstract description 32
- 239000000203 mixture Substances 0.000 title claims description 55
- 150000005829 chemical entities Chemical class 0.000 claims abstract description 61
- 102000003505 Myosin Human genes 0.000 claims abstract description 34
- 108060008487 Myosin Proteins 0.000 claims abstract description 34
- 102000007469 Actins Human genes 0.000 claims abstract description 27
- 108010085238 Actins Proteins 0.000 claims abstract description 27
- 210000002235 sarcomere Anatomy 0.000 claims abstract description 16
- 208000008589 Obesity Diseases 0.000 claims abstract description 14
- 102000005937 Tropomyosin Human genes 0.000 claims abstract description 14
- 108010030743 Tropomyosin Proteins 0.000 claims abstract description 14
- 235000020824 obesity Nutrition 0.000 claims abstract description 14
- 108090000362 Lymphotoxin-beta Proteins 0.000 claims abstract description 12
- 208000007101 Muscle Cramp Diseases 0.000 claims abstract description 12
- 102000013534 Troponin C Human genes 0.000 claims abstract description 12
- 208000010428 Muscle Weakness Diseases 0.000 claims abstract description 11
- 206010028372 Muscular weakness Diseases 0.000 claims abstract description 11
- 208000005392 Spasm Diseases 0.000 claims abstract description 11
- 102000013394 Troponin I Human genes 0.000 claims abstract description 11
- 108010065729 Troponin I Proteins 0.000 claims abstract description 11
- 208000010399 Wasting Syndrome Diseases 0.000 claims abstract description 11
- 208000018360 neuromuscular disease Diseases 0.000 claims abstract description 11
- 208000001076 sarcopenia Diseases 0.000 claims abstract description 11
- 206010006895 Cachexia Diseases 0.000 claims abstract description 10
- 208000036119 Frailty Diseases 0.000 claims abstract description 10
- 206010003549 asthenia Diseases 0.000 claims abstract description 10
- 150000001875 compounds Chemical class 0.000 claims description 123
- 125000000217 alkyl group Chemical group 0.000 claims description 109
- -1 hex-1-enyl Chemical group 0.000 claims description 98
- LAQJGAKLLZAETL-UHFFFAOYSA-N 2h-pyrazin-3-one Chemical compound O=C1CN=CC=N1 LAQJGAKLLZAETL-UHFFFAOYSA-N 0.000 claims description 64
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 54
- HUTNOYOBQPAKIA-UHFFFAOYSA-N 1h-pyrazin-2-one Chemical compound OC1=CN=CC=N1 HUTNOYOBQPAKIA-UHFFFAOYSA-N 0.000 claims description 53
- 125000001072 heteroaryl group Chemical group 0.000 claims description 51
- 125000003118 aryl group Chemical group 0.000 claims description 36
- 239000001257 hydrogen Substances 0.000 claims description 33
- 229910052739 hydrogen Inorganic materials 0.000 claims description 33
- 150000003839 salts Chemical class 0.000 claims description 32
- 125000005843 halogen group Chemical group 0.000 claims description 31
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 28
- 125000005346 substituted cycloalkyl group Chemical group 0.000 claims description 26
- 125000002252 acyl group Chemical group 0.000 claims description 25
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 24
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 24
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 23
- 229910052757 nitrogen Inorganic materials 0.000 claims description 23
- 201000010099 disease Diseases 0.000 claims description 21
- 125000000547 substituted alkyl group Chemical group 0.000 claims description 21
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 20
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 19
- 125000003107 substituted aryl group Chemical group 0.000 claims description 17
- 239000008194 pharmaceutical composition Substances 0.000 claims description 16
- 239000000843 powder Substances 0.000 claims description 16
- 125000003545 alkoxy group Chemical group 0.000 claims description 15
- 150000003857 carboxamides Chemical class 0.000 claims description 15
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 15
- 125000003342 alkenyl group Chemical group 0.000 claims description 14
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims description 14
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims description 14
- 125000003396 thiol group Chemical group [H]S* 0.000 claims description 14
- 239000002253 acid Substances 0.000 claims description 13
- 125000004429 atom Chemical group 0.000 claims description 13
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 13
- 125000005017 substituted alkenyl group Chemical group 0.000 claims description 13
- 125000005415 substituted alkoxy group Chemical group 0.000 claims description 12
- 125000004426 substituted alkynyl group Chemical group 0.000 claims description 12
- 125000004122 cyclic group Chemical group 0.000 claims description 10
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 claims description 10
- 125000000304 alkynyl group Chemical group 0.000 claims description 9
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Chemical group C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 claims description 8
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 8
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 7
- 239000003937 drug carrier Substances 0.000 claims description 7
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 7
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 claims description 7
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 claims description 7
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 claims description 6
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 claims description 6
- 125000003277 amino group Chemical group 0.000 claims description 6
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 6
- 229920002554 vinyl polymer Chemical group 0.000 claims description 6
- 101100521345 Mus musculus Prop1 gene Proteins 0.000 claims description 5
- 108700017836 Prophet of Pit-1 Proteins 0.000 claims description 5
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 5
- 239000007788 liquid Substances 0.000 claims description 5
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 5
- 125000003226 pyrazolyl group Chemical group 0.000 claims description 5
- 239000000725 suspension Substances 0.000 claims description 5
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 5
- WAXQRVPDPGLRKE-QMMMGPOBSA-N 5-bromo-3-[(1s)-1-phenylethyl]-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound C1([C@H](C)N2C(NC3=NC=C(Br)N=C32)=O)=CC=CC=C1 WAXQRVPDPGLRKE-QMMMGPOBSA-N 0.000 claims description 4
- JMZLLOCPIPPQSP-UHFFFAOYSA-N 5-bromo-3-pentan-3-yl-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound C1=C(Br)N=C2N(C(CC)CC)C(O)=NC2=N1 JMZLLOCPIPPQSP-UHFFFAOYSA-N 0.000 claims description 4
- 239000000443 aerosol Substances 0.000 claims description 4
- 125000005605 benzo group Chemical group 0.000 claims description 4
- 150000007942 carboxylates Chemical class 0.000 claims description 4
- 125000004663 dialkyl amino group Chemical group 0.000 claims description 4
- 125000001153 fluoro group Chemical group F* 0.000 claims description 4
- CKJNUZNMWOVDFN-UHFFFAOYSA-N methanone Chemical compound O=[CH-] CKJNUZNMWOVDFN-UHFFFAOYSA-N 0.000 claims description 4
- 125000003538 pentan-3-yl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 claims description 4
- XGYMKEPKOZVQSB-UHFFFAOYSA-N 5-(hydroxymethyl)-1,6-dimethyl-3h-imidazo[4,5-b]pyrazin-2-one Chemical compound N1=C(CO)C(C)=NC2=C1NC(=O)N2C XGYMKEPKOZVQSB-UHFFFAOYSA-N 0.000 claims description 3
- RSQGZEAXODVTOL-UHFFFAOYSA-N 5-ethynyl-3-pentan-3-yl-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound C#CC1=CN=C2NC(=O)N(C(CC)CC)C2=N1 RSQGZEAXODVTOL-UHFFFAOYSA-N 0.000 claims description 3
- JIEZRCLDDSWWHV-VIFPVBQESA-N 5-methylsulfanyl-3-[(1s)-1-phenylethyl]-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound C1([C@H](C)N2C(=O)NC3=NC=C(N=C32)SC)=CC=CC=C1 JIEZRCLDDSWWHV-VIFPVBQESA-N 0.000 claims description 3
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 3
- 125000004369 butenyl group Chemical group C(=CCC)* 0.000 claims description 3
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 3
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 3
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 claims description 3
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 claims description 3
- 239000003826 tablet Substances 0.000 claims description 3
- 230000000472 traumatic effect Effects 0.000 claims description 3
- VGMPXCLEQITWTP-UHFFFAOYSA-N 3-methyl-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound C1=CN=C2NC(=O)N(C)C2=N1 VGMPXCLEQITWTP-UHFFFAOYSA-N 0.000 claims description 2
- AEUJTZJJOJMFJG-UHFFFAOYSA-N 3-piperidin-4-yl-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound O=C1NC2=NC=CN=C2N1C1CCNCC1 AEUJTZJJOJMFJG-UHFFFAOYSA-N 0.000 claims description 2
- LCZJTRRQEFNMEF-VIFPVBQESA-N 5-acetyl-3-[(1s)-1-phenylethyl]-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound C1([C@H](C)N2C3=NC(=CN=C3N=C2O)C(C)=O)=CC=CC=C1 LCZJTRRQEFNMEF-VIFPVBQESA-N 0.000 claims description 2
- BKRHNTRJIUKUOI-UHFFFAOYSA-N 5-bromo-3-(2-morpholin-4-ylethyl)-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound C12=NC(Br)=CN=C2NC(=O)N1CCN1CCOCC1 BKRHNTRJIUKUOI-UHFFFAOYSA-N 0.000 claims description 2
- DLGLLQCQYOSWFA-UHFFFAOYSA-N 5-bromo-3-heptan-4-yl-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound C1=C(Br)N=C2N(C(CCC)CCC)C(O)=NC2=N1 DLGLLQCQYOSWFA-UHFFFAOYSA-N 0.000 claims description 2
- SBJUQVUTJXSWQG-UHFFFAOYSA-N 5-ethenyl-3-pentan-3-yl-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound C=CC1=CN=C2NC(=O)N(C(CC)CC)C2=N1 SBJUQVUTJXSWQG-UHFFFAOYSA-N 0.000 claims description 2
- 101100091482 Caenorhabditis elegans rop-1 gene Proteins 0.000 claims description 2
- 239000002775 capsule Substances 0.000 claims description 2
- 125000006038 hexenyl group Chemical group 0.000 claims description 2
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 claims description 2
- RUZLIIJDZBWWSA-INIZCTEOSA-N methyl 2-[[(1s)-1-(7-methyl-2-morpholin-4-yl-4-oxopyrido[1,2-a]pyrimidin-9-yl)ethyl]amino]benzoate Chemical group COC(=O)C1=CC=CC=C1N[C@@H](C)C1=CC(C)=CN2C(=O)C=C(N3CCOCC3)N=C12 RUZLIIJDZBWWSA-INIZCTEOSA-N 0.000 claims description 2
- 125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 claims description 2
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 2
- 125000000286 phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 claims description 2
- 239000000829 suppository Substances 0.000 claims description 2
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims description 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 2
- AUEBQUCREPKUBN-QMMMGPOBSA-N 2-oxo-3-[(1s)-1-phenylethyl]-1h-imidazo[4,5-b]pyrazine-5-carboxylic acid Chemical compound C1([C@H](C)N2C3=NC(=CN=C3N=C2O)C(O)=O)=CC=CC=C1 AUEBQUCREPKUBN-QMMMGPOBSA-N 0.000 claims 2
- JCLOPOHRCQTTGK-UHFFFAOYSA-N 5-methoxy-3-pentan-3-yl-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound C1=C(OC)N=C2N(C(CC)CC)C(O)=NC2=N1 JCLOPOHRCQTTGK-UHFFFAOYSA-N 0.000 claims 2
- 101710167936 Troponin T, skeletal muscle Proteins 0.000 claims 2
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 2
- FDOLAMRYHDWRIS-UHFFFAOYSA-N (4-methylpiperazin-1-yl)methanone Chemical compound CN1CCN([C]=O)CC1 FDOLAMRYHDWRIS-UHFFFAOYSA-N 0.000 claims 1
- FAICLJXBBVXJHR-QMMMGPOBSA-N 2-oxo-3-[(1s)-1-phenylethyl]-1h-imidazo[4,5-b]pyrazine-5-carboxamide Chemical compound C1([C@H](C)N2C3=NC(=CN=C3N=C2O)C(N)=O)=CC=CC=C1 FAICLJXBBVXJHR-QMMMGPOBSA-N 0.000 claims 1
- HGXDYLNWUSYQKP-NSHDSACASA-N 3-[(1s)-1-phenylethyl]-5-propyl-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound C1([C@H](C)N2C(=O)NC3=NC=C(N=C32)CCC)=CC=CC=C1 HGXDYLNWUSYQKP-NSHDSACASA-N 0.000 claims 1
- 125000004195 4-methylpiperazin-1-yl group Chemical group [H]C([H])([H])N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 claims 1
- DXQMTYNFSGEMLQ-JTQLQIEISA-N 5-(2-hydroxypropan-2-yl)-3-[(1s)-1-phenylethyl]-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound C1([C@H](C)N2C(NC3=NC=C(N=C32)C(C)(C)O)=O)=CC=CC=C1 DXQMTYNFSGEMLQ-JTQLQIEISA-N 0.000 claims 1
- JPWVZDIMURSFIS-LBPRGKRZSA-N 5-(2-methylprop-1-enyl)-3-[(1s)-1-phenylethyl]-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound C1([C@H](C)N2C(NC3=NC=C(C=C(C)C)N=C32)=O)=CC=CC=C1 JPWVZDIMURSFIS-LBPRGKRZSA-N 0.000 claims 1
- SFPQZTPFSOQKEW-LBPRGKRZSA-N 5-(morpholine-4-carbonyl)-3-[(1s)-1-phenylethyl]-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound C1([C@H](C)N2C3=NC(=CN=C3N=C2O)C(=O)N2CCOCC2)=CC=CC=C1 SFPQZTPFSOQKEW-LBPRGKRZSA-N 0.000 claims 1
- LNSUVMJIGLAFPI-NSHDSACASA-N 5-[(dimethylamino)methyl]-3-[(1s)-1-phenylethyl]-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound C1([C@H](C)N2C(NC3=NC=C(CN(C)C)N=C32)=O)=CC=CC=C1 LNSUVMJIGLAFPI-NSHDSACASA-N 0.000 claims 1
- QFFFSTQFQPYCHG-UHFFFAOYSA-N 5-bromo-3-(oxan-4-yl)-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound OC1=NC2=NC=C(Br)N=C2N1C1CCOCC1 QFFFSTQFQPYCHG-UHFFFAOYSA-N 0.000 claims 1
- HRHMIFIUUCUENC-RXMQYKEDSA-N 5-bromo-3-[(2r)-1-hydroxybutan-2-yl]-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound C1=C(Br)N=C2N([C@@H](CO)CC)C(O)=NC2=N1 HRHMIFIUUCUENC-RXMQYKEDSA-N 0.000 claims 1
- YQOCSKOMOMCTOF-VIFPVBQESA-N 5-bromo-3-[(2s)-1-morpholin-4-ylbutan-2-yl]-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound C([C@H](CC)N1C(NC2=NC=C(Br)N=C21)=O)N1CCOCC1 YQOCSKOMOMCTOF-VIFPVBQESA-N 0.000 claims 1
- QZFCGAULXPKETL-UHFFFAOYSA-N 5-bromo-3-cyclopropyl-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound C12=NC(Br)=CN=C2NC(=O)N1C1CC1 QZFCGAULXPKETL-UHFFFAOYSA-N 0.000 claims 1
- BQHUECBTWVGPTM-UHFFFAOYSA-N 5-cyclopropyl-3-pentan-3-yl-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound C=1N=C2NC(=O)N(C(CC)CC)C2=NC=1C1CC1 BQHUECBTWVGPTM-UHFFFAOYSA-N 0.000 claims 1
- NDZAPLNYXZLOQS-JTQLQIEISA-N 5-ethenyl-3-[(1s)-1-phenylethyl]-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound C1([C@H](C)N2C(NC3=NC=C(C=C)N=C32)=O)=CC=CC=C1 NDZAPLNYXZLOQS-JTQLQIEISA-N 0.000 claims 1
- JPDFKESEFQRCBE-UHFFFAOYSA-N 5-ethyl-3-pentan-3-yl-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound CCC1=CN=C2NC(=O)N(C(CC)CC)C2=N1 JPDFKESEFQRCBE-UHFFFAOYSA-N 0.000 claims 1
- GMOWAKFCILZILA-GFCCVEGCSA-N 5-ethynyl-3-[(2r)-1-morpholin-4-ylbutan-2-yl]-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound C([C@@H](CC)N1C2=NC(=CN=C2N=C1O)C#C)N1CCOCC1 GMOWAKFCILZILA-GFCCVEGCSA-N 0.000 claims 1
- JIEZRCLDDSWWHV-SECBINFHSA-N 5-methylsulfanyl-3-[(1r)-1-phenylethyl]-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound C1([C@@H](C)N2C(O)=NC3=NC=C(N=C32)SC)=CC=CC=C1 JIEZRCLDDSWWHV-SECBINFHSA-N 0.000 claims 1
- LELOWRISYMNNSU-UHFFFAOYSA-N Hydrocyanic acid Natural products N#C LELOWRISYMNNSU-UHFFFAOYSA-N 0.000 claims 1
- TXVGPPMUKXOWMV-UHFFFAOYSA-N methyl 4-[2-(5-bromo-2-oxo-1h-imidazo[4,5-b]pyrazin-3-yl)butyl]piperazine-1-carboxylate Chemical compound C12=NC(Br)=CN=C2NC(=O)N1C(CC)CN1CCN(C(=O)OC)CC1 TXVGPPMUKXOWMV-UHFFFAOYSA-N 0.000 claims 1
- LCEDQNDDFOCWGG-UHFFFAOYSA-N morpholine-4-carbaldehyde Chemical compound O=CN1CCOCC1 LCEDQNDDFOCWGG-UHFFFAOYSA-N 0.000 claims 1
- QYQZBGDQEVAJKO-VIFPVBQESA-N n-methyl-2-oxo-3-[(1s)-1-phenylethyl]-1h-imidazo[4,5-b]pyrazine-5-carboxamide Chemical compound C1([C@H](C)N2C(O)=NC3=NC=C(N=C32)C(=O)NC)=CC=CC=C1 QYQZBGDQEVAJKO-VIFPVBQESA-N 0.000 claims 1
- 125000004194 piperazin-1-yl group Chemical group [H]N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 claims 1
- 210000002027 skeletal muscle Anatomy 0.000 abstract description 18
- 102000004987 Troponin T Human genes 0.000 abstract description 10
- 108090001108 Troponin T Proteins 0.000 abstract description 10
- 239000012634 fragment Substances 0.000 abstract description 10
- 102000001708 Protein Isoforms Human genes 0.000 abstract description 9
- 108010029485 Protein Isoforms Proteins 0.000 abstract description 9
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 52
- 239000000243 solution Substances 0.000 description 37
- 238000006243 chemical reaction Methods 0.000 description 35
- SECXISVLQFMRJM-UHFFFAOYSA-N NMP Substances CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 28
- 235000019439 ethyl acetate Nutrition 0.000 description 26
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 24
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 24
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 24
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 21
- 125000004432 carbon atom Chemical group C* 0.000 description 20
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 18
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 17
- 125000001188 haloalkyl group Chemical group 0.000 description 17
- 239000007787 solid Substances 0.000 description 17
- WYURNTSHIVDZCO-UHFFFAOYSA-N tetrahydrofuran Substances C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 17
- 239000000872 buffer Substances 0.000 description 15
- 239000002904 solvent Substances 0.000 description 15
- 239000003795 chemical substances by application Substances 0.000 description 14
- 239000000284 extract Substances 0.000 description 14
- 238000003756 stirring Methods 0.000 description 14
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 14
- 125000005842 heteroatom Chemical group 0.000 description 13
- 150000002431 hydrogen Chemical class 0.000 description 13
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 12
- 241000124008 Mammalia Species 0.000 description 12
- 238000003820 Medium-pressure liquid chromatography Methods 0.000 description 12
- 230000000694 effects Effects 0.000 description 12
- 125000001424 substituent group Chemical group 0.000 description 12
- 238000003419 tautomerization reaction Methods 0.000 description 12
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N EtOH Substances CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 11
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 11
- 239000008188 pellet Substances 0.000 description 11
- 239000011734 sodium Substances 0.000 description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- CGKLYWOFLUIKCX-UHFFFAOYSA-N 1,3-dihydroimidazo[4,5-b]pyrazin-2-one Chemical compound C1=CN=C2NC(=O)NC2=N1 CGKLYWOFLUIKCX-UHFFFAOYSA-N 0.000 description 10
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 10
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 10
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 10
- 239000002585 base Substances 0.000 description 10
- 125000004043 oxo group Chemical group O=* 0.000 description 10
- 239000000047 product Substances 0.000 description 10
- 229910001868 water Inorganic materials 0.000 description 10
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 9
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 9
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 9
- 239000012267 brine Substances 0.000 description 9
- 150000002500 ions Chemical class 0.000 description 9
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 9
- 239000012044 organic layer Substances 0.000 description 9
- 102000004169 proteins and genes Human genes 0.000 description 9
- 108090000623 proteins and genes Proteins 0.000 description 9
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 9
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 8
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 8
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 8
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 8
- 239000011575 calcium Substances 0.000 description 8
- 229910052791 calcium Inorganic materials 0.000 description 8
- 238000003818 flash chromatography Methods 0.000 description 8
- 239000008177 pharmaceutical agent Substances 0.000 description 8
- 239000000546 pharmaceutical excipient Substances 0.000 description 8
- 238000003786 synthesis reaction Methods 0.000 description 8
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 7
- 210000003205 muscle Anatomy 0.000 description 7
- 201000001119 neuropathy Diseases 0.000 description 7
- 230000007823 neuropathy Effects 0.000 description 7
- 229910000160 potassium phosphate Inorganic materials 0.000 description 7
- 235000011009 potassium phosphates Nutrition 0.000 description 7
- 238000000746 purification Methods 0.000 description 7
- 125000006413 ring segment Chemical group 0.000 description 7
- 229920006395 saturated elastomer Polymers 0.000 description 7
- 229910052938 sodium sulfate Inorganic materials 0.000 description 7
- 235000011152 sodium sulphate Nutrition 0.000 description 7
- 125000005037 alkyl phenyl group Chemical group 0.000 description 6
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 6
- 230000008602 contraction Effects 0.000 description 6
- 230000003993 interaction Effects 0.000 description 6
- 210000003632 microfilament Anatomy 0.000 description 6
- 229910052760 oxygen Inorganic materials 0.000 description 6
- 239000001301 oxygen Substances 0.000 description 6
- 208000033808 peripheral neuropathy Diseases 0.000 description 6
- 239000000651 prodrug Substances 0.000 description 6
- 229940002612 prodrug Drugs 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 229940086542 triethylamine Drugs 0.000 description 6
- 108091006112 ATPases Proteins 0.000 description 5
- 102000057290 Adenosine Triphosphatases Human genes 0.000 description 5
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 5
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 5
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 5
- 102000004903 Troponin Human genes 0.000 description 5
- 108090001027 Troponin Proteins 0.000 description 5
- 238000003556 assay Methods 0.000 description 5
- 125000002837 carbocyclic group Chemical group 0.000 description 5
- 229910052799 carbon Inorganic materials 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 239000006260 foam Substances 0.000 description 5
- 239000003112 inhibitor Substances 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 150000003254 radicals Chemical class 0.000 description 5
- 229910052708 sodium Inorganic materials 0.000 description 5
- 239000006228 supernatant Substances 0.000 description 5
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 4
- 239000007983 Tris buffer Substances 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 239000013543 active substance Substances 0.000 description 4
- 239000002671 adjuvant Substances 0.000 description 4
- 125000002947 alkylene group Chemical group 0.000 description 4
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 4
- 230000003197 catalytic effect Effects 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 229940088598 enzyme Drugs 0.000 description 4
- 239000012458 free base Substances 0.000 description 4
- 239000010410 layer Substances 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 4
- DHHVAGZRUROJKS-UHFFFAOYSA-N phentermine Chemical compound CC(C)(N)CC1=CC=CC=C1 DHHVAGZRUROJKS-UHFFFAOYSA-N 0.000 description 4
- 238000002953 preparative HPLC Methods 0.000 description 4
- 125000006239 protecting group Chemical group 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 4
- 239000000741 silica gel Substances 0.000 description 4
- 229910002027 silica gel Inorganic materials 0.000 description 4
- 239000012453 solvate Substances 0.000 description 4
- 229910052717 sulfur Inorganic materials 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 238000004809 thin layer chromatography Methods 0.000 description 4
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 4
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 3
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 229910019142 PO4 Inorganic materials 0.000 description 3
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 3
- 150000001412 amines Chemical class 0.000 description 3
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 3
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000002425 crystallisation Methods 0.000 description 3
- 230000008025 crystallization Effects 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 238000000502 dialysis Methods 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 229940011871 estrogen Drugs 0.000 description 3
- 239000000262 estrogen Substances 0.000 description 3
- 239000007789 gas Substances 0.000 description 3
- 229910052736 halogen Inorganic materials 0.000 description 3
- 150000002367 halogens Chemical class 0.000 description 3
- 230000007062 hydrolysis Effects 0.000 description 3
- 238000006460 hydrolysis reaction Methods 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- 229910052740 iodine Chemical group 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 235000013372 meat Nutrition 0.000 description 3
- PSGAAPLEWMOORI-PEINSRQWSA-N medroxyprogesterone acetate Chemical compound C([C@@]12C)CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2CC[C@]2(C)[C@@](OC(C)=O)(C(C)=O)CC[C@H]21 PSGAAPLEWMOORI-PEINSRQWSA-N 0.000 description 3
- 229960002985 medroxyprogesterone acetate Drugs 0.000 description 3
- 230000002503 metabolic effect Effects 0.000 description 3
- 150000007522 mineralic acids Chemical class 0.000 description 3
- 230000004118 muscle contraction Effects 0.000 description 3
- 210000004165 myocardium Anatomy 0.000 description 3
- 150000007524 organic acids Chemical class 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- 239000010452 phosphate Substances 0.000 description 3
- 239000011591 potassium Substances 0.000 description 3
- 229910052700 potassium Inorganic materials 0.000 description 3
- 229910000027 potassium carbonate Inorganic materials 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 239000011593 sulfur Chemical group 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- CXWXQJXEFPUFDZ-UHFFFAOYSA-N tetralin Chemical compound C1=CC=C2CCCCC2=C1 CXWXQJXEFPUFDZ-UHFFFAOYSA-N 0.000 description 3
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 3
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 3
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 3
- WWYNJERNGUHSAO-XUDSTZEESA-N (+)-Norgestrel Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 WWYNJERNGUHSAO-XUDSTZEESA-N 0.000 description 2
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- 125000004974 2-butenyl group Chemical group C(C=CC)* 0.000 description 2
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 2
- SYUYQEHWWBTQJK-KTROKBFUSA-N 3-[(1s)-1-phenylethyl]-5-[(e)-prop-1-enyl]-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound C1([C@H](C)N2C(=O)NC3=NC=C(N=C32)/C=C/C)=CC=CC=C1 SYUYQEHWWBTQJK-KTROKBFUSA-N 0.000 description 2
- WYRAXYZTIXGPNA-DAXSKMNVSA-N 3-pentan-3-yl-5-[(z)-prop-1-enyl]-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound C\C=C/C1=CN=C2NC(=O)N(C(CC)CC)C2=N1 WYRAXYZTIXGPNA-DAXSKMNVSA-N 0.000 description 2
- GCNTZFIIOFTKIY-UHFFFAOYSA-N 4-hydroxypyridine Chemical compound OC1=CC=NC=C1 GCNTZFIIOFTKIY-UHFFFAOYSA-N 0.000 description 2
- WIDNVEJXWVITNT-UHFFFAOYSA-N 5-bromo-3-n-pentan-3-ylpyrazine-2,3-diamine Chemical compound CCC(CC)NC1=NC(Br)=CN=C1N WIDNVEJXWVITNT-UHFFFAOYSA-N 0.000 description 2
- 125000004008 6 membered carbocyclic group Chemical group 0.000 description 2
- OGSPWJRAVKPPFI-UHFFFAOYSA-N Alendronic Acid Chemical compound NCCCC(O)(P(O)(O)=O)P(O)(O)=O OGSPWJRAVKPPFI-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 2
- 208000010693 Charcot-Marie-Tooth Disease Diseases 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 239000005909 Kieselgur Substances 0.000 description 2
- 102000003855 L-lactate dehydrogenase Human genes 0.000 description 2
- 108700023483 L-lactate dehydrogenases Proteins 0.000 description 2
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 2
- 150000001204 N-oxides Chemical class 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 2
- 101100028920 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) cfp gene Proteins 0.000 description 2
- 102000003982 Parathyroid hormone Human genes 0.000 description 2
- 108090000445 Parathyroid hormone Proteins 0.000 description 2
- 101150003085 Pdcl gene Proteins 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 102000013009 Pyruvate Kinase Human genes 0.000 description 2
- 108020005115 Pyruvate Kinase Proteins 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 2
- 241000347391 Umbrina cirrosa Species 0.000 description 2
- CBMCZKMIOZYAHS-IHWYPQMZSA-N [(z)-prop-1-enyl]boronic acid Chemical compound C\C=C/B(O)O CBMCZKMIOZYAHS-IHWYPQMZSA-N 0.000 description 2
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 2
- YRKCREAYFQTBPV-UHFFFAOYSA-N acetylacetone Chemical compound CC(=O)CC(C)=O YRKCREAYFQTBPV-UHFFFAOYSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 210000001789 adipocyte Anatomy 0.000 description 2
- 239000000556 agonist Substances 0.000 description 2
- 229910052782 aluminium Inorganic materials 0.000 description 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 2
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 2
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 2
- 235000011130 ammonium sulphate Nutrition 0.000 description 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- YNHIGQDRGKUECZ-UHFFFAOYSA-L bis(triphenylphosphine)palladium(ii) dichloride Chemical compound [Cl-].[Cl-].[Pd+2].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 YNHIGQDRGKUECZ-UHFFFAOYSA-L 0.000 description 2
- 125000001246 bromo group Chemical group Br* 0.000 description 2
- 229910001424 calcium ion Inorganic materials 0.000 description 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- ZHXTWWCDMUWMDI-UHFFFAOYSA-N dihydroxyboron Chemical compound O[B]O ZHXTWWCDMUWMDI-UHFFFAOYSA-N 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 238000001030 gas--liquid chromatography Methods 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 150000004677 hydrates Chemical class 0.000 description 2
- PQNFLJBBNBOBRQ-UHFFFAOYSA-N indane Chemical compound C1=CC=C2CCCC2=C1 PQNFLJBBNBOBRQ-UHFFFAOYSA-N 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 239000000543 intermediate Substances 0.000 description 2
- 229960004400 levonorgestrel Drugs 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 239000012035 limiting reagent Substances 0.000 description 2
- 238000004811 liquid chromatography Methods 0.000 description 2
- 229910052744 lithium Inorganic materials 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 2
- 201000000585 muscular atrophy Diseases 0.000 description 2
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 125000006574 non-aromatic ring group Chemical group 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- AHLBNYSZXLDEJQ-FWEHEUNISA-N orlistat Chemical compound CCCCCCCCCCC[C@H](OC(=O)[C@H](CC(C)C)NC=O)C[C@@H]1OC(=O)[C@H]1CCCCCC AHLBNYSZXLDEJQ-FWEHEUNISA-N 0.000 description 2
- 229960001243 orlistat Drugs 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 239000000199 parathyroid hormone Substances 0.000 description 2
- PQPFFKCJENSZKL-UHFFFAOYSA-N pentan-3-amine Chemical compound CCC(N)CC PQPFFKCJENSZKL-UHFFFAOYSA-N 0.000 description 2
- 229940117803 phenethylamine Drugs 0.000 description 2
- 229960003562 phentermine Drugs 0.000 description 2
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- RFIOZSIHFNEKFF-UHFFFAOYSA-M piperazine-1-carboxylate Chemical compound [O-]C(=O)N1CCNCC1 RFIOZSIHFNEKFF-UHFFFAOYSA-M 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- YPFDHNVEDLHUCE-UHFFFAOYSA-N propane-1,3-diol Chemical compound OCCCO YPFDHNVEDLHUCE-UHFFFAOYSA-N 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 229940076279 serotonin Drugs 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- RMBAVIFYHOYIFM-UHFFFAOYSA-M sodium methanethiolate Chemical compound [Na+].[S-]C RMBAVIFYHOYIFM-UHFFFAOYSA-M 0.000 description 2
- MFRIHAYPQRLWNB-UHFFFAOYSA-N sodium tert-butoxide Chemical compound [Na+].CC(C)(C)[O-] MFRIHAYPQRLWNB-UHFFFAOYSA-N 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 229960003604 testosterone Drugs 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 102000004217 thyroid hormone receptors Human genes 0.000 description 2
- 108090000721 thyroid hormone receptors Proteins 0.000 description 2
- FJXYMVBFBYAWDR-UHFFFAOYSA-N tributyl(prop-1-enyl)stannane Chemical compound CCCC[Sn](CCCC)(CCCC)\C=C\C FJXYMVBFBYAWDR-UHFFFAOYSA-N 0.000 description 2
- AQRLNPVMDITEJU-UHFFFAOYSA-N triethylsilane Chemical compound CC[SiH](CC)CC AQRLNPVMDITEJU-UHFFFAOYSA-N 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 208000016261 weight loss Diseases 0.000 description 2
- 230000004580 weight loss Effects 0.000 description 2
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- NWQWNCILOXTTHF-HLCSKTDOSA-N (2s)-6-amino-2-[[(2r)-2-[[(2s)-2-[[(2s)-2-[[(2r)-2-[[(2s)-2-[[(2s)-2-aminopropanoyl]amino]-3-(1h-imidazol-5-yl)propanoyl]amino]-3-naphthalen-2-ylpropanoyl]amino]propanoyl]amino]-3-(1h-indol-3-yl)propanoyl]amino]-3-phenylpropanoyl]amino]hexanamide Chemical compound C([C@H](NC(=O)[C@@H](N)C)C(=O)N[C@H](CC=1C=C2C=CC=CC2=CC=1)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCCN)C(N)=O)C1=CNC=N1 NWQWNCILOXTTHF-HLCSKTDOSA-N 0.000 description 1
- WZHKXNSOCOQYQX-FUAFALNISA-N (2s)-6-amino-2-[[(2r)-2-[[(2s)-2-[[(2s)-2-[[(2r)-2-[[(2s)-2-amino-3-(1h-imidazol-5-yl)propanoyl]amino]-3-(1h-indol-3-yl)propanoyl]amino]propanoyl]amino]-3-(1h-indol-3-yl)propanoyl]amino]-3-phenylpropanoyl]amino]hexanamide Chemical compound C([C@H](N)C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCCN)C(N)=O)C1=CN=CN1 WZHKXNSOCOQYQX-FUAFALNISA-N 0.000 description 1
- HRNLPPBUBKMZMT-SSSXJSFTSA-N (2s)-6-amino-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2r)-2-[[(2r)-2-aminopropanoyl]amino]-3-naphthalen-2-ylpropanoyl]amino]propanoyl]amino]-3-(1h-indol-3-yl)propanoyl]amino]-3-phenylpropanoyl]amino]hexanamide Chemical compound C([C@H](NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](C)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(=O)[C@H](N)C)C(=O)N[C@@H](CCCCN)C(N)=O)C1=CC=CC=C1 HRNLPPBUBKMZMT-SSSXJSFTSA-N 0.000 description 1
- KNKOUDKOHSNMEL-UHFFFAOYSA-N (7-oxo-5,6-dihydro-4h-1-benzothiophen-4-yl)urea Chemical compound NC(=O)NC1CCC(=O)C2=C1C=CS2 KNKOUDKOHSNMEL-UHFFFAOYSA-N 0.000 description 1
- KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 description 1
- ICLYJLBTOGPLMC-KVVVOXFISA-N (z)-octadec-9-enoate;tris(2-hydroxyethyl)azanium Chemical compound OCCN(CCO)CCO.CCCCCCCC\C=C/CCCCCCCC(O)=O ICLYJLBTOGPLMC-KVVVOXFISA-N 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- NUBQKPWHXMGDLP-UHFFFAOYSA-N 1-[4-benzyl-2-hydroxy-5-[(2-hydroxy-2,3-dihydro-1h-inden-1-yl)amino]-5-oxopentyl]-n-tert-butyl-4-(pyridin-3-ylmethyl)piperazine-2-carboxamide;sulfuric acid Chemical compound OS(O)(=O)=O.C1CN(CC(O)CC(CC=2C=CC=CC=2)C(=O)NC2C3=CC=CC=C3CC2O)C(C(=O)NC(C)(C)C)CN1CC1=CC=CN=C1 NUBQKPWHXMGDLP-UHFFFAOYSA-N 0.000 description 1
- 125000004973 1-butenyl group Chemical group C(=CCC)* 0.000 description 1
- 125000004972 1-butynyl group Chemical group [H]C([H])([H])C([H])([H])C#C* 0.000 description 1
- BFPYWIDHMRZLRN-UHFFFAOYSA-N 17alpha-ethynyl estradiol Natural products OC1=CC=C2C3CCC(C)(C(CC4)(O)C#C)C4C3CCC2=C1 BFPYWIDHMRZLRN-UHFFFAOYSA-N 0.000 description 1
- DUGMCDWNXXFHDE-VZYDHVRKSA-N 2-amino-2-methyl-n-[(2r)-1-(1-methylsulfonylspiro[2h-indole-3,4'-piperidine]-1'-yl)-1-oxo-3-phenylmethoxypropan-2-yl]propanamide;methanesulfonic acid Chemical compound CS(O)(=O)=O.C([C@@H](NC(=O)C(C)(N)C)C(=O)N1CCC2(C3=CC=CC=C3N(C2)S(C)(=O)=O)CC1)OCC1=CC=CC=C1 DUGMCDWNXXFHDE-VZYDHVRKSA-N 0.000 description 1
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
- IVHKZCSZELZKSJ-UHFFFAOYSA-N 2-hydroxyethyl sulfonate Chemical compound OCCOS(=O)=O IVHKZCSZELZKSJ-UHFFFAOYSA-N 0.000 description 1
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 1
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 125000004485 2-pyrrolidinyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])C1([H])* 0.000 description 1
- 108010070743 3(or 17)-beta-hydroxysteroid dehydrogenase Proteins 0.000 description 1
- SSZWKKQDZMVWCW-UHFFFAOYSA-N 3,5,6-trimethyl-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound N1=C(C)C(C)=NC2=C1N(C)C(=O)N2 SSZWKKQDZMVWCW-UHFFFAOYSA-N 0.000 description 1
- DTLBKXRFWUERQN-UHFFFAOYSA-N 3,5-dibromopyrazin-2-amine Chemical compound NC1=NC=C(Br)N=C1Br DTLBKXRFWUERQN-UHFFFAOYSA-N 0.000 description 1
- GXTJPCRFZLLAQY-VIFPVBQESA-N 3-[(1s)-1-phenylethyl]-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound C1([C@H](C)N2C(NC3=NC=CN=C32)=O)=CC=CC=C1 GXTJPCRFZLLAQY-VIFPVBQESA-N 0.000 description 1
- SYUYQEHWWBTQJK-UFVHFEBBSA-N 3-[(1s)-1-phenylethyl]-5-[(z)-prop-1-enyl]-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound C1([C@H](C)N2C(=O)NC3=NC=C(N=C32)\C=C/C)=CC=CC=C1 SYUYQEHWWBTQJK-UFVHFEBBSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- FMCGTDCYKPWFQL-UHFFFAOYSA-N 3-benzyl-5-bromo-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound C12=NC(Br)=CN=C2NC(=O)N1CC1=CC=CC=C1 FMCGTDCYKPWFQL-UHFFFAOYSA-N 0.000 description 1
- 125000000474 3-butynyl group Chemical group [H]C#CC([H])([H])C([H])([H])* 0.000 description 1
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 1
- NOFJFBHOKPHILH-UHFFFAOYSA-N 3-chloroquinoxalin-2-amine Chemical compound C1=CC=C2N=C(Cl)C(N)=NC2=C1 NOFJFBHOKPHILH-UHFFFAOYSA-N 0.000 description 1
- 125000005917 3-methylpentyl group Chemical group 0.000 description 1
- BWUOGGRBOBDYKI-UHFFFAOYSA-N 3-n-pentan-3-ylquinoxaline-2,3-diamine Chemical compound C1=CC=C2N=C(N)C(NC(CC)CC)=NC2=C1 BWUOGGRBOBDYKI-UHFFFAOYSA-N 0.000 description 1
- OQTVWLOQVMHOME-UHFFFAOYSA-N 3-pentan-3-yl-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound C1=CN=C2N(C(CC)CC)C(O)=NC2=N1 OQTVWLOQVMHOME-UHFFFAOYSA-N 0.000 description 1
- QWIGXPXZXMRYFN-UHFFFAOYSA-N 3-pentan-3-yl-1h-imidazo[4,5-b]quinoxalin-2-one Chemical compound C1=CC=C2N=C(NC(N3C(CC)CC)=O)C3=NC2=C1 QWIGXPXZXMRYFN-UHFFFAOYSA-N 0.000 description 1
- TUPQQYNBJJLKFQ-UHFFFAOYSA-N 3-pentan-3-yl-5-(trifluoromethyl)-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound FC(F)(F)C1=CN=C2NC(=O)N(C(CC)CC)C2=N1 TUPQQYNBJJLKFQ-UHFFFAOYSA-N 0.000 description 1
- WYRAXYZTIXGPNA-QPJJXVBHSA-N 3-pentan-3-yl-5-[(e)-prop-1-enyl]-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound C/C=C/C1=CN=C2NC(=O)N(C(CC)CC)C2=N1 WYRAXYZTIXGPNA-QPJJXVBHSA-N 0.000 description 1
- ZUKQRELSXSZGNR-UHFFFAOYSA-N 3-pentan-3-yl-5-prop-1-en-2-yl-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound CC(=C)C1=CN=C2NC(=O)N(C(CC)CC)C2=N1 ZUKQRELSXSZGNR-UHFFFAOYSA-N 0.000 description 1
- LQLUETZNTCJOCT-UHFFFAOYSA-N 3-pentan-3-yl-5-propan-2-yl-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound CC(C)C1=CN=C2NC(=O)N(C(CC)CC)C2=N1 LQLUETZNTCJOCT-UHFFFAOYSA-N 0.000 description 1
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 1
- LHCOVOKZWQYODM-CPEOKENHSA-N 4-amino-1-[(2r,5s)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]pyrimidin-2-one;1-[(2r,4s,5s)-4-azido-5-(hydroxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound O=C1N=C(N)C=CN1[C@H]1O[C@@H](CO)SC1.O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 LHCOVOKZWQYODM-CPEOKENHSA-N 0.000 description 1
- GAMYYCRTACQSBR-UHFFFAOYSA-N 4-azabenzimidazole Chemical compound C1=CC=C2NC=NC2=N1 GAMYYCRTACQSBR-UHFFFAOYSA-N 0.000 description 1
- POILWHVDKZOXJZ-UHFFFAOYSA-N 4-hydroxypent-3-en-2-one Chemical compound CC(O)=CC(C)=O POILWHVDKZOXJZ-UHFFFAOYSA-N 0.000 description 1
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 1
- 125000004606 5,6,7,8-tetrahydroisoquinolinyl group Chemical group C1(=NC=CC=2CCCCC12)* 0.000 description 1
- UEPSYMITWMMTTJ-UHFFFAOYSA-N 5-(1-methylpyrazol-4-yl)-3-pentan-3-yl-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound C=1N=C2NC(=O)N(C(CC)CC)C2=NC=1C=1C=NN(C)C=1 UEPSYMITWMMTTJ-UHFFFAOYSA-N 0.000 description 1
- NYEFRVNUSQHDBP-LBPRGKRZSA-N 5-(2-methylpropyl)-3-[(1s)-1-phenylethyl]-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound C1([C@H](C)N2C(=O)NC3=NC=C(N=C32)CC(C)C)=CC=CC=C1 NYEFRVNUSQHDBP-LBPRGKRZSA-N 0.000 description 1
- XLKNITFKTUIDMX-UHFFFAOYSA-N 5-bromo-3-(2-methyl-1-morpholin-4-ylpropan-2-yl)-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound OC1=NC2=NC=C(Br)N=C2N1C(C)(C)CN1CCOCC1 XLKNITFKTUIDMX-UHFFFAOYSA-N 0.000 description 1
- JVUXJJNMSWDQNZ-MRVPVSSYSA-N 5-bromo-3-[(2r)-1-morpholin-4-ylpropan-2-yl]-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound C([C@@H](C)N1C2=NC(Br)=CN=C2N=C1O)N1CCOCC1 JVUXJJNMSWDQNZ-MRVPVSSYSA-N 0.000 description 1
- HRHMIFIUUCUENC-YFKPBYRVSA-N 5-bromo-3-[(2s)-1-hydroxybutan-2-yl]-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound BrC1=CN=C2NC(=O)N([C@H](CO)CC)C2=N1 HRHMIFIUUCUENC-YFKPBYRVSA-N 0.000 description 1
- QUCSBNPOJMPNDS-UHFFFAOYSA-N 5-bromo-3-[(3-nitrophenyl)methyl]-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound [O-][N+](=O)C1=CC=CC(CN2C(NC3=NC=C(Br)N=C32)=O)=C1 QUCSBNPOJMPNDS-UHFFFAOYSA-N 0.000 description 1
- KIXVDSJCGANIHE-JTQLQIEISA-N 5-ethyl-3-[(1s)-1-phenylethyl]-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound C1([C@H](C)N2C(O)=NC3=NC=C(N=C32)CC)=CC=CC=C1 KIXVDSJCGANIHE-JTQLQIEISA-N 0.000 description 1
- POBMWJBUNZNVBG-VIFPVBQESA-N 5-methoxy-3-[(1s)-1-phenylethyl]-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound C1([C@H](C)N2C(O)=NC3=NC=C(N=C32)OC)=CC=CC=C1 POBMWJBUNZNVBG-VIFPVBQESA-N 0.000 description 1
- XZIIFPSPUDAGJM-UHFFFAOYSA-N 6-chloro-2-n,2-n-diethylpyrimidine-2,4-diamine Chemical compound CCN(CC)C1=NC(N)=CC(Cl)=N1 XZIIFPSPUDAGJM-UHFFFAOYSA-N 0.000 description 1
- DHSSDEDRBUKTQY-UHFFFAOYSA-N 6-prop-2-enyl-4,5,7,8-tetrahydrothiazolo[4,5-d]azepin-2-amine Chemical compound C1CN(CC=C)CCC2=C1N=C(N)S2 DHSSDEDRBUKTQY-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 206010000159 Abnormal loss of weight Diseases 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 235000006491 Acacia senegal Nutrition 0.000 description 1
- 206010061666 Autonomic neuropathy Diseases 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 229940122361 Bisphosphonate Drugs 0.000 description 1
- 108030001720 Bontoxilysin Proteins 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 206010068597 Bulbospinal muscular atrophy congenital Diseases 0.000 description 1
- WSAKXJHRPDBBJH-XFNAGHOKSA-N C(C)(=O)C1=CN=C2C(=N1)N(C(N2)=O)[C@@H](C)C2=CC=CC=C2.OC2=NC=1C(=NC(=CN1)C(C)=O)N2[C@@H](C)C2=CC=CC=C2 Chemical compound C(C)(=O)C1=CN=C2C(=N1)N(C(N2)=O)[C@@H](C)C2=CC=CC=C2.OC2=NC=1C(=NC(=CN1)C(C)=O)N2[C@@H](C)C2=CC=CC=C2 WSAKXJHRPDBBJH-XFNAGHOKSA-N 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 108090000625 Cathepsin K Proteins 0.000 description 1
- 102000004171 Cathepsin K Human genes 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical group [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 206010057645 Chronic Inflammatory Demyelinating Polyradiculoneuropathy Diseases 0.000 description 1
- 208000030939 Chronic inflammatory demyelinating polyneuropathy Diseases 0.000 description 1
- 108090000317 Chymotrypsin Proteins 0.000 description 1
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- GJSURZIOUXUGAL-UHFFFAOYSA-N Clonidine Chemical compound ClC1=CC=CC(Cl)=C1NC1=NCCN1 GJSURZIOUXUGAL-UHFFFAOYSA-N 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 102000010831 Cytoskeletal Proteins Human genes 0.000 description 1
- 108010037414 Cytoskeletal Proteins Proteins 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 102100034067 Dehydrogenase/reductase SDR family member 11 Human genes 0.000 description 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- BXZVVICBKDXVGW-NKWVEPMBSA-N Didanosine Chemical compound O1[C@H](CO)CC[C@@H]1N1C(NC=NC2=O)=C2N=C1 BXZVVICBKDXVGW-NKWVEPMBSA-N 0.000 description 1
- 108010092674 Enkephalins Proteins 0.000 description 1
- RSEPBGGWRJCQGY-RBRWEJTLSA-N Estradiol valerate Chemical compound C1CC2=CC(O)=CC=C2[C@@H]2[C@@H]1[C@@H]1CC[C@H](OC(=O)CCCC)[C@@]1(C)CC2 RSEPBGGWRJCQGY-RBRWEJTLSA-N 0.000 description 1
- BFPYWIDHMRZLRN-SLHNCBLASA-N Ethinyl estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 BFPYWIDHMRZLRN-SLHNCBLASA-N 0.000 description 1
- 206010063006 Facial spasm Diseases 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- 208000024412 Friedreich ataxia Diseases 0.000 description 1
- 102000018997 Growth Hormone Human genes 0.000 description 1
- 108010051696 Growth Hormone Proteins 0.000 description 1
- 102000038461 Growth Hormone-Releasing Hormone Human genes 0.000 description 1
- 239000000095 Growth Hormone-Releasing Hormone Substances 0.000 description 1
- 208000035895 Guillain-Barré syndrome Diseases 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- 208000037357 HIV infectious disease Diseases 0.000 description 1
- 208000004095 Hemifacial Spasm Diseases 0.000 description 1
- 208000006411 Hereditary Sensory and Motor Neuropathy Diseases 0.000 description 1
- 102000002265 Human Growth Hormone Human genes 0.000 description 1
- 108010000521 Human Growth Hormone Proteins 0.000 description 1
- 239000000854 Human Growth Hormone Substances 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 description 1
- 108090001117 Insulin-Like Growth Factor II Proteins 0.000 description 1
- 102000048143 Insulin-Like Growth Factor II Human genes 0.000 description 1
- 102100022337 Integrin alpha-V Human genes 0.000 description 1
- SFBODOKJTYAUCM-UHFFFAOYSA-N Ipriflavone Chemical compound C=1C(OC(C)C)=CC=C(C2=O)C=1OC=C2C1=CC=CC=C1 SFBODOKJTYAUCM-UHFFFAOYSA-N 0.000 description 1
- 208000027747 Kennedy disease Diseases 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 201000010743 Lambert-Eaton myasthenic syndrome Diseases 0.000 description 1
- 206010024229 Leprosy Diseases 0.000 description 1
- URLZCHNOLZSCCA-VABKMULXSA-N Leu-enkephalin Chemical class C([C@@H](C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)CNC(=O)CNC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=CC=C1 URLZCHNOLZSCCA-VABKMULXSA-N 0.000 description 1
- 229940086609 Lipase inhibitor Drugs 0.000 description 1
- 229940124761 MMP inhibitor Drugs 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- ZPXSCAKFGYXMGA-UHFFFAOYSA-N Mazindol Chemical compound N12CCN=C2C2=CC=CC=C2C1(O)C1=CC=C(Cl)C=C1 ZPXSCAKFGYXMGA-UHFFFAOYSA-N 0.000 description 1
- 206010068836 Metabolic myopathy Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229910020101 MgC2 Inorganic materials 0.000 description 1
- 102000002151 Microfilament Proteins Human genes 0.000 description 1
- 108010040897 Microfilament Proteins Proteins 0.000 description 1
- 101100366942 Mus musculus Ston1 gene Proteins 0.000 description 1
- 206010028289 Muscle atrophy Diseases 0.000 description 1
- 206010028424 Myasthenic syndrome Diseases 0.000 description 1
- 201000009623 Myopathy Diseases 0.000 description 1
- 206010028643 Myopathy endocrine Diseases 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010029315 Neuromuscular blockade Diseases 0.000 description 1
- 101100030361 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) pph-3 gene Proteins 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- IMONTRJLAWHYGT-ZCPXKWAGSA-N Norethindrone Acetate Chemical compound C1CC2=CC(=O)CC[C@@H]2[C@@H]2[C@@H]1[C@@H]1CC[C@](C#C)(OC(=O)C)[C@@]1(C)CC2 IMONTRJLAWHYGT-ZCPXKWAGSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 208000004286 Osteochondrodysplasias Diseases 0.000 description 1
- 206010033307 Overweight Diseases 0.000 description 1
- 108010015181 PPAR delta Proteins 0.000 description 1
- 108010016731 PPAR gamma Proteins 0.000 description 1
- 102000000536 PPAR gamma Human genes 0.000 description 1
- 108090000526 Papain Proteins 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 206010034203 Pectus Carinatum Diseases 0.000 description 1
- 206010067633 Peripheral nerve lesion Diseases 0.000 description 1
- MFOCDFTXLCYLKU-CMPLNLGQSA-N Phendimetrazine Chemical compound O1CCN(C)[C@@H](C)[C@@H]1C1=CC=CC=C1 MFOCDFTXLCYLKU-CMPLNLGQSA-N 0.000 description 1
- PIJVFDBKTWXHHD-UHFFFAOYSA-N Physostigmine Natural products C12=CC(OC(=O)NC)=CC=C2N(C)C2C1(C)CCN2C PIJVFDBKTWXHHD-UHFFFAOYSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 206010036105 Polyneuropathy Diseases 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 208000032319 Primary lateral sclerosis Diseases 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- RVOLLAQWKVFTGE-UHFFFAOYSA-N Pyridostigmine Chemical compound CN(C)C(=O)OC1=CC=C[N+](C)=C1 RVOLLAQWKVFTGE-UHFFFAOYSA-N 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- 208000030934 Restrictive pulmonary disease Diseases 0.000 description 1
- FTALBRSUTCGOEG-UHFFFAOYSA-N Riluzole Chemical compound C1=C(OC(F)(F)F)C=C2SC(N)=NC2=C1 FTALBRSUTCGOEG-UHFFFAOYSA-N 0.000 description 1
- NCDNCNXCDXHOMX-UHFFFAOYSA-N Ritonavir Natural products C=1C=CC=CC=1CC(NC(=O)OCC=1SC=NC=1)C(O)CC(CC=1C=CC=CC=1)NC(=O)C(C(C)C)NC(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-UHFFFAOYSA-N 0.000 description 1
- 102000001332 SRC Human genes 0.000 description 1
- IRHXGOXEBNJUSN-YOXDLBRISA-N Saquinavir mesylate Chemical compound CS(O)(=O)=O.C([C@@H]([C@H](O)CN1C[C@H]2CCCC[C@H]2C[C@H]1C(=O)NC(C)(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)C=1N=C2C=CC=CC2=CC=1)C1=CC=CC=C1 IRHXGOXEBNJUSN-YOXDLBRISA-N 0.000 description 1
- 208000018675 Schwartz-Jampel syndrome Diseases 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 101710142969 Somatoliberin Proteins 0.000 description 1
- 102000013275 Somatomedins Human genes 0.000 description 1
- 102000005157 Somatostatin Human genes 0.000 description 1
- 108010056088 Somatostatin Proteins 0.000 description 1
- XNKLLVCARDGLGL-JGVFFNPUSA-N Stavudine Chemical compound O=C1NC(=O)C(C)=CN1[C@H]1C=C[C@@H](CO)O1 XNKLLVCARDGLGL-JGVFFNPUSA-N 0.000 description 1
- 206010072148 Stiff-Person syndrome Diseases 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 208000024799 Thyroid disease Diseases 0.000 description 1
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
- KJADKKWYZYXHBB-XBWDGYHZSA-N Topiramic acid Chemical compound C1O[C@@]2(COS(N)(=O)=O)OC(C)(C)O[C@H]2[C@@H]2OC(C)(C)O[C@@H]21 KJADKKWYZYXHBB-XBWDGYHZSA-N 0.000 description 1
- QHMBSVQNZZTUGM-UHFFFAOYSA-N Trans-Cannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1C1C(C(C)=C)CCC(C)=C1 QHMBSVQNZZTUGM-UHFFFAOYSA-N 0.000 description 1
- 206010046298 Upper motor neurone lesion Diseases 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 108010048673 Vitronectin Receptors Proteins 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 208000006269 X-Linked Bulbo-Spinal Atrophy Diseases 0.000 description 1
- WREGKURFCTUGRC-POYBYMJQSA-N Zalcitabine Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](CO)CC1 WREGKURFCTUGRC-POYBYMJQSA-N 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- FJWGYAHXMCUOOM-QHOUIDNNSA-N [(2s,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6s)-4,5-dinitrooxy-2-(nitrooxymethyl)-6-[(2r,3r,4s,5r,6s)-4,5,6-trinitrooxy-2-(nitrooxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-3,5-dinitrooxy-6-(nitrooxymethyl)oxan-4-yl] nitrate Chemical compound O([C@@H]1O[C@@H]([C@H]([C@H](O[N+]([O-])=O)[C@H]1O[N+]([O-])=O)O[C@H]1[C@@H]([C@@H](O[N+]([O-])=O)[C@H](O[N+]([O-])=O)[C@@H](CO[N+]([O-])=O)O1)O[N+]([O-])=O)CO[N+](=O)[O-])[C@@H]1[C@@H](CO[N+]([O-])=O)O[C@@H](O[N+]([O-])=O)[C@H](O[N+]([O-])=O)[C@H]1O[N+]([O-])=O FJWGYAHXMCUOOM-QHOUIDNNSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000003070 absorption delaying agent Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 238000003811 acetone extraction Methods 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000012042 active reagent Substances 0.000 description 1
- 208000027093 acute inflammatory demyelinating polyradiculoneuropathy Diseases 0.000 description 1
- 125000004423 acyloxy group Chemical group 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 239000000048 adrenergic agonist Substances 0.000 description 1
- 239000000695 adrenergic alpha-agonist Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 108010083553 alanyl-histidyl-(2-naphthyl)alanyl-tryptophyl-phenylalanyl-lysinamide Proteins 0.000 description 1
- NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 description 1
- 229940062527 alendronate Drugs 0.000 description 1
- FPQFYIAXQDXNOR-QDKLYSGJSA-N alpha-Zearalenol Chemical compound O=C1O[C@@H](C)CCC[C@H](O)CCC\C=C\C2=CC(O)=CC(O)=C21 FPQFYIAXQDXNOR-QDKLYSGJSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 229940125709 anorectic agent Drugs 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 239000000883 anti-obesity agent Substances 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 229940125710 antiobesity agent Drugs 0.000 description 1
- 239000002830 appetite depressant Substances 0.000 description 1
- 125000003710 aryl alkyl group Chemical group 0.000 description 1
- 125000004104 aryloxy group Chemical group 0.000 description 1
- 238000011914 asymmetric synthesis Methods 0.000 description 1
- 238000000065 atmospheric pressure chemical ionisation Methods 0.000 description 1
- 108010014210 axokine Proteins 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 150000001555 benzenes Chemical class 0.000 description 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
- YXKTVDFXDRQTKV-HNNXBMFYSA-N benzphetamine Chemical compound C([C@H](C)N(C)CC=1C=CC=CC=1)C1=CC=CC=C1 YXKTVDFXDRQTKV-HNNXBMFYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 125000006580 bicyclic heterocycloalkyl group Chemical group 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 150000004663 bisphosphonates Chemical class 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000002617 bone density conservation agent Substances 0.000 description 1
- 229940053031 botulinum toxin Drugs 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical group BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 125000005514 but-1-yn-3-yl group Chemical group 0.000 description 1
- HGXJOXHYPGNVNK-UHFFFAOYSA-N butane;ethenoxyethane;tin Chemical compound CCCC[Sn](CCCC)(CCCC)C(=C)OCC HGXJOXHYPGNVNK-UHFFFAOYSA-N 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 125000000480 butynyl group Chemical group [*]C#CC([H])([H])C([H])([H])[H] 0.000 description 1
- 150000001669 calcium Chemical class 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229940069978 calcium supplement Drugs 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 229950011318 cannabidiol Drugs 0.000 description 1
- QHMBSVQNZZTUGM-ZWKOTPCHSA-N cannabidiol Chemical compound OC1=CC(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)=C)CCC(C)=C1 QHMBSVQNZZTUGM-ZWKOTPCHSA-N 0.000 description 1
- ZTGXAWYVTLUPDT-UHFFFAOYSA-N cannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1C1C(C(C)=C)CC=C(C)C1 ZTGXAWYVTLUPDT-UHFFFAOYSA-N 0.000 description 1
- 125000003739 carbamimidoyl group Chemical group C(N)(=N)* 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 210000004413 cardiac myocyte Anatomy 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- MVCQKIKWYUURMU-UHFFFAOYSA-N cetilistat Chemical compound C1=C(C)C=C2C(=O)OC(OCCCCCCCCCCCCCCCC)=NC2=C1 MVCQKIKWYUURMU-UHFFFAOYSA-N 0.000 description 1
- 229950002397 cetilistat Drugs 0.000 description 1
- 239000013522 chelant Substances 0.000 description 1
- 239000012069 chiral reagent Substances 0.000 description 1
- 239000000460 chlorine Chemical group 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 208000019902 chronic diarrheal disease Diseases 0.000 description 1
- 229960002376 chymotrypsin Drugs 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 229960002896 clonidine Drugs 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 238000010668 complexation reaction Methods 0.000 description 1
- 229940035811 conjugated estrogen Drugs 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 239000012059 conventional drug carrier Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 206010066336 critical illness polyneuropathy Diseases 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 210000004292 cytoskeleton Anatomy 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 201000001981 dermatomyositis Diseases 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- VILAVOFMIJHSJA-UHFFFAOYSA-N dicarbon monoxide Chemical compound [C]=C=O VILAVOFMIJHSJA-UHFFFAOYSA-N 0.000 description 1
- 229960002656 didanosine Drugs 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- XXEPPPIWZFICOJ-UHFFFAOYSA-N diethylpropion Chemical compound CCN(CC)C(C)C(=O)C1=CC=CC=C1 XXEPPPIWZFICOJ-UHFFFAOYSA-N 0.000 description 1
- 229960004890 diethylpropion Drugs 0.000 description 1
- RGLYKWWBQGJZGM-ISLYRVAYSA-N diethylstilbestrol Chemical compound C=1C=C(O)C=CC=1C(/CC)=C(\CC)C1=CC=C(O)C=C1 RGLYKWWBQGJZGM-ISLYRVAYSA-N 0.000 description 1
- 125000004982 dihaloalkyl group Chemical group 0.000 description 1
- PCXRACLQFPRCBB-ZWKOTPCHSA-N dihydrocannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)C)CCC(C)=C1 PCXRACLQFPRCBB-ZWKOTPCHSA-N 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- UXGNZZKBCMGWAZ-UHFFFAOYSA-N dimethylformamide dmf Chemical compound CN(C)C=O.CN(C)C=O UXGNZZKBCMGWAZ-UHFFFAOYSA-N 0.000 description 1
- 239000001177 diphosphate Substances 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
- 235000011180 diphosphates Nutrition 0.000 description 1
- 239000002612 dispersion medium Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- DLNKOYKMWOXYQA-UHFFFAOYSA-N dl-pseudophenylpropanolamine Natural products CC(N)C(O)C1=CC=CC=C1 DLNKOYKMWOXYQA-UHFFFAOYSA-N 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000009881 electrostatic interaction Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 229960005309 estradiol Drugs 0.000 description 1
- 229930182833 estradiol Natural products 0.000 description 1
- 229960004766 estradiol valerate Drugs 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- YFXCNIVBAVFOBX-UHFFFAOYSA-N ethenylboronic acid Chemical compound OB(O)C=C YFXCNIVBAVFOBX-UHFFFAOYSA-N 0.000 description 1
- 229960002568 ethinylestradiol Drugs 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N ethylene glycol Natural products OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000011536 extraction buffer Substances 0.000 description 1
- RWTNPBWLLIMQHL-UHFFFAOYSA-N fexofenadine Chemical group C1=CC(C(C)(C(O)=O)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 RWTNPBWLLIMQHL-UHFFFAOYSA-N 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- RMBPEFMHABBEKP-UHFFFAOYSA-N fluorene Chemical compound C1=CC=C2C3=C[CH]C=CC3=CC2=C1 RMBPEFMHABBEKP-UHFFFAOYSA-N 0.000 description 1
- 229940091249 fluoride supplement Drugs 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 102000034356 gene-regulatory proteins Human genes 0.000 description 1
- 108091006104 gene-regulatory proteins Proteins 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- 108010015153 growth hormone releasing hexapeptide Proteins 0.000 description 1
- 239000003324 growth hormone secretagogue Substances 0.000 description 1
- 108010085742 growth hormone-releasing peptide-2 Proteins 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 125000004475 heteroaralkyl group Chemical group 0.000 description 1
- 125000005553 heteroaryloxy group Chemical group 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000012145 high-salt buffer Substances 0.000 description 1
- 238000002657 hormone replacement therapy Methods 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- DOUHZFSGSXMPIE-UHFFFAOYSA-N hydroxidooxidosulfur(.) Chemical compound [O]SO DOUHZFSGSXMPIE-UHFFFAOYSA-N 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 125000005113 hydroxyalkoxy group Chemical group 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000002390 hyperplastic effect Effects 0.000 description 1
- 230000001969 hypertrophic effect Effects 0.000 description 1
- 201000008319 inclusion body myositis Diseases 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 229960004243 indinavir sulfate Drugs 0.000 description 1
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 1
- 239000012442 inert solvent Substances 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004941 influx Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000011630 iodine Chemical group 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 229960005431 ipriflavone Drugs 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 238000006317 isomerization reaction Methods 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000000555 isopropenyl group Chemical group [H]\C([H])=C(\*)C([H])([H])[H] 0.000 description 1
- JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 125000003971 isoxazolinyl group Chemical group 0.000 description 1
- 229940043355 kinase inhibitor Drugs 0.000 description 1
- JTEGQNOMFQHVDC-NKWVEPMBSA-N lamivudine Chemical compound O=C1N=C(N)C=CN1[C@H]1O[C@@H](CO)SC1 JTEGQNOMFQHVDC-NKWVEPMBSA-N 0.000 description 1
- 229960001627 lamivudine Drugs 0.000 description 1
- 229940033984 lamivudine / zidovudine Drugs 0.000 description 1
- 201000010901 lateral sclerosis Diseases 0.000 description 1
- 210000005240 left ventricle Anatomy 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 229960000299 mazindol Drugs 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229960004296 megestrol acetate Drugs 0.000 description 1
- RQZAXGRLVPAYTJ-GQFGMJRRSA-N megestrol acetate Chemical compound C1=C(C)C2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 RQZAXGRLVPAYTJ-GQFGMJRRSA-N 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- ZEDPIMIYEJBDRX-UHFFFAOYSA-N methyl 2-oxo-1-pentan-3-yl-3h-imidazo[4,5-b]pyrazine-5-carboxylate Chemical compound COC(=O)C1=CN=C2N(C(CC)CC)C(O)=NC2=N1 ZEDPIMIYEJBDRX-UHFFFAOYSA-N 0.000 description 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 description 1
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 125000002950 monocyclic group Chemical group 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 230000002969 morbid Effects 0.000 description 1
- 125000004312 morpholin-2-yl group Chemical group [H]N1C([H])([H])C([H])([H])OC([H])(*)C1([H])[H] 0.000 description 1
- 125000004572 morpholin-3-yl group Chemical group N1C(COCC1)* 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 208000005264 motor neuron disease Diseases 0.000 description 1
- 206010065579 multifocal motor neuropathy Diseases 0.000 description 1
- 230000020763 muscle atrophy Effects 0.000 description 1
- 201000006938 muscular dystrophy Diseases 0.000 description 1
- 206010028417 myasthenia gravis Diseases 0.000 description 1
- 230000003274 myotonic effect Effects 0.000 description 1
- 210000001087 myotubule Anatomy 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 239000006199 nebulizer Substances 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 1
- BOPGDPNILDQYTO-NNYOXOHSSA-N nicotinamide-adenine dinucleotide Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-N 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- UMRZSTCPUPJPOJ-KNVOCYPGSA-N norbornane Chemical group C1C[C@H]2CC[C@@H]1C2 UMRZSTCPUPJPOJ-KNVOCYPGSA-N 0.000 description 1
- 229960001652 norethindrone acetate Drugs 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- NIHNNTQXNPWCJQ-UHFFFAOYSA-N o-biphenylenemethane Natural products C1=CC=C2CC3=CC=CC=C3C2=C1 NIHNNTQXNPWCJQ-UHFFFAOYSA-N 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 125000005968 oxazolinyl group Chemical group 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- 239000006179 pH buffering agent Substances 0.000 description 1
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 229940055729 papain Drugs 0.000 description 1
- 235000019834 papain Nutrition 0.000 description 1
- 229960001319 parathyroid hormone Drugs 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 229960000436 phendimetrazine Drugs 0.000 description 1
- DLNKOYKMWOXYQA-APPZFPTMSA-N phenylpropanolamine Chemical compound C[C@@H](N)[C@H](O)C1=CC=CC=C1 DLNKOYKMWOXYQA-APPZFPTMSA-N 0.000 description 1
- 229960000395 phenylpropanolamine Drugs 0.000 description 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 1
- 230000037081 physical activity Effects 0.000 description 1
- PIJVFDBKTWXHHD-HIFRSBDPSA-N physostigmine Chemical compound C12=CC(OC(=O)NC)=CC=C2N(C)[C@@H]2[C@@]1(C)CCN2C PIJVFDBKTWXHHD-HIFRSBDPSA-N 0.000 description 1
- 229960001697 physostigmine Drugs 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 208000005987 polymyositis Diseases 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920006316 polyvinylpyrrolidine Polymers 0.000 description 1
- 235000015320 potassium carbonate Nutrition 0.000 description 1
- 229960000208 pralmorelin Drugs 0.000 description 1
- 238000011533 pre-incubation Methods 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 229960004618 prednisone Drugs 0.000 description 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000186 progesterone Substances 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
- RUOJZAUFBMNUDX-UHFFFAOYSA-N propylene carbonate Chemical compound CC1COC(=O)O1 RUOJZAUFBMNUDX-UHFFFAOYSA-N 0.000 description 1
- 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 229940127293 prostanoid Drugs 0.000 description 1
- 150000003814 prostanoids Chemical class 0.000 description 1
- XNSAINXGIQZQOO-SRVKXCTJSA-N protirelin Chemical compound NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@H]1NC(=O)CC1)CC1=CN=CN1 XNSAINXGIQZQOO-SRVKXCTJSA-N 0.000 description 1
- 201000003651 pulmonary sarcoidosis Diseases 0.000 description 1
- 125000004944 pyrazin-3-yl group Chemical group [H]C1=C([H])N=C(*)C([H])=N1 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 125000006513 pyridinyl methyl group Chemical group 0.000 description 1
- 229960002290 pyridostigmine Drugs 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000004527 pyrimidin-4-yl group Chemical group N1=CN=C(C=C1)* 0.000 description 1
- 125000004528 pyrimidin-5-yl group Chemical group N1=CN=CC(=C1)* 0.000 description 1
- 229940107700 pyruvic acid Drugs 0.000 description 1
- 208000022587 qualitative or quantitative defects of dystrophin Diseases 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- LUDZVVVPVCUUBP-UHFFFAOYSA-N quinoxaline-2,3-diamine Chemical compound C1=CC=C2N=C(N)C(N)=NC2=C1 LUDZVVVPVCUUBP-UHFFFAOYSA-N 0.000 description 1
- GZUITABIAKMVPG-UHFFFAOYSA-N raloxifene Chemical compound C1=CC(O)=CC=C1C1=C(C(=O)C=2C=CC(OCCN3CCCCC3)=CC=2)C2=CC=C(O)C=C2S1 GZUITABIAKMVPG-UHFFFAOYSA-N 0.000 description 1
- 229960004622 raloxifene Drugs 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000012501 relaxation of skeletal muscle Effects 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 229910052702 rhenium Inorganic materials 0.000 description 1
- 229960004181 riluzole Drugs 0.000 description 1
- NCDNCNXCDXHOMX-XGKFQTDJSA-N ritonavir Chemical compound N([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1SC=NC=1)CC=1C=CC=CC=1)C(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-XGKFQTDJSA-N 0.000 description 1
- 229960000311 ritonavir Drugs 0.000 description 1
- 229910052701 rubidium Inorganic materials 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229960002052 salbutamol Drugs 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- QWAXKHKRTORLEM-UGJKXSETSA-N saquinavir Chemical compound C([C@@H]([C@H](O)CN1C[C@H]2CCCC[C@H]2C[C@H]1C(=O)NC(C)(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)C=1N=C2C=CC=CC2=CC=1)C1=CC=CC=C1 QWAXKHKRTORLEM-UGJKXSETSA-N 0.000 description 1
- 229960001852 saquinavir Drugs 0.000 description 1
- 229960003542 saquinavir mesylate Drugs 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical class O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 239000000849 selective androgen receptor modulator Substances 0.000 description 1
- 229940095743 selective estrogen receptor modulator Drugs 0.000 description 1
- 239000000333 selective estrogen receptor modulator Substances 0.000 description 1
- 239000000952 serotonin receptor agonist Substances 0.000 description 1
- UNAANXDKBXWMLN-UHFFFAOYSA-N sibutramine Chemical compound C=1C=C(Cl)C=CC=1C1(C(N(C)C)CC(C)C)CCC1 UNAANXDKBXWMLN-UHFFFAOYSA-N 0.000 description 1
- 229960004425 sibutramine Drugs 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 210000002363 skeletal muscle cell Anatomy 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 description 1
- 229960000553 somatostatin Drugs 0.000 description 1
- 229940035044 sorbitan monolaurate Drugs 0.000 description 1
- 108010087686 src-Family Kinases Proteins 0.000 description 1
- 229960001203 stavudine Drugs 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 229950007447 sulbenox Drugs 0.000 description 1
- KQKPFRSPSRPDEB-UHFFFAOYSA-N sumatriptan Chemical compound CNS(=O)(=O)CC1=CC=C2NC=C(CCN(C)C)C2=C1 KQKPFRSPSRPDEB-UHFFFAOYSA-N 0.000 description 1
- 229960003708 sumatriptan Drugs 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 229960001603 tamoxifen Drugs 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- OGBMKVWORPGQRR-UMXFMPSGSA-N teriparatide Chemical compound C([C@H](NC(=O)[C@H](CCSC)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H](N)CO)C(C)C)[C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CNC=N1 OGBMKVWORPGQRR-UMXFMPSGSA-N 0.000 description 1
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 1
- 229960000278 theophylline Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100001274 therapeutic index Toxicity 0.000 description 1
- 125000005305 thiadiazolinyl group Chemical group 0.000 description 1
- 125000002769 thiazolinyl group Chemical group 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 208000021510 thyroid gland disease Diseases 0.000 description 1
- WZDGZWOAQTVYBX-XOINTXKNSA-N tibolone Chemical compound C([C@@H]12)C[C@]3(C)[C@@](C#C)(O)CC[C@H]3[C@@H]1[C@H](C)CC1=C2CCC(=O)C1 WZDGZWOAQTVYBX-XOINTXKNSA-N 0.000 description 1
- 229960001023 tibolone Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 229960004394 topiramate Drugs 0.000 description 1
- 125000005424 tosyloxy group Chemical group S(=O)(=O)(C1=CC=C(C)C=C1)O* 0.000 description 1
- 230000002463 transducing effect Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- 229940117013 triethanolamine oleate Drugs 0.000 description 1
- PQDJYEQOELDLCP-UHFFFAOYSA-N trimethylsilane Chemical compound C[SiH](C)C PQDJYEQOELDLCP-UHFFFAOYSA-N 0.000 description 1
- CWMFRHBXRUITQE-UHFFFAOYSA-N trimethylsilylacetylene Chemical group C[Si](C)(C)C#C CWMFRHBXRUITQE-UHFFFAOYSA-N 0.000 description 1
- UCPYLLCMEDAXFR-UHFFFAOYSA-N triphosgene Chemical compound ClC(Cl)(Cl)OC(=O)OC(Cl)(Cl)Cl UCPYLLCMEDAXFR-UHFFFAOYSA-N 0.000 description 1
- YFTHZRPMJXBUME-UHFFFAOYSA-N tripropylamine Chemical compound CCCN(CCC)CCC YFTHZRPMJXBUME-UHFFFAOYSA-N 0.000 description 1
- UPCXAARSWVHVLY-UHFFFAOYSA-N tris(2-hydroxyethyl)azanium;acetate Chemical compound CC(O)=O.OCCN(CCO)CCO UPCXAARSWVHVLY-UHFFFAOYSA-N 0.000 description 1
- 230000003156 vasculitic effect Effects 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 229960000523 zalcitabine Drugs 0.000 description 1
- 229960002300 zeranol Drugs 0.000 description 1
- 229960002555 zidovudine Drugs 0.000 description 1
- HBOMLICNUCNMMY-XLPZGREQSA-N zidovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-XLPZGREQSA-N 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Landscapes
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Abstract Provided are certain chemical entities, and methods of use to modulate skeletal myosin, skeletal actin, skeletal tropomyosin, skeletal troponin C, skeletal troponin I, skeletal troponin T, and skeletal muscle, including fragments and isoforms thereof, as well as the skeletal sarcomere, and methods of use in the treatment of obesity, sarcopenia, wasting syndrome, frailty, cachexia, muscle spasm, post-surgical and post-traumatic muscle weakness, neuromuscular disease, and other indications.
Description
CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS [001] This application claims the benefit of U.S. Provisional Patent Application No. 601835,272, filed August 2, 2006, and U.S. Provisional Patent Application No.60/921,054, filed March 30, 2007, each of which is incorporated herein by reference for all purposes. [0023 Provided are certain chemical entities that modulate skeletal myosin, skeletal actin, skeletal tropomyosin, skeletal troponin C, skeletal troponin I, skeletal troponin T, and skeletal muscle, including fragments and isoforms thereof, as well as the skeletal sarcomere. Also provided are certain chemical entities, pharmaceutical compositions and methods of treatment of one or more of obesity, sarcopenia, wasting syndrome, frality, cachexia, muscle spasm, post-surgical and post-traumatic muscle weakness, and neuromuscular disease. [003] The cytoskeleton of skeletal and cardiac muscle cells is unique compared to that of all other cells. It consists of a nearly crystalline array of closely packed cytoskeletal proteins called the sarcomere. The sarcomere is elegantly organized as an interdigitating array of thin and thick filaments. The thick filaments are composed of myosin, the motor protein responsible for transducing the chemical energy of ATP hydrolysis into force and directed movement. The thin filaments are composed of actin monomers arranged in a helical array. There are four regulatory proteins bound to the actin filaments, which allows the contraction to be modulated by calcium ions, An influx of intracellular calcium initiates muscle contraction; thick and thin filaments slide past each other driven by repetitive interactions of the myosin motor domains with the thin actin filaments. [004] Myosin is the most extensively studied of all the motor proteins. Of the thirteen distinct classes of myosin in human cells, the myosin-i class is responsible for contraction of skeletal, cardiac, and smooth muscle. This class of myosin is significantly different in amino acid composition and in overall structure from myosin in the other twelve distinct classes. Myosin-li consists of two globular head domains linked together by a long alpha-helical coiled-coiled tail that assembles with other myosin-Ils to form the core of the sarcomere's thick filament. The globular heads have a catalytic domain 1 where the actin binding and ATP functions of myosin take place. Once bound to an actin filament, the release of phosphate (cf. ATP to ADP) leads to a change in structural conformation of the catalytic domain that in turn alters the orientation of the light-chain binding lever arm domain that extends from the globular head; this movement is termed the powerstroke. This change in orientation of the myosin head in relationship to actin causes the thick filament of which It Is a part to move with respect to the thin actin filament to which it is bound. Un-binding of the globular head from the actin filament (also Cab modulated) coupled with return of the catalytic domain and light chain to their starting conformation/orientation completes the contraction and relaxation cycle, responsible for intracellular movement and muscle contraction. [005] Tropomyosin and troponin mediate the calcium effect on the interaction on actin and myosin. The skeletal troponin complex regulates the action of several actin units at once, and is comprised of three polypepetide chains; skeletal troponin C, which binds calcium ions; troponin I, which binds to actin; and troponin T, which binds to tropomyosin. [006] Abnormal contraction of skeletal muscle is thought to be a pathogenetic cause of several disorders, including obesity, sarcopenia, wasting syndrome, frailty, cachexia, muscle spasm, post-surgical and post-traumatic rnuscle weakness, and neuromuscular disease, which pose serious health problems as adult diseases. The contraction and relaxation of skeletal muscle are mainly controlled by increases and decreases of intracellular calcium. [007] Accordingly, there is a need for the development of new compounds modulate skeletal muscle. There remains a need for agents that exploit new mechanisms of action and which may have better outcomes in terms of relief of symptoms, safety, and patient mortality, both short-term and long-term and an improved therapeutic index. [008] Provided is at least one chemical entity chosen from compounds of Formula I and compounds of Formula II: 2 R4 N N OR ON >_ OH N N N R2 R2 Formula I Formula I and pharmaceutically acceptable salts thereof, wherein
R
1 and R 4 are independently selected from hydrogen, halo, hydroxy, optionally substituted acyl, optionally substituted alkyl, optionally substituted amino, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted heteroaryl, optionally substituted alkoxy, optionally substituted aminocarbonyl, sulfonyl. sulfanyl. sulfinyl, carboxy, optionally substituted alkoxycarbonyl, and cyano; and in the alternative, R 4 and R 1 , taken together with any intervening atoms, form a fused ring system selected from optionally substituted fused aryl, optionally substituted fused heteroaryl, optionally substituted fused cycloalkyl, and optionally substituted fused heterocycloalkyl; and
R
2 is is selected from optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, and optionally substituted heterocycloalkyl; provided that
R
1 is not hex-I-enyl; and further provided that the compound of Formula I or the compound of Formula II is not (S)-6-bromo-1-(1.-phenylethyl)-1 H-imidazo[4,5-b]pyrazin-2(3H)-one; 1,5,6-trimethyl-IH-imidazo[4,5-b]pyrazin-2(3H)-one; 1-methyl-1 H-imidazo[4,5-bjpyrazin-2(3H)-one; 6-bromo-1-(3-nitrobenzyl)-1 H-imidazo[4,5-b]pyrazin-2(3H)-one; 5-(hydroxymethyl)-1,6-dimethyl-1 H-imidazo[4,5-b]pyrazin-2(3H)-one; or 1-(piperidin-4-yl)-1 H-imidazo[4,5-b]pyrazin-2(3H)-one. [009] Also provided is a pharmaceutically acceptable composition comprising a pharmaceutically acceptable carrier and at least one chemical entity described herein. 3 [010] Also provided are methods for treating a patient having a disease chosen from obesity, sarcopenia, wasting syndrome, frailty, cachexia, muscle spasm, post surgical and post-traumatic muscle weakness, and neuromuscular disease, comprising administering to the patient a therapeutically effective amount of at least one chemical entity described herein. [011] Also provided is a method of treating one or more of obesity, sarcopenia, wasting syndrome, frailty, cachexia, muscle spasm, post-surgical and post-traumatic muscle weakness, neuromuscular disease, and other indications In a mammal which method comprises administering to a mammal in need thereof a therapeutically effective amount of at least one chemical entity described herein or a pharmaceutical composition comprising a pharmaceutically acceptable excipient, carrier or adjuvant and at least one chemical entity described herein. [012] Also provided is a method for treating a patient having a disease responsive to modulation of one or more of skeletal myosin, skeletal actin, skeletal tropomyosin, skeletal troponin C, skeletal troponin I, skeletal troponin T, and skeletal muscle, including fragments and isoforms thereof, as well as the skeletal sarcomere in a mammal which method comprises administering to a mammal in need thereof a therapeutically effective amount of at least one chemical entity described herein or a pharmaceutical composition comprising a pharmaceutically acceptable excipient, carrier or adjuvant and at least one chemical entity described herein. [013] Also provided. is a method for treating a patient having a disease responsive to potentiation of one or more of skeletal myosin, skeletal actin, skeletal tropomyosin, skeletal troponin C, skeletal troponin 1, skeletal troponin T, and skeletal muscle, including fragments and isoforms thereof, as well as the skeletal sarcomere in a mammal which method comprises administering to a mammal in need thereof a therapeutically effective amount of at least one chemical entity described herein or a pharmaceutical composition comprising a pharmaceutically acceptable excipient, carrier or adjuvant and at least one chemical entity described herein, [014] . Also provided is a method for treating a patient having a disease responsive to inhibition of one or more of skeletal myosin, skeletal actin, skeletal tropornyosin, skeletal troponin C, skeletal troponin I, skeletal troponin T, and skeletal muscle, 4 including fragments and isoforms thereof, as well as the skeletal sarcomere in a mammal which method comprises administering to a mammal in need thereof a therapeutically effective amount of at least one chemical entity described herein or a pharmaceutical composition comprising a pharmaceutically acceptable excipient, carrier or adjuvant and at least one chemical entity described herein. [015] Other aspects and embodiments will be apparent to those skilled in the art from the following detailed description. [016] As used in the present specification, the following words and phrases are generally intended to have the meanings as set forth below, except to the extent that the context in which they are used indicates otherwise. [017] The following abbreviations and terms have the indicated meanings throughout: Ac = acetyl APCI = atmospheric pressure chemical ionization atm = atomosphere Boc = tert-butoxycarbonyl c-= cyclo CBZ = carbobenzyloxy = benzyloxycarbonyl CDI = carbonyldiimidazole DCM = dichloromethane = methylene chloride = CH 2 C1 2 DIEA = DIPEA = N,N-diisopropylethylamine DMF N,N-dimethylformamide DMSO = dimethyl sulfoxide (DPPF)PdC 2 = [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladlum(ll) Et = ethyl EtOAc ethyl acetate EtOH = ethanol g = gram GC gas chromatograghy horhr = hour HPLC high pressure liquid chromatography 5 i- = iso kg or Kg kilogram I or L =-liter LCMS = liquid chromatography-mass spectrometry m/z = mass-to-charge ratio Me = methyl NMP = 1-methyl-2-pyrrolidinone NMR = nuclear magnetic resonance MPLC = medium pressure liquid chromatography min = minute mg = milligram mL or ml = milliliter MW microwave n-= normal Ph phenyl (Ph 3
P)
4 Pd = tetrakis(triphenylphosphine)palladium(O) (Ph 3
P)
2 PdCl 2 = dichlorobis(triphenylphosphine)palladium(II) rt or RT = room temperature s- sec- = secondary t-= tert-= tertiary TES = triethylsilyl or triethylsilane TMS = trimethylsilyl or trimethylsilane TFA trifluoroacetic acid THF = tetrahydrofuran TLC = thin layer chromatography UV ultraviolet vol = volume equivalent in mUg or JKg for the limiting reagent unless otherwise indicated [018] By "optional" or "optionally" is meant that the subsequently described event or circumstance may or may not occur, and that the description includes instances where the event or circumstance occurs and instances in which it does not. For 6 example, "optionally substituted alkyl" encompasses both "alkyl" and "substituted alkyl" as defined below. It will be understood by those skilled in the art, with respect to any group containing one or more substituents, that such groups are not intended to introduce any substitution or substitution patterns that are sterically impractical, synthetically non-feasible, and/or inherently unstable. [019J "Alkyl" encompasses straight chain and branched chain having the indicated number of carbon atoms, usually from 1 to 20 carbon atoms, for example 1 to 8 carbon atoms, such as 1 to 6 carbon atoms. For example C-Cs alkyl encompasses both straight and branched chain alkyl of from I to 6 carbon atoms. When an alkyl residue having a specific number of carbons is named, all branched and straight chain versions having that number of carbons are intended to be encompassed; thus, for example, "butyl" is meant to include n-butyl, sec-butyl, isobutyl and t-butyl; "propyl" Includes n propyl and isopropyl. "Lower alkyl" refers to alkyl groups having one to seven carbons. In certain embodiments, "lower alkyl" refers to alkyl groups having one to six carbons. Examples of alkyl groups Include methyl, ethyl, propyl, isopropyl, n-butyl, sec-butyl, tert butyl, pentyl, 2-pentyl, isopentyl, neopentyl, hexyl, 2-hexyl, 3-hexyl, 3-methylpentyl, and the like. Alkylene is a subset of alkyl, referring to the same residues as alkyl, but having two points of attachment. Alkylene groups will usually have from 2 to 20 carbon atoms, for example 2 to 8 carbon atoms, such as from 2 to 6 carbon atoms. For example, Co alkylene indicates a covalent bond and C, alkylene is a methylene group. (020] "Alkenyl" refers to an unsaturated branched or straight-chain alkyl group having at least one carbon-carbon double bond derived by the removal of one molecule of hydrogen from adjacent carbon atoms of the parent alkyl. The group may be in either the cis or trans configuration about the double bond(s). Typical alkenyl groups include, but are not limited to, ethenyl; propenyls such as prop-1-en-1-yi, prop-1-en-2-yl, prop-2 en-1-yl (allyl), prop-2-en-2-yl; butenyls such as but-1-en-1-yl, but-i-en-2-yl, 2-methyl prop-i-en-1-yl, but-2-en-1-yl, but-2-en-1-yl, but-2-en-2-yl, buta-1,3-dien-1-yl, buta-1,3 dien-2-yl; and the like. In certain embodiments, an alkenyl group has from 2 to 20 carbon atoms and in other embodiments, from 2 to 6 carbon atoms. "Lower alkenyl" refers to alkenyl groups having two to six carbons. [021] "Alkynyl" refers to an unsaturated branched or straight-chain alkyl group 7 having at least one carbon-carbon triple bond derived by the removal of two molecules of hydrogen from adjacent carbon atoms of the parent alkyl. Typical alkynyl groups include, but are not limited to, ethynyl; propynyls such as prop-1-yn-1-yl, prop-2-yn-1-yl; butynyls such as but-1-yn-1-yl, but-1-yn-3-yl, but-3-yn-1-yl; and the like. In certain embodiments, an alkynyl group has from 2 to 20 carbon atoms and in other embodiments, from 3 to 6 carbon atoms. "Lower alkynyl" refers to alkynyl groups having two to six carbons. [022] ~ "Cycloalkyl" indicates a non-aromatic carbocyclic ring, usually having from 3 to 7 ring carbon atoms. The ring may be saturated or have one or more carbon-carbon double bonds. Examples of cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, and cyclohexenyl, as well as bridged and caged ring groups such as norbornane. [023] The term "alkoxy" refers to the group -0-alkyl, including from I to 8 carbon atoms of a straight, branched, cyclic configuration and combinations thereof attached to the parent structure through an oxygen. Examples include methoxy, ethoxy, propoxy, isopropoxy, cyclopropyloxy, cyclohexyloxy and the like. "Lower alkoxy" refers to alkoxy groups containing one to six carbons. [024] The term "substituted alkoxy" refers to alkoxy wherein the alkyl constituent is substituted (i.e., -O-(substituted alkyl)) wherein "substituted alkyl" refers to alkyl wherein one or more (such as up to 5, for example, up to 3) hydrogen atoms are replaced by a substituent independently chosen from:
-R
8 , -ORb, optionally substituted amino (including -NR"CORb, -NR"CO 2 Ra, -NR"CONRbRc, -NRbC(NRc)NRbR", -NRbC(NCN)NRbR*, and -NR"SO 2 R"), halo, cyano, nitro, oxo (as a substitutent for cycloalkyl, heterocycloalkyl, and heteroaryl), optionally substituted acyl (such as -COR ), optionally substituted alkoxycarbonyl (such as
-CO
2 Rb), aminocarbonyl (such as -CONRbR"), -OCORb, -OCO 2 R, -OCONRbR", -OCONRbRc, -OP(O)(ORb)ORc, sulfanyl (such as SRb), sulfinyl (such as -SORa), and sulfonyl (such as -SO 2 Ra and -SO 2 NRbRe), where R" is chosen from optionally substituted C 1
-C
0 alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl, and optionally substituted h'eteroaryl; 8 R is chosen from H, optionally substituted CrCs alkyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, and optionally substituted heteroaryl; and R4 is independently chosen from hydrogen and optionally substituted C-C 4 alkyl; or Rb and RC, and the nitrogen to which they are attached, form an optionally substituted heterocycloalkyl group; and where each optionally substituted group is unsubstituted or independently substituted with one or more, such as one, two, or three, substituents independently selected from C 1
-C
4 alkyl, aryl, heteroaryl, aryl-C 1
-C
4 alkyl-, heteroaryl-Cj-C 4 alkyl-,
C-C
4 haloalkyl, -OC-C 4 alkyl, -OC-C4 alkylphenyl, -Cj-C4 alkyl-OH, -OC-C4 haloalkyl, halo, -OH, -NH 2 , -C-C4 alkyl-NH 2 , -N(C-C 4 alkyl)(CI-C 4 alkyl), -NH(CI-C 4 alkyl),
-N(CI-C
4 alkyl)(CI-C 4 alkylphenyl), -NH(Cl-C 4 alkylphenyl), cyano, nitro, oxo (as a substitutent for cycloalkyl, heterocycloalkyl, or heteroaryl), -CO 2 H, -C(O)OCrC4 alkyl,
-CON(CI-C
4 alkyl)(CI-C 4 alkyl), -CONH(C-C 4 alkyl), -CONH2, -NHC(O)(Cj-C 4 alkyl), -NHC(O)(phenyl), -N(CrC4 alkyl)C(O)(C-C4 alkyl), -N(C,-C 4 alkyl)C(O)(phenyl), -C(O)C rC4 alkyl, -C(O)CC4 alkylphenyl, -C(O)C 1
-C
4 haloalkyl, -OC(O)C-C 4 alkyl, S2(CI-C 4 alkyl), -SO 2 (phenyl), -SO 2 (Cl-C 4 haloalkyl), -SO 2
NH
2 , -SO 2
NH(CI-C
4 alkyl),
-SO
2 NH(phenyl), -N HSO 2
(C-C
4 alkyl), -NHSO 2 (phenyl), and -NHSO 2
(C-C
4 haloalkyl). [025] In some embodiments, a substituted aikoxy group is "polyalkoxy" or -0 (optionally substituted alkylene)-(optionally substituted alkoxy), and includes groups such as -OCH 2
CH
2
OCH
3 , and residues of glycol ethers such as polyethyleneglycol, and
-O(CH
2
CH
2 O)xCH3, where x is an integer of 2-20, such as 2-10, and for example, 2-5. Another substituted alkoxy group is hydroxyalkoxy or -OCH 2
(CH
2 )yOH, where y is an integer of 1-10, such as 1-4. [026] The term "alkoxycarbonyl" refers to a group of the formula (alkoxy)(C=O) attached through the carbonyl carbon wherein the alkoxy group has the indicated number of carbon atoms. Thu's a CrCs alkoxycarbonyl group is an alkoxy group having from 1 to 6 carbon atoms attached through its oxygen to a carbonyl linker. "Lower alkoxycarbonyP' refers to an alkoxycarbonyl group wherein the alkoxy group is a lower alkoxy group. 9 [027] The term "substituted alkoxycarbonyl" refers to the group (substituted alkyl) O-C(O)- wherein the group is attached to the parent structure through the carbony functionality and wherein substituted refers to alkyl wherein one or more (such as up to 5, for example, up to 3) hydrogen atoms are replaced by a substituent independently chosen from: -R", -ORb, optionally substituted amino (including -NRCCORb, -NR"CO 2 R", -NR"CONRbR, -NRbC(NR")NRbR", -NRbC(NCN)NRbR", and -NR*SQ 2 R"), halo, cyano, nitro, oxo (as a substitutent for cycloalky, heterocycloakyl, and heteroaryl), optionally substituted acyl (such as -CORb), optionally substituted alkoxycarbonyl (such as
-CQ
2 Rb), aminocarbonyl (such as -CONRbR"), -OCORb, -OC0 2 R", -OCONRbR", -OCONRbR", -OP(O)(OR )ORc, sulfanyl (such as SRb), sulfinyl (such as -SOR), and sulfonyl (such as -SO 2 Ra and -SO 2 NRbR"), where Ra is chosen from optionally substituted C-Cs alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl, and optionally substituted heteroaryl; Rb is chosen from H, optionally substituted C 1
-C
5 alkyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, and optionally substituted heteroaryl; and Re is independently chosen from hydrogen and optionally substituted C-C4 alkyl; or Rb and R", and the nitrogen to which they are attached, form an optionally substituted heterocycloalkyl group; and where each optionally substituted group is unsubstituted or independently substituted with one or more, such as one, two, or three, substituents independently selected from CrC4 alkyl, aryl, heteroaryl, aryl-CI-C 4 alkyl-, heteroary-C-C 4 alkyl-,
C-C
4 haloalkyl, -OC-C 4 alkyl, -OC,-C 4 alkylphenyl, -C-C 4 alkyl-OH, -OC 1
-C
4 haloalkyl, halo, -OH, -NH 2 , -C-C 4 alkyl-NH 2 , -N(Cl-C 4 alkyl)(CI-C 4 alkyl), -NH(C-C 4 alkyl),
-N(C-C
4 alkyl)(C-C 4 alkylphenyl), -NH(0 1
-C
4 alkylphenyl), cyano, nitro, oxo (as a substitutent for cycloalky, heterocycloalkyl, or heteroaryl), -C02H, -C(O)OC-C 4 alkyl,
-CON(C-C
4 alkyl)(C-C 4 alkyl), -CONH(C-C 4 alkyl), -CONH2, -NHC(O)(CI-C 4 alkyl), -NH C(O)(phenyl), -N(C-C 4 alkyl)C(O)(CI-C 4 alkyl), -N(CI-C 4 alkyl)C(O)(phenyl), 10 -C(O)C-C4 alkyl, -C(O)CC-4 alkylphenyl, -C(O)CC 4 haloalkyl, -OC(0)C-C4 alkyl, SO2(CrC4 alkyl), -S0 2 (phenyl), -S0 2 (C -C4 haloalkyl), -SO 2
NH
2 , -SO 2
NH(C-C
4 alkyl),
-SO
2 NH(phenyl), -NHSO 2 (Cr 1
C
4 alkyl), -NHSO2(phenyl), and -NHSO 2 (CrC 4 haloalkyl). [028] "Acyl" refers to the groups H-C(O)-, (alkyl)-C(O)-, (aryl)-C(O)-, (heteroaryl) C(O)-, and (heterocycloalkyl)-C(O)-, wherein the group is attached to the parent structure through the carbonyl functionality, and wherein alkyl, aryl, heteroaryl, and heterocycloalkyl are optionally substituted as described herein. Examples include acetyl, benzoyl, propionyl, isobutyryl, t-butoxycarbonyl, benzyloxycarbonyl and the like. "Lower-acyl" refers to groups containing one to six carbons and "acyloxy" refers to the group O-acyl. [029] The term "amino" refers to the group -NH 2 . [030] The term "substituted amino" refers to the group -NHRd or -NRdRe wherein Rd is chosen from hydroxy, optionally substituted alkoxy, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted acyl, optionally substituted carbamimidoyl, aminocarbonyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted heterocycloalkyl, optionally substituted alkoxycarbonyl, sulfinyl and sulfonyl, and Re is chosen from optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, and optionally substituted heterocycloalkyl, and wherein substituted alkyl, cycloalkyl, aryl, heterocycloalkyl, and heteroaryl refer respectively to alkyl, cycloalkyl, aryl, heterocycloalkyl, and heteroaryl wherein one or more (such as up to 5, for example, up to 3) hydrogen atons are replaced by a substituent independently chosen from: -Ra, -ORb, optionally substituted amino (including -NR"CORb, -NR"C0 2 R", -NRCCONRbRC, -NRbC(NRC)NRbRc, -NRbC(NCN)NRbR", and -NR"SO 2 Ra), halo, cyano, nitro, oxo (as a substitutent for cycloalkyl, heterocycloalkyl, and heteroaryl), optionally substituted acyl (such as -COR ), optionally substituted alkoxycarbonyl (such as -C0 2 R b), aminocarbonyl (such as -CONRbR"), -OCORb, -OCO 2 Ra, -OCONRbR", -OCONRbRc, -OP(O)(OR)OR*, sulfanyl (such as SRb), sulfinyl (such as -SOR), and 11 sulfonyl (such as -SO 2 Ra and -SO 2 NRbR4), where R" is chosen from optionally substituted C-C 8 alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl, and optionally substituted heteroaryl; Rb is chosen from H, optionally substituted C,-C 6 alkyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, and optionally substituted heteroaryl; and
R
0 is independently chosen from hydrogen and optionally substituted C-C 4 alkyl; or Rb and Re, and the nitrogen to which they are attached, form an optionally substituted heterocycloalkyl group; and where each optionally substituted group is unsubstituted or independently substituted with one or more, such as one, two, or three, substituents independently selected from CrC 4 alkyl, aryl, heteroaryl, aryl-C1-C 4 alkyl-, heteroaryl-C-C 4 alkyl-, CrC4 haloalkyl, -OC-C 4 alkyl, -OC-C 4 alkylphenyl, -CrC 4 alkyl-OH, -OC-C 4 haloalkyl, halo, -OH, -NH 2 , -CrC4 alkyl-NH 2 , -N(C-C 4 alkyl)(C-C 4 alkyl), -NH(C-C 4 alkyl), -N(C-C 4 alkyl)(C-C 4 alkylphenyl), -NH(C1-C 4 alkylphenyl), cyano, nitro, oxo (as a substitutent for cycloalkyl, heterocycloalkyl, or heteroaryl),
-CO
2 H, -C(O)OC-C 4 alkyl, -CON(C-C 4 alkyl)(C-C 4 alkyl), -CONH(CI-C 4 alkyl),
-CONH
2 , -NHC(O)(C-C 4 alkyl), -NHC(O)(phenyl), -N(CI-C 4 alkyl)C(O)(C-C 4 alkyl), -N(CIrC4 alkyl)C(O)(phenyl), -C(O)C 1
-C
4 alkyl, -C(O)CI-C 4 alkylphenyl, -C(O)CI-C 4 haloalkyl, -OC(O)C-C 4 alkyl, -S02(CIC4 alkyl), -SO 2 (phenyl), -SO 2
(CI-C
4 haloalkyl), SO 2
NH
2 , -SO 2
NH(C-C
4 alkyl), -SO 2 NH(phenyl), -NHSO 2
(C
1
-C
4 alkyl), -NHSO 2 (phenyl), and -NHSO 2
(CI-C
4 haloalkyl); and wherein optionally substituted acyl, optionally substituted alkoxycarbonyl, sulfinyl and sulfonyl are as defined herein. [031] The term "substituted amino" also refers to N-oxides of the groups -NHRd, and NRdRd each as described above. N-oxides can be prepared by treatment of the corresponding amino group with, for example, hydrogen peroxide or m chloroperoxybenzoic acid. The person skilled in the art is familiar with reaction conditions for carrying out the N-oxidation. [032] The term "aminocarbonyl" refers to the group -CONRbRC, where Rb is chosen from H, optionally substituted Ci-Ce alkyl, optionally substituted cycloalkyl, optionally 12 substituted heterocycloalkyl, optionally substituted aryl, and optionally substituted heteroaryl; and R' is independently chosen from hydrogen and optionally substituted CI-C4 alkyl; or Rb and Rc taken together with the nitrogen to which they are bound, form an optionally substituted 5- to 7-membered nitrogen-containing heterocycloalkyl which optionally includes I or 2 additional heteroatoms selected from 0, N, and S in the heterocycloalkyl ring; where each substituted group is independently substituted with one or more substituents independently selected from CrC4 alkyl, aryl, heteroaryl, aryl-Cr-C 4 alkyl-, heteroaryl-C-C 4 alkyl-, C-C 4 haloalkyl, -OC 1
-C
4 alkyl, -OC-C 4 alkylphenyl, -CrC4 alkyl-OH, -OC-C 4 haloalkyl, halo, -OH, -NH 2 , -C 1
-C
4 alkyl-NH 2 , -N(C-C 4 alkyl)(C-C4 alkyl), -NH(C-C 4 alkyl), -N(CI-C 4 alkyl)(C-C 4 alkylphenyl), -NH(C-C 4 alkylphenyl), cyano, nitro, oxo (as a substitutent for cycloalkyl, heterocycloalkyl, or heteroaryl),
-CO
2 H, -C(O)OC-C4 alkyl, -CON(C-C 4 alkyl)(CI-C 4 alkyl), -CONH(C-C 4 alkyl),
-CONH
2 , -NHC(O)(C-C 4 alkyl), -NHC(O)(phenyl), -N(C-C 4 alkyl)C(O)(CrC 4 alkyl),
-N(C
1
-C
4 alkyl)C(O)(phenyl), -C(O)CI-C 4 alkyl, -C(O)C-C 4 alkylphenyl, -C(O)C-C 4 haloalkyl, -OC(O)C-C 4 alkyl, -SO 2
(C-C
4 alkyl), -SO2(phenyl), -S0 2 (CI-C4 haloalkyl), SO 2
NH
2 , -SO 2
NH(C
1
-C
4 alkyl), -SO 2 NH(phenyl), -NHSO 2
(C-C
4 alkyl), -NHSO2(phenyl), and -NHSO 2
(CI-C
4 haloalkyl). [033] "Aryl" encompasses: 6-membered carbocyclic aromatic rings, for example, benzene; bicyclic ring systems wherein at least one ring is carbocyclic and aromatic, for example, naphthalene, indane, and tetralin; and tricyclic ring systems wherein at least one ring is carbocyclic and aromatic, for example, fluorene. [034] For example, aryl includes 6-membered carbocyclic aromatic rings fused to a 5- to 7-membered heterocycloalkyl ring containing 1 or more heteroatoms chosen from N, 0, and S. For such fused, bicyclic ring systems wherein only one of the rings is a carbocyclic aromatic ring, the point of attachment may be at the carbocyclic aromatic ring or the heterocycloalkyl ring. Bivalent radicals formed from substituted benzene 13 derivatives and having the free valences at ring atoms are named as substituted phenylene radicals. Bivalent radicals derived from univalent polycyclic hydrocarbon radicals whose names end in "-yl" by removal of one hydrogen atom from the carbon atom with the free valence are named by adding "-idene" to the name of the corresponding univalent radical, e.g., a naphthyl group with two points of attachment is termed naphthylidene. Aryl, however, does not encompass or overlap in any way with heteroaryl, separately defined below. Hence, if one or more carbocyclic aromatic rings is fused with a heterocycloalkyl aromatic ring, the resulting ring system is heteroaryl, not aryl, as defined herein. [0353 "Aralkoxy" refers to the group -0-arakyl. Similary, "heteroaralkoxy" refers to the group -0-heteroaralkyl; "aryloxy" refers to -0-aryl; and "heteroaryloxy" refers to the group -0-heteroaryl. [0361 "Aralkyl" refers to a residue in which an aryl moiety is attached to the parent structure via an alkyl residue. Examples include benzyl, phenethyl, phenylvinyl, phenylallyl and the like. "Heteroaralkyl" refers to a residue in which a heteroaryl moiety is attached to the parent structure via an alkyl residue. Examples include furanylmethyl, pyridinylmethyl, pyrimidinylethyl and the like. [037J "Halogen" or "halo" refers to fluorine, chlorine, bromine or iodine. Dihaloaryl, dihaloalkyl, trihaloaryl etc. refer to aryl and alkyl substituted with a plurality of halogens, but not necessarily a plurality of the same halogen; thus 4-chloro-3-fluorophenyl is within the scope of dihaloaryl. [038] "Heteroaryl" encompasses: 5- to 7-membered aromatic, monocyclic rings containing one or more, for example, from I to 4, or in certain embodiments, from 1 to 3, heteroatoms chosen from N, 0, and S, with the remaining ring atoms being carbon; bicyclic heterocycloalkyl rings containing one or more, for example, from 1 to 4, or in certain embodiments, from 1 to 3, heteroatoms chosen from N, 0, and S, with the remaining ring atoms being carbon and wherein at least one heteroatom is present in an aromatic ring; and tricyclic heterocycloalkyl rings containing one or more, for example, from 1 to 5, or in certain embodiments, from 1 to 4, heteroatoms chosen from N, 0, and S, with 14 the remaining ring atoms being carbon and wherein at least one heteroatom is present in an aromatic ring. [039] For example, heteroaryl includes a 5- to 7-membered heterocycloalkyl, aromatic ring fused to a 5- to 7-membered cycloalkyl or heterocycloalkyl ring. For such fused, bicyclic heteroaryl ring systems wherein only one of the rings contains one or more heteroatoms, the point of attachment may be at either ring. When the total number of S and 0 atoms in the heteroaryl group exceeds 1, those heteroatoms are not adjacent to one another. In certain embodiments, the total number of S and 0 atoms in the heteroaryl group is not more than 2. In certain embodiments, the total number of S and 0 atoms in the aromatic heterocycle is not more than 1. Examples of heteroaryl groups include, but are not limited to, (as numbered from the linkage position assigned priority 1), 2-pyridyl, 3-pyridyl, 4-pyridyl, 2,3-pyrazinyl, 3,4-pyrazinyl, 2,4-pyrimidinyl, 3,5 pyrimidinyl, 2,3-pyrazolinyl, 2,4-imidazolinyl, isoxazolinyl, oxazolinyl, thiazolinyl, thiadiazolinyl, tetrazolyl, thienyl, benzothiophenyl, furanyl, benzofuranyl, benzoimidazolinyl, indolinyl, pyridazinyl, triazolyl, quinolinyl, pyrazolyl, and 5,6,7,8 tetrahydroisoquinolinyl. Bivalent radicals derived from univalent heteroaryl radicals whose names end in "-yl" by removal of one hydrogen atom from the atom with the free valence are named by adding "-idene" to the name of the corresponding univalent radical, e.g., a pyridyl group with two points of attachment is a pyridylidene. Heteroaryl does not encompass or overlap with aryl, cycloalkyl, or heterocycloalkyl, as defined herein [040] Substituted heteroaryl also includes ring systems substituted with one or more oxide (-0) substituents, such as pyridinyl N-oxides. [041] By "heterocycloalkyl" is meant a single, non-aromatic ring, usually with 3 to 7 ring atoms, containing at least 2 carbon atoms in addition to 1-3 heteroatoms independently selected from oxygen, sulfur, and nitrogen, as well as combinations comprising at least one of the foregoing heteroatoms. The ring may be saturated or have one or more carbon-carbon double bonds. Suitable heterocycloalkyl groups include, for example (as numbered from the linkage position assigned priority 1), 2 pyrrolidinyl, 2,4-imidazolidinyl, 2,3-pyrazolidinyl, 2-piperidyl, 3-piperidyl, 4-piperidyl, and 2,5-piperizinyl. Morpholinyl groups are also contemplated, including 2-morpholinyl and 15 3-morpholinyl (numbered wherein the oxygen is assigned priority 1). Substituted heterocycloalkyl also includes ring systems substituted with one or more oxo (=0) or oxide (-0') substituents, such as piperidinyl N-oxide, morpholinyl-N-oxide, 1-oxo-1 thiomorpholinyl and 1,1-dioxo-1-thiomorpholinyl. [042] "Heterocycloalkyl" also includes bicyclic ring systems wherein one non aromatic ring, usually with 3 to 7 ring atoms, contains at least 2 carbon atoms in addition to 1-3 heteroatoms independently selected from oxygen, sulfur, and nitrogen, as well as combinations comprising at least one of the foregoing heteroatoms; and the other ring, usually with 3 to 7 ring atoms, optionally contains 1-3 heteratoms independently selected from oxygen, sulfur, and nitrogen and is not aromatic. [043] "Isomers" are different compounds that have the same molecular formula. "Stereoisomers" are isomers that differ only in the way the atoms are arranged in space. "Enantiomers" are a pair of stereolsomers that are non-superimposable mirror images of each other. A 1:1 mixture of a pair of enantiomers is a racemicc" mixture. The term "(.±.)" is used to designate a racemic mixture where appropriate. "Diastereoisomers" are stereolsomers that have at least two asymmetric atoms, but which are not mirror-images of each other. The absolute stereochemistry is specified according to the Cahn-Ingold-Prelog R-S system. When a compound is a pure enantiomer the stereochemistry at each chiral carbon can be specified by either R or S. Resolved compounds whose absolute configuration is unknown can be designated (+) or (-) depending on the direction (dextro- or levorotatory) which they rotate plane polarized light at the wavelength of the sodium D line. Certain of the compounds described herein contain one or more asymmetric centers and can thus give rise to enantiomers, diastereomers, and other stereoisomeric forms that can be defined, in terms of absolute stereochemistry, as (R)- or (S)-. The present invention is meant to include all such possible isomers, including racemic mixtures, optically pure forms and intermediate mixtures. Optically active (R)- and (S)- isomers can be prepared using chiral synthons or chiral reagents, or resolved using conventional techniques. When the compounds described herein contain olefinic double bonds or other centers of geometric asymmetry, and unless specified otherwise, it is intended that the compounds include both E and Z geometric isomers. 16 [044] "Tautomers" are structurally distinct isomers that interconvert by tautomerization. "Tautomerization" is a form of isomerization and includes prototropic or proton-shift tautomerization, which is considered a subset of acid-base chemistry. "Prototropic tautomerization" or "proton-shift tautomerization" involves the migration of a proton accompanied by changes in bond order, often the interchange of a single bond with an adjacent double bond. Where tautomerization is possible (e.g. in solution), a chemical equilibrium of tautorners can be reached. An example of tautomerization is keto-enol tautomerization. A specific example of keto-enol tautomerization is the interconverision of pentane-2,4-dione and 4-hydroxypent-3-en-2-one tautomers. Another example of tautomerization is phenol-keto tautomerization. A specific example of phenol-keto tautomerization is the interconverision of pyridin-4-ol and pyridin-4(1H) one tautomers. Compounds of Formula I and compounds of Formula I are tautomeric. [045] A leaving group or atom is any group or atom that will, under the reaction conditions, cleave from the starting material, thus promoting reaction at a specified site. Suitable examples of such groups unless otherwise specified are halogen atoms, mesyloxy, p-nitrobenzensulphonyloxy and tosyloxy groups. [046] The term "pharmaceutically acceptable carrier" or "pharmaceutically acceptable excipient" includes any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents and the like. The use of such media and agents for pharmaceutically active substances is well known in the art, Except insofar as any conventional media or agent is incompatible with the active ingredient, its use in the therapeutic compositions is contemplated. Supplementary active ingredients can also be incorporated into the compositions. [0471 Protecting group has the meaning conventionally associated with it in organic synthesis, i.e. a group that selectively blocks one or more reactive sites in a multifunctional compound such that a chemical reaction can be carried out selectively on another unprotected reactive site and such that the group can readily be removed after the selective reaction is complete. A variety of protecting groups are disclosed, for example, in T.H. Greene and P. G. M. Wuts, Protective Groups in Organic Synthesis, Third Edition, John Wiley & Sons, New York (1999). For example, a hydroxy protected form is where at least one of the hydroxy groups present in a compound is protected 17 with a hydroxy protecting group. Likewise, amines and other reactive groups may similarly be protected. [048] The term "pharmaceutically acceptable salf refers to salts that retain the biological effectiveness and properties of the compounds described herein and, which are not biologically or otherwise undesirable. In many cases, the compounds described herein are capable of forming acid and/or base salts by virtue of the presence of amino and/or carboxyl groups or groups similar thereto. Pharmaceutically acceptable acid addition salts can be formed with inorganic acids and organic acids. Inorganic acids from which salts can be derived include, for example, hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like. Organic acids from which salts can be derived include, for example, acetic acid, propionic acid, glycolic acid, pyruvic acid, oxalic acid, maleic acid, malonic acid, succinic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, salicylic acid, and the like. Pharmaceutically acceptable base addition salts can be formed with inorganic and organic bases Inorganic bases from which salts can be derived include, for example, sodium, potassium, lithium, ammonium, calcium, magnesium, iron, zinc, copper, manganese, aluminum, and the like. Organic bases from which salts can be derived include, for example, primary, secondary, and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines, basic ion exchange resins, and the like, specifically such as isopropylamine, trimethylamine, diethylamine, triethylamine, tripropylamine, and ethanolamine, In some embodiments, the pharmaceutically acceptable base addition salt is chosen from ammonium, potassium, sodium, calcium, and magnesium salts. [049} The term "solvate" refers to a compound (e.g., a compound selected from Formula I and Formula 11, or a pharmaceutically acceptable salt thereof) in physical association with one or more molecules of a pharmaceutically acceptable solvent. It will be understood that "a compound of Formula I" and "a compound of Formula 11" encompass the compound of Formula I and the compound of Formula 11, and solvates of those compounds, as well as mixtures thereof. [050] The terms "substituted" alkyl, cycloalkyl, aryl, heterocycloalkyl, and 18 heteroaryl, unless otherwise expressly defined, refer respectively to alkyl, cycloalkyl, aryl, heterocycloalkyl, and heteroaryl wherein one or more (such as up to 5, for example, up to 3) hydrogen atoms are replaced by a substituent independently chosen from: -R, -ORb, optionally substituted amino (including -NROCORb, -NR"O 0 2 R, -NRcCONRbRG, -NRbC(NR)NIRbR", -NRbC(NCN)NRbR4, and -NR"SO 2 R), halo, cyano, nitro, oxo (as a substitutent for cycloalkyl, heterocycloalkyl, and heteroaryl), optionally substituted acyl (such as -CORb), optionally substituted alkoxycarbonyl (such as
-CO
2 Rb), aminocarbonyl (such as -CONRbR*), -OCORb, -OC0 2 R", -OCONRbR4, -OCONRbRC, -OP(O)(ORb)OR', sulfanyl (such as SR"), sulfinyl (such as -OR"), and sulfonyl (such as -SO 2 Ra and -SO 2 NRbRc), where R' is chosen from optionally substituted C 1
-C
6 alkyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl, and optionally substituted heteroaryl; Rb is chosen from hydrogen, optionally substituted C 1 -Cr alkyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, and optionally substituted heteroaryl; and RC is independently chosen from hydrogen and optionally substituted C-C4 alkyl; or Rb and R 0 , and the nitrogen to which they are attached, form an optionally substituted heterocycloalkyl group; and where each optionally substituted group is unsubstituted or independently substituted with one or more, such as one, two, or three, substituents independently selected from C 1
-C
4 alkyl, aryl, heteroaryl, aryl-C1-C4 alkyl-, heteroaryl-C-C 4 alkyl-,
C-C
4 haloalkyl, -OC-C 4 alkyl, -OC1-C4 alkylphenyl, -CI-C 4 alkyl-OH, -OC-C4 haloalkyl, halo, -OH, -NH 2 , -C1C4 alkyl-NH 2 , -N(Cj-C 4 alkyl)(C-C 4 alkyl), -NH(CI-C 4 alkyl),
-N(C-C
4 alkyl)(CI-C 4 alkylphenyl), -NH(Cr 1
C
4 alkylphenyl), cyano, nitro, oxo (as a substitutent for cycloalkyl or heterocycloalkyl), -CO 2 H, -C(O)OC-C 4 alkyl, -CON(C,-C 4 19 alkyl)(C 1
-C
4 alkyl), -CONH(C-C 4 alkyl), -CONH 2 , -NHC(O)(C-C 4 alkyl), -NHC(O)(phenyl), -N(CI-C 4 alkyl)C(O)(C-C 4 alkyl), -N(C-C 4 alkyl)C(O)(phenyl), -C(O)CrC4 alkyl, -C(O)CrC4 alkylphenyl, -C(O)CrC4 haloalkyl, -OC(O)C-C 4 alkyl, S0 2
(CC
4 alkyl), -SO2(phenyl), -S0 2 (Ct-C 4 haloalkyl), -SO 2
NH
2 , -SO 2 NH(Cr-C 4 alkyl),
-SO
2 NH(phenyl), -NHSO 2 (Cr 1
C
4 alkyl), -NHSO 2 (phenyl), and -NHSQ 2 (Cl-C 4 haloalkyl). [051] The term "sulfanyl" refers to the groups: -S-(optionally substituted alkyl), -S (optionally substituted cycloalkyl), -S-(optionally substituted aryl), -S-(optionally substituted heteroaryl), and -S-(optionally substituted heterocycloalkyl). [052J The term "sulfinyl" refers to the groups: -S(O)-H, -S(O)-(optionally substituted alkyl), -S(O)-(optionally substituted cycloalkyl), -S(O)-(optionally substituted amino), S(O)-(optionally substituted aryl), -S(O)-(optionally substituted heteroaryl), and -S(O) (optionally substituted heterocycloalkyl). [053] The term "sulfonyl" refers to the groups: -S(0 2 )-H, -S(0 2 )-(optionally substituted alkyl), -S(0 2 )-(optionally substituted cycloalkyl), -S(02)-(optionally substituted amino), -S(02)-(optionally substituted aryl), -S(0 2 )-(optionally substituted heteroaryl), and -S(0 2 )-(optionally substituted heterocycloalkyl). [054] The term "therapeutically effective amount" or "effective amount" refers to that amount of a compound selected from Formula I and Formula It that is sufficient to effect treatment, as defined below, when administered to a mammal in need of such treatment. The therapeutically effective amount will vary depending upon the subject and disease condition being treated, the weight and age of the subject, the severity of the disease condition, the particular compound selected from Formula I and Formula 11, the dosing regimen to be followed, timing of administration, the manner of administration and the like, all of which can readily be determined by one of ordinary skill in the art. [055] "ATPase" refers to an enzyme that hydrolyzes ATP. ATPases include proteins comprising molecular motors such as the myosins. [056] As used herein, "frailty" is a syndrome characterized by meeting three of the of the following five attributes: unintentional weight loss, muscle weakness, slow walking speed, exhaustion, and low physical activity. [057] As used herein, "cachexia" means a metabolic defect often associated with 20 cancer that is characterized by progressive weight loss due to the deletion of adipose tissue and skeletal muscle. [058] As used herein, "muscle spasm" means an involuntary contraction of a muscle. Muscle spasms may lead to cramps. [059] As used herein, "post-surgical muscle weakness" refers to a reduction in the strength of one or more muscles following surgical procedure. Weakness may be generalized (i.e. total body weakness) or localized to a specific area, side of the body, limb, or muscle. [060] As used herein, "post-traumatic muscle weakness" refers to a reduction in the strength of one or more muscles following a traumatic episode (e.g. bodily injury). Weakness may be generalized (i.e. total body weakness) or localized to a specific area, side of the body, limb, or muscle. [061] As used herein, "neuromuscular disease" means any disease that affects any part of the nerve and muscle. Neuromuscular disease encompasses critical illness polyneuropathy, prolonged neuromuscular blockade, acute myopathy as well as acute inflammatory demyelinating polyradiculoneuropathy, amyotrophic lateral sclerosis (ALS), autonomic neuropathy, Charcot-Marie-Tooth disease and other hereditary motor and sensory neuropathies, chronic inflammatory demyelinating polyradiculoneuropathy, dermatomyositis/polymyositis, diabetic neuropathy, dystrophi nopathies, endocrine myopathies, focal muscular atrophies, hemifacial spasm, hereditary neuropathies of the Charcot-Marie-Tooth disease type, inclusion body myositis, Kennedy disease, Lambert Eaton myasthenic syndrome, muscular dystrophy (e.g., limb-girdle, Duchenne, Becker, myotonic, facioscapulohumeral, etc.), metabolic myopathies, metabolic neuropathy, multifocal motor neuropathy with conduction blocks, myasthenia gravis, neuropathy of Friedreich Ataxia, neuropathy of leprosy, nutritional neuropathy, periodic paralyses, primary lateral sclerosis, restrictive lung disease, sarcoidosis and neuropathy, Schwartz-Jampel Syndrome, spinal muscle atrophy, stiff person syndrome, thyroid disease, traumatic peripheral nerve lesions, vasculitic neuropathy, among others. [062] As used herein "obesity" means having a body mass index (BMI) greater than or equal to 30 kg/M 2 . BMI is defined as weight (kg) divided by height (M). Obesity encompasses hyperplastic obesity, an increase in the number of fat cells, and 21 hypertrophic obesity, an increase in the size of the fat cells. Overweight is defined as having a BMI from 25 up to 30 kg/m 2 ; obesity as a BMI greater than or equal to 30 kg/m 2 , as stated above, and severe (or morbid) obesity Is defined as a BMI greater than or quality to 40 kg/m 2 . [063] As used herein, "sarcopenia" means a loss of skeletal muscle mass, quality, and strength. Often sarcopenia is attributed to ageing, but is also associated with HIV infection. Sarcopenia may lead to frailty, for example, in the elderly. [064] As used herein, "wasting syndrome" means a condition characterized by involuntary weight loss associated with chronic fever and diarrhea. In some instances, patients with wasting syndrome lose 10% of baseline body weight within one month. [065] Compounds of Formula I and compounds of Formula i also include crystalline and amorphous forms of those compounds, including, for example, polymorphs, pseudopolymorphs, solvates, hydrates, unsolvated polymorphs (including anhydrates), conformational polymorphs, and amorphous forms of the compounds, as well as mixtures thereof. "Crystalline form," "polymorph," and "novel form" may be used interchangeably herein, and are meant to include all crystalline and amorphous forms of the compound, including, for example, polymorphs, pseudopolymorphs, solvates, hydrates, unsolvated polymorphs (including anhydrates), conformational polymorphs, and amorphous forms, as well as mixtures thereof, unless a particular crystalline or amorphous form is referred to. [086] Chemical entities include, but are not limited to, compounds of Formula I, compounds of Formula 11, and all pharmaceutically acceptable forms thereof. Pharmaceutically acceptable forms of the compounds recited herein include pharmaceutically acceptable salts, chelates, non-covalent complexes, prodrugs, and mixtures thereof. In certain embodiments, the compounds described herein are in the form of pharmaceutically acceptable salts. Hence, the terms "chemical entity" and "chemical entities" also encompass pharmaceutically acceptable salts, chelates, non covalent complexes, prodrugs, and mixtures. [067] "Pharmaceutically acceptable salts" include, but are not limited to salts with inorganic acids, such as hydrochlorate, phosphate, diphosphate, hydrobromate, sulfate, sulfinate, nitrate, and like salts; as well as salts with an organic acid, such as malate, 22 maleate, fumarate, tartrate, succinate, citrate, acetate, lactate, methanesulfonate, p toluenesulfonate, 2-hydroxyethylsulfonate, benzoate, salicylate, stearate, and alkanoate such as acetate, HOOC-(CH 2 )n-COOH where n ranges from 0 to 4, and like salts. Similarly, pharmaceutically acceptable cations include, but are not limited to sodium, potassium, calcium, aluminum, lithium, and ammonium. [068] In addition, if the compound of Formula I or the compound of Formula 11 is obtained as an acid addition salt, the free base can be obtained by basifying a solution of the acid salt. Conversely, if the product is a free base, an addition salt, particularly a pharmaceutically acceptable addition salt, may be produced by dissolving the free base in a suitable organic solvent and treating the solution with an acid, in accordance with conventional procedures for preparing acid addition salts from base compounds. Those skilled in the art will recognize various synthetic methodologies that may be used to prepare non-toxic pharmaceutically acceptable addition salts. [069) As noted above, prodrugs also fall within the scope of chemical entities, for example, ester or amide derivatives of the compounds selected from Formula I and Formula II. The term "prodrug" includes any compound that becomes a compound of Formula I or a compound of Formula 11 when administered to a patient, e.g., upon metabolic processing of the prodrug. Examples of prodrugs include, but are not limited to, acetate, formate, benzoate, and like derivatives of functional groups (such as alcohol or amine groups) in the compounds selected from Formula I and Formula I1. [070] The term "chelate" refers to the chemical entity formed by the coordination of a compound to a metal ion at two (or more) points. [071] The term "non-covalent complex" refers to the chemical entity formed by the interaction of a compound and another molecule wherein a covalent bond is not formed between the compound and the molecule. For example, complexation can occur through van der Waals interactions, hydrogen bonding, and electrostatic interactions (also called ionic bonding). [072] The term "active agent" is used to Indicate a chemical entity which has biological activity. In certain embodiments, an "active agent" is a compound having pharmaceutical utility. [073] The term "therapeutically effective amount" of a chemical entity means an 23 amount effective, when administered to a human or non-human patient, to treat a disease, e.g., a therapeutically effective amount may be an amount sufficient to treat a disease or disorder responsive to myosin activation. The therapeutically effective amount may be ascertained experimentally, for example by assaying blood concentration of the chemical entity, or theoretically, by calculating bioavailabilfty. [074 By "significant" is meant any detectable change that is statistically significant in a standard parametric test of statistical significance such as Student's T-test, where p < 0.05. [075] "Patient" refers to an animal, such as a mammal, for example a human, that has been or will be the object of treatment, observation or experiment. The methods described herein can be useful in both human therapy and veterinary applications. In some embodiments, the patient is a mammal, and in some embodiments, the patient is human. [076] "Treatment" or "treating" means any treatment of a disease in a patient, including: (a) preventing the disease, that is, causing the clinical symptoms of the disease not to develop; (b) inhibiting the disease; (c) slowing or arresting the development of clinical symptoms; and/or (d) relieving the disease, that is, causing the regression of clinical symptoms. [077] As used herein, "modulation" refers to a change in one or more of skeletal myosin, skeletal actin, skeletal tropomyosin, skeletal troponin C, skeletal troponin I, skeletal troponin T, and skeletal muscle, including fragments and isoforms thereof, as well as the skeletal sarcomere as a direct or indirect response to the presence of at least one chemical entity described herein, relative to the activity of the myosin or sarcomere in the absence of the compound. The change may be an increase in activity (potentiation) or a decrease in activity (inhibition), and may be due to the direct interaction of the compound with myosin or the sarcomere, or due to the interaction of the compound with one or more other factors that in turn effect one or more of skeletal myosin, skeletal actin, skeletal tropomyosin, skeletal troponin C, skeletal troponin I, skeletal troponin T, and skeletal muscle, including fragments and isoforms thereof, as 24 well as the skeletal sarcomere. [078] Provided is at least one chemical entity chosen from compounds of Formula I and compounds of Formula II: N N H \>NOH o RINRI N R2 R2 Formula I Formula Il and pharmaceutically acceptable salts thereof, wherein
R
1 and R 4 are independently selected from hydrogen, halo, hydroxy, optionally substituted acyl, optionally substituted alkyl, optionally substituted amino, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted heteroaryl, optionally substituted alkoxy, optionally substituted aminocarbonyl, sulfonyl, sulfanyl, sulfinyl, carboxy, optionally substituted alkoxycarbonyl, and cyano; and in the alternative, R4 and R 1 , taken together with any intervening atoms, form a fused ring system selected from optionally substituted fused aryl, optionally substituted fused heteroaryl, optionally substituted fused cycloalkyl, and optionally substituted fused heterocycloalkyl; and
R
2 is is selected from optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, and optionally substituted heterocycloalkyl; provided that
R
1 is not hex-I -eny; and further provided that the compound of Formula I or the compound of Formula 11 is not (S)-6-bromo-1-(1-phenylethyl)-1 H-imidazo[4,5-b]pyrazin-2(3H)-one; 1,5,6-trimethyl-I H-imidazo[4,5-bjpyrazin-2(3H)-one; 1 -methyl-iH-imidazo[4,5-b]pyrazin-2(3H)-one; 6-bromo-1 -(3-nitrobenzyl)-1 H-imidazo[4,5-bjpyrazin-2(3H)-one; 25 5-(hydroxymethyl)-1,6-dimethyl-IH-imidazo[4,5-b]pyrazin-2(3H)-one; or I -(piperidin-4-y)-1 H-imidazo[4,5-blpyrazin-2(3H)-one. [079] In some embodiments, R 2 is selected from optionally substituted lower alkyl, optionally substituted cycloalkyl, optionally substituted alkoxy, and optionally substituted heterocycloalkyl. [080] In some embodiments, R 2 is selected from heterocycloalkyl, cycloalkyl, lower alkyl, and lower alkyl substituted with optionally substituted phenyl, hydroxy, optionally substituted alkoxy, optionally substituted amino and optionally substituted heterocycioalkyl. [081] In some embodiments, R 2 Is selected from I-(R)-phenylethyl, 1-(S) phenylethyl, benzyl, 3-pentyl, 4-heptyl, 4-methyl-I-morpholinopentan-2-yl isobutyl, cyclohexyl, cyclopropyl, sec-butyl, tert-butyl, isopropyl, 1-hydroxybutan-2-yi, tetrahydro 2H-pyran-4-yI, 1-methoxybutan-2-yl, i-aminobutan-2-yl, and 1-morpholinobutan-2-yl. [082] In some embodiments, R 1 is selected from hydrogen, halo, acyl, optionally substituted lower alkyl, optionally substituted amino, optionally substituted pyrazolyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted lower alkoxy, and -S-(optidnally substituted lower alkyl). [083] In some embodiments, R 1 is selected from hydrogen, halo, acyl, optionally substituted lower alkyl, dialkylamino, amino substituted with an alkyl group and with a group chosen from acyl, aminocarbonyl, alkoxycarbonyl, and sulfonyl; optionally substituted pyrazolyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted lower alkoxy, and -S-(optionally substituted lower alkyl). [084] In some embodiments, R 1 is selected from hydrogen, halo, acyl, alkenyl, alkynyl, lower alkoxy, optionally substituted amino, pyrazolyl substituted with lower alkyl, -S-(optionally substituted lower alkyl), lower alkyl, and lower alkyl substituted with halo. [085] In some embodiments, R 1 is selected from hydrogen, halo, acyl, alkenyl, alkynyl, lower alkoxy, dialkylamino, amino substituted with an alkyl group and with a group chosen from acyl, aminocarbonyl, alkoxycarbonyl, and sulfonyl, pyrazolyl substituted with lower alkyl, -S-(optionally substituted lower alkyl), lower alkyi, and lower alkyl substituted with halo. [086] In some embodiments, R 1 is selected from hydrogen, bromo, chloro, fluoro, 26 methyl, ethyl, propyl, hexenyl, butenyl, propenyl, vinyl, ethynyl, methoxy, ethoxy, methylsulfanyl, dimethylamino, and methyl substituted with up to three fluoro groups. [087] In some embodiments, R 1 is selected from hydrogen, bromo, chloro, fluoro, methyl, ethyl, n-propyl, isopropyl, dimethylamino, isobuten-1-yl, (Z)-propen-1-yl, (E) propen-1-yl, propen-2-yl, vinyl, ethynyl, methoxy, ethoxy, rnethylsulfanyl, and trifluoromethyl. [088] In some embodiments, R 4 Is selected from hydrogen, halo, acyl, optionally substituted alkyl, alkenyl, optionally substituted cycloalkyl, optionally substituted aminocarbonyl, sulfanyl, optionally substituted amino, and optionally substituted alkoxycarbonyl. [0891 In some embodiments, R 4 is selected from hydrogen, halo, acy, optionally substituted lower alkyl, lower alkenyl, optionally substituted cycloalkyl, optionally substituted aminocarbonyl, sulfany, optionally substituted amino, and optionally substituted lower alkoxycarbonyl. [090] In some embodiments, R4 is selected from hydrogen, halo, acyl, lower alkyl, lower alkenyl, cycloalkyl, optionally substituted aminocarbonyl, sulfanyl, and lower alkoxycarbonyl. [091] In some embodiments, R 4 is selected from hydrogen, bromo, chloro, fluoro, acetyl, methyl, ethyl, vinyl, cyclohexen-1-yl, methylcarbamoyl, dimethylcarbamoyl, methylsulfanyl, and methoxycarbonyl. [092] In some embodiments, R 4 is hydrogen. [093] In some embodiments, R 4 and R1, taken together with any intervening atoms, form a fused ring system selected from optionally substituted fused aryl, optionally substituted fused cycloalkyl, and optionally substituted fused heterocycloalkyl. [0943 In some embodiments, R 4 and R 1 are taken together to form an optionally substituted benzo group. [095] In some embodiments, 114 and R 1 are taken together to form a benzo group. [096] In some embodiments, the compound of Formula I is chosen from 1-((1R)-1-methyl-2-morpholin-4-ylethyl)-6-bromoimidazo[4,5-b]pyrazin-2-ol; 1-(ethylpropyl)-6-ethynylimidazo[4,5-blpyrazin-2-ol; I -(ethylpropyl)-6-methoxyimidazo[4,5-b]pyrazin-2-ol; 27 I -(I, I -dimethyl-2-mor-pholin-4-ylethyl)-6-bromoimidaza[4, 5-bjpyrazin-24o; 6-(lI H-i ,2, 3-triazolA4-yl)-1 -(ethylpropyl)iniidazoI4,5-blpyrazin-2-ol;, I -(ethylpropyt)-6-(trifluoromethy)imidazo[4,-blpyrain-2-O; 1 -[(1 R)-1 -(morpholin-4-ylmethyl)propyl-6-ethynylrnidazo[45-b]pyrazin-2o; 1 -(ethylp ropyl)-6-12-f1 -(ethylpropyl)-2-hydroxyimidezo[4,5-ejpyrazin-6 yljethynyllimidazo[4, 5-b]pyrazin-2-o; 6-(dimethylamirio)-I -(ethylpropyl)imidazof4, 5-bjpyrazin-2-oI; 6-ethyl-i -(ethylpropyl)imidazo[4,5-bjpyrazin-2-o; (E)- I -(pentan-3-yI)-6-(prop-1 -enyl)- I H-imidazo(4 1 5-b]pyrazin-2-oI; (E)-l -cyclohexyl-6-(prop-1 -any!)- I H-Tmidazo[4,5-b]pyrazin-2-oI; (E)-I -cyclopropyl-6-(p rep-I -enyl)-I H-inidaroi4, 5-hpyrazin-2-ol; (E)-1 -isopropyl-6-(prop-I -enyl)-1 H-imidazo[4.5-b]pyrazin-2-oI; (E)-6-(prop-I -enyl)-1 -(tetrahyd ro-2H-pyrari-4-yI)-1 IH--imid azo[4,5-bjpyrazin-2 01; (R)-6-(methylthio)-1 -(1 -phenylethyl)-1 L-imidaro[4, 5-b]pyrazin-2-ol; (R)-6-brormo-I -(I -hyd roxybutan-2-y)-1 H-imldaro[4,5-b]pyrazin-2-o; (R)-6-bromo-1 -(l -morpholinobutan-2-yi)- I --imidazo[4, 5-bjfpyrazin-2-oI; (R)-6-bromo-I -(1 -morph olinopropan-2-yl)-1 H--imid azo[4, 5-blpyrazin-2-oI; (R)-6-bromo-1 -(I -phenylethyl)-I H-imidazo[4, 5-b~pyrazin-2-ol; (R)-6-bromo-l -sec-butyl-1 H-imidazo[4,5-bjpyr-azin-2-ol; (S)-(2-hydroxy-1 -(1 -phenylethyl)-I H-imid azo[4 1 5-b]pyrazin-6-yl)(4 methylpiperazin-I -yl)methanone; (S)-(2-hydroxy-I -(I -phenylethyl)- I H-imid azo[4?5-bjpyrazin-6 yI)(morpholino)mnethan one; (S)-(2-hyd rowy-I -(1 -phenylethyl)- I H-imidazo[4,5-bjpyrazin-6-yI)(piperidin-I yl)methanone; (5)-i -(I-phenylethyl)-1 H-imidazo[4, 5-b] pyrazin-2-oI; (S)-I -( I-phenylethyl)-1 H-iniidezo[4, 5-bjquinoxalln-2-ot; (5)-I -(1 -phenylethyl)-6-(piperidhn-1I-ylmethyl)- I H -imidazo[4, 5-b]pyrazin-2-ot; (S)-1 -(1-p henylethyl)-6-propyl-I H-imidazo[4, -bjpyrazin-2-ol;, (5)-i -(I -phenylethyl)-6-vinyl- 1 H-imnidazo[4, 5-bjpyrazin-2-oI; 28 (S)- I -(2-hydroxy-1 -(1 -phenylethyl)-1 H-imidazo(4,5-bjpyrazin-6-yI)ethanone; (S)-2-hydroxy-1 -(1 -phenylethyQ)-I H-imidazo[4, 5-b]pyrazirie-6-carbotrile; (S)-2-hyd rowy-I -(1 -p henylethyl)-1 H-imidazo(4, 5-bjpyrszine-6-csrboxamide; (S)-2-hydroxy-I -(1 -phenyethy)-1 H-Imldazo(4 5-bjpyrazine-6-carboxylic -acid; (S)-2-hydroxy-N, N-dimethyl-1 -(1 -phenylethyl)- I H-imid azo(4, 5-b~pyrazine-6 carboxanide; (S)-2-hydroxy-N-methyl- 1 -(1 -p henylethyl)-1 H-Imidazo[4 1 5-bjpyrazine-6 carboxarnide; (S)-6-((4-methylpiperazin-1 -yI)methyl)-i -(1 -phenylethyl)-1 H-imid azoj4 1 5 b~pyrazin-2-oI; (S)-6-((dimethylamino)mnethyl) -1-(1 -phenylethy 1)-l H-imidazo[4 1 5-b]pyrazirw2 0i; (S)-6-(2-hydroxypropan-2-yl)-1 -(1 -phenylethyl)-1 H-im idazol4r5-blpyrazin-2-o; (S)-6-(2-methylprop-1 -enyI)-1 -(I -phenylethy)-1 H-imidazo[4 1 5-b] pyrazin-2-oI; (S)-6-(methylsu Ifonyl)-I-( I-phe nyiethyi)-I H-imidazo[4 1 5-bjpyrazin-2-oI; (S)-6-(methylthio)-1 -(1 -phenylethyI}-i H-imidazo[4, 5-b]pyrazin-2-oi; (S)-B-(morpholi nomethyl)-I -(1 -phenylethy)-1 H-imidazo[4,5-blpyrazin-2-o; (S)-6-bromo-1 -(1 -hyd roxybutan-2-y)-1 H-imidazo[4,5-bjpyrazin-2-o; (S)-8-brom o-I -(I -morpholinobutan-2-yI)- I H-im~d azo!4, 5-bJpyrazin-2-ol; (S)-5-brorno-1 -(1 -morphollnopropan-2-yi)- I H-imidazol4,5-blpyrazin-2-o; (S)-6-bromo-I -(I -pheriylethyl)- I H-imidazo[4, 5-b]pyrazin-2-o; (S)-6-bromo-1 -sec-buty-1 H-imidazo[4 ,5-bjpyrazin-2-oI; (S}-6-cyclohexenyil--(1 -phenylethyl)-i H-imidazo[4,5-b]pyrazin-2-oI; (S)-6-cyclohexyl-1 -(1 -phenyiethyl)-i H-imidazo(4 .5-b]pyrazin-2-oI; (S)-6-ethoxy-1 -(1-p henylethyi)-I H-imidazo[4,5-bjpyraz-in-2-o; (S)-8-ethyI- 1 -(1 -phenylethyl)- 1 H-imidazo[4,5-bjpyrazin-2-o; (S)-6-hexyI-l1-(1 -phenylethyl)-1 H-imidazo[4,5-bjpyrazin-2-o;, (S)-6-Tsob utyl-I -( 1-phenylethyl)- 1 H-imidazo[4, 5-b]pyrazin-2-o; (S)-6-methoxy- 1 -(1 -phenylethyl)- H-imidazo(4,6-bjpyrazin-2-o; (S)-methyI 2-hydroxy-I -(1 -phenylethy)-1 H-imidaro[4, 5-blpyrazine-6 carboxylate; 29 (S)-N ,N-diethyl-2-hydraxy- 1 -(1 -phenylethyl)- I H-imidazo[4,5-b]pyrazine-6 carboxam ide; (S)-N-benzyl-2-hydraxy-1 -(1-ph enylethyl)-1 H-imnidazo[4,5-b]pyrezine-6 carboxarnide; (S, E)-1 -(1 -phenylethyl)-6-(prop-1 -enyl)-i H-imidezo[4, 5-bjpyrazln-2-o; (S,Z)-1 -(1 -phenytethyfl-6-(prop-1 -enyl)-1 H-imidazo(4, 5-bjpyrazin-2-al;, (S,Z)-6-(hex-2-enyl)-1 -(1 -phenylethyl)-1 H-imidazo[4 1 5-bjpyrazin-2-o;, (Z)-1 -(pentan-3-yI)-6-(prap-l1-enyl)-1 H-imidezo[4,5-b~pyrazir-2-aI; (Z)-1 -cyclohexyl-6-(p rap-I -enyl)-1 H-imldazc44, 5-bjpyrazin-2-ol; (Z)-1 -cyclopropyi-6-(prop-1 -enyl)-1I--imidezo[4,5-b~pyrazin-2-o; (Z)-l1-isapropyl-6-(prop-1 -enyl)-1 H-imidazol4,5-blpyrazin-2-aI; (Z)-6-(prop-1 -enyl)-1 -(tetrahydro-2H-pyran-4-yI)-1 H-Imidazo[4,5-bjpyrazin-2 ol; 1 -(1 -aminobutari-2-yi)-6-bromo-1 H-imidazo[4,5-h~pyrazin-2-aI; 1 -(l -marphalinabutan-2-yi)-1 H-imidazo(4,5-blpyrazin-2-al; 1-(2-hydroxy- I-(penten-3-yi)-1 H-imidazo[4, 5-bjpyrazin-5-yI)ethanone; 1 -(pentan-3-yI)-1 H-imidazoj4,5-b~pyrazin-2-ol; 1 -(pentan-3-yl)- I H-imidazo[4,5-blpyrazine-2 ,6-d Io; 1 -(pentan-3-yI)-1 H-imidazo[4, 5-b~quinoxalin-2-aI; 1 -(pentan-3-yI)-5-vinyl-i I1-imidazoj4,5-bjpyrazn-2-o; I -(pentan-3-yI)-6-(prop-1 -ynyl)-1 H-I1midazoj4,5-bjpyrazin-2-ol; 1 -(pentan-3-y)-6-(trifluoromethyl)-1 H-imidaza[4,5-bjpyrazin-2-o 1: 1 -benzyl-6-(methylthlo)-1 H-imidazoj4, 5-b]pyrazin-2-ol; 1 -benzyl-6-bromo-I H-im idaza j4, 5-bjpyrazin-2-o; 1 -cyclohexyl-6-Q'nethylth 10)-i H-imldazo[4,5-blpyrazin -2-al; 1 -cycloprapyl-6-(methylthio)-1 H-iniidazoj4, 5-bjpyrazin-2-aI; 1 -isopropyl-6-(methylth 10)-i H-imidazoj4,5-bjpyrazn-2-aI; 2-(6-bromo-2-hyd rowy-I H-imidazoj4,5-b]pyrazin-I -yl)- 1 -marpholinabutan-1 one; 2-(6-brama-2-hydraxy- IH-imidazaj4, 5-b]pyrazin-I -yl)butarioic acid; 2-(8-bromo-2-hyd roxy- 1 H-imidazo[4,5-b~pyrazin-I -yl)propane- 1,.3-dial; 30 2-hyd roxy- I -(penta n-3-y)- 1 H-i midsazo[4, 5-b]pyrazi ne-5-cerboxy lie acid; 2-hydro~xy-I-(pentan-3-yI)-I H-imida3zo[4,5-b]pyrazine-6-cerbonitile; 2-hyd row-N. N-dimethyl-i -(pentan-3-yi)-1 H-imldazo[4,5-bjpyrazlne-5 carboxamide; 2-hydroxy-N-methyl-i-(pentan-3-yI)-i H-imidazo[4,5-b]pyrazIne-5 carboxamide; 5-(methyhthio)-1 -(pentan-3-yI)-i H-lmidazo[4 ,5-b]pyrazin-2-oI; 5-bromo-I -(pentan-3-yI)-i H-irnidazo[4, 5-b jpyrazin-2-ol; 5-ethyl-i -(pentan-3-yI)-1 H-imidazo[4, 5-bjpyrazin-2-oI; 6-(methylsulfinyi)-1 -((S)-i -phenylethyl)-i H-Imidazo[4, 5-b] pyrazin-2-oi; 6-(methylthio)-1 -(pentan-3-yl)-1 t--imidazo[4, 5-b]pyrazin-2-o; 6-(methythio), i -(tetrahydro-21--pyran-4-yI)-i H-im idazoI4, 5-b]pyrazin-2-oI; 6-bromo-i -(1 -(4-(methylsulfonyl)piperazin-i -yI)butan-2-yl)-i H-imidazol4, 5 b]pyrazin-2-ol; 6-b romo- 1 -(1 -(4-methylpiperazin-1I-yl)buta n-2-yI)- I K-imidazo(4,5-blpyrazin-2 ol; 6-bromo-1 -(1 -(dimethylamino)butan-2-yI)-1 H-imidazo(4.5-bjpyrazin-2-oI; 6-bromo- 1 -( I-(methylarrino)butan-2-yl)-i H-imidazot4,5-blpyrazIn-2-oI; 6-bromo-1 -(1 -rethoxybutan-2-yl)-1 H-imidazof4, 5-blpyrazin-2-oI; 6-bromo- 1 -(2-methyl-i -morpholinopropan-2-yI)-1 H-Imidazo[4,5-b]pyrazin-2-o; 6-bromo-1 -(2-morpholinoethyl)-i H-imidazo[4 ,5-bjpyrazin-2-oi; 6-b romo- 1 -(pentan-3-yl)- 1 H-imidazo[4,5-b]pyrazn-2-oI; 6-bromo- I-(tetrahydro-2H-pyran-4-yI)-1 H-i mid azo[4,5-blpyrazi n-2-oI; 6-bromo- 1 -cyclohexyl- I k--iridazo[4, 5-b]pyrazin-2-o; 6-bromo- I -cyclopropyl-1 H-imidazof4 .5-blpyrazin-2-oI; 6-bromo- 1 -isopropyl- I H-imldazo[4,5-b]pyra zin-2-oI; 6-briomo-lI-tert-butyl-i H-imidazo[4,5-b]pyrazin-2-oI; 6-cyclopropyl-i -(pentan-3-y)-1 H-imidazol4. 5-bjpyrazin-2-ol; 6-ethynyl-i-(pentan-3-yI)-i H-imidazof4,5-blpyrazin-2-o; 6-methoxy- I-(pants n-3-yI)-1 H-imidazot4, 5-blpyrazin-2-ol; 6-methyl-i -(pentan-3-yQ)-i H-imidazoII4,5-b]pyrazin-2-ol; 31 methyl 2-hydroxy-1-(pentan-3-yl)-1H-imidazo[4,5-b]pyrazine-5-carboxylate; methyl 4-(2-(6-bromo-2-hydroxy-1H-imidazo[4,5-blpyrazin-1 yl)butyl)piperazine- 1 -carboxylate; 1 -(ethylpropyl)-6-(1 -methylpyrazol-4-yl)imidazo[4,5-b]pyrazin-2-ol; 6-bromo-1 -(propylbutyl)imidazo[4,5-b]pyrazin-2-ol; 1-[(1 R)-3-methyl-1-(morpholin-4-ylmethyl)butyl]-6-bromoimidazo(4,5 b]pyrazin-2-ol; 1-(ethylpropyl)-6-vinylimidazo[4,5-bjpyrazin-2-ol; 1-(ethylpropyl)-6-(1-methylvinyl)imidazo[4,5-b]pyrazin-2-ol; 1-(ethylpropyl)-6-(methylethyl)imidazo[4,5-blpyrazin-2-ol; 6-chloro-1 -(ethylpropyl)lmidazo[4,5-b]pyrazin-2-ol; and 6-(dimethylamino)-1-(ethylpropyl)imidazo[4,5-bjpyrazin-2-ol. [097] In some embodiments, the compound of Formula Il is chosen from the following tautomers of compounds of Formula I: (R)-6-bromo-1-(1-morpholinopropan-2-yl)-1H-imidazo[4,5-blpyrazin-2(3H) one; 6-ethynyl-1 -(pentan-3-yl)-1 H-imidazo[4,5-b]pyrazin-2(3H)-one; 6-methoxy-1 -(pentan-3-yl)-1 H-imidazo[4,5-bpyrazin-2(3H)-one; 6-bromo-1 -(2-methyl-1-morpholinopropan-2-yl)-1 H-imidazo[4,5-b]pyrazin 2(3H)-one; 1-(pentan-3-yl)-6-(1 H-1,2,3-triazol-4-yI)-1H-imidazo[4,5-bjpyrazin-2(3H)-one; 1-(pentan-3-yl)-6-(trifluoromethyl)-1 H-imidazo[4,5-b]pyrazin-2(3H)-one; (R)-6-ethynyl-1 -(1-morpholinobutan-2-y)-1 H-imidazo[4,5-b]pyrazin-2(3H) one; 6-((2-hydroxy-1 -(pentan-3-yl)-i H-imidazo[4,5-b]pyrazin-6-yl)ethyny)-1 (pentan-3-yl)-1 H-imidazo[4,5-b]pyrazin-2(3H)-one; 6-(dimethylamino)-1-(pentan-3-yl)-1 H-imidazo[4,5-bjpyrazin-2(3H)-one; 6-ethyl- 1 -(pentan-3-yl)-1 H-imidazo[4,5-bjpyrazin-2(3H)-one; (E)-1 -(pentan-3-yl)-6- (prop-1 -enyl)-1 H-imidazo[4,5-b]pyrazin-2(3H)-one; (E)-I1-cyclohexyl-6-(prop-1-enyl)-1 H-imidazo[4,5-b]pyrazin-2(3H)-one; (E)-1 -cyclopropyl-6-(prop-1-enyl)-I H-imidazo[4,5-bjpyrazin-2(3H)-one; 32 (E)-I -isopropyl-6-(prop-1 -enyQ)-1 N-irnidazo[4, 5-bjpyrazin-2(3H)-one; (E)-6-(prop- I -enyl)-1 -(tetrahydro-2H-pyran-4-yl)-1 H-imidazo[45-b)pyrazin 2(SH)-one; (R)-6-(methylthio)-1 -(1 -phenylethyl)-1 H-imidazo[4, 5-blpyrezin-2(SH)-one; (R)-6-bromo-1 -(l -hyd roxybutan-2-yi)-1 H-imidazo[4, 5-b]pyrazin-2(3H)-one; (R)-6-bromo-1 -(I -morpholinobuta n-2-yI)-1 H-imidazol4 ,5-blpyrazin-2(SH)-one; (R)-6-broino-I-(1 -morpholinoprop? n-2-yI)-1 H-imidazo[4 1 5-b~pyrazin-2(3H) one; (R)-6-bromo-1 1-Cl-phenylethyl)-1 H-imidazo[4, 5-b]pyrazin-2( 3H)-one; (R)-6-bromo-1 -sec-butyl-1 H-imidazo[4,5-b]pyrazin-2(SH)-one; (5)-I -(1 -phenyiethy)-1 H-im ida zo[4,5-bjpyrazin-2(3H)-one; (5)-i -(I -p henyl ethyl)- I H-imidazo[4 .5-b jquinoxalin-2(3H)-one; (S)-I -(1 -phenylethyl)-6-(piperldin-1 -ylmethyl)-i H-Imidazo[4,5-blpyrazin-2(3H) one; (S)-i -(l -pheriylethyl)-6-(piperidine- I -carbonyi)- I H-imidazo[4,5-b]pyrazin 2(3H)-one; (5)-i -(1 -phenylethyi)-6-propyl- 1 H-imidazo[4,5-b]pyrazin-2(3H)-one; (5)-i -(1-phenylethyl)-6-vinyl-l H-imidazo[4,5-b)pyrazin-2(3H)-one; (S)-2-oxo-3-( I-phenylethyl)-2, 3-dihyd ro-1 H-imidazo[4,5-bjpyrazine-5 carbonitrife; (S)-2-oxo-3-(l -phenylethyl)-2 ,3-d ihydro-I H-imidazo[4,5-bjpyrazine-5 carboxamide; (S)-2-oxo-3-( 1-phenylethyl)-2,3-d ihydro-1 H-imldazo[4,5-b]pyrazine-5 carboxylic acid,, (S)-6-((4-methylpiperazin-1 -yl)methyl)-i -(1 -phenylethyl)-1 H-imidazo[4,5 blpyrazin-2(3H)-one; (S)-6-((d imethylamino)methyl)-1 -(1 -phenyrethyl)-1 H-imidazo[4, 5-b]pyrazin 2(3H)-one; ($)-6-(2-h yd roxypropan-2-yl)-l1-(i-p henylethyl)-l H-imidazot4, 5-bjpyrazin 2(3H)-one; (S)-6-(2-methylprop-i -enyl)-i -(1 -phenylethyl)-1 H-im idazot4, 5-bjpyrazin 33 2(31-)-one; (S)-6-(4-methylpiperazine-1 -carbonyl)-1 -(l -phenylethyl)-1 H-imiciazo[4, 5 b~pyrazin-2 (3H)-one; (S)-6-(mnethylsulfonyl)-1 -(l -phenylethyl)-i H-Imiciazo[4,5-b]pyrazin-2(3H)-one; (S)-6-(methylthio)-1 -(1 -phenylethyl)-1 H-imidazof4,5-b]pyrazin-2(3-Q-one;, (S)-5-(rnorphoiine-4-oarbonyl)-1 -(1 -phenylethyl)-1 H-imtdazo[4,5-bjjpyrazin 2(3H-)-one; (S)-6-(morpholinomethyl)-1 -(1 -phenylethyl)-1 H-irnidazo[4, 5-blpyrazin-2(3H) one; (S)-6-acetyl-1 -(I -phenylethyl)-1 H-imidazo[4,5-b]pyrazin-2(3H)-one; (S)-6-b romo- 1 -(l -hydroxybutan-2-y)-1 H-imidazo[4,5-bjpyrazi n-2(3H)-one; (S)-6-bromo-1 -(1 -morpholinobutan-2-yi)-1 H-imidazo[4,5-bjpyrazin-2(3H)-ofle, (S)-6-bromo- 1 -(1 -morpholinop ropan-2-y)-1 H-imidazo(4 1 5-b]pyrazin-2(3H) one; (S)-6-b romo- 1-(1 -phenylethyQ-1 I--imidazo[4,5-bjpyrazin-2(SH)-one; (S)-6-bromo-1 -seo-buWIl-1 H-imidazo[4,5-b]pyrazin-2(3H)-one; (S)-6-oyolohexenyl- 1 -(I-p henylethyl)-1 H-imidazo[4 1 5-b]pyrazin-2(3H)-one; (S)-6-cyolohexyl-I -(1 -phenylethyl)-1 H-imidazo[4 ,5-bjpyrazin-2(3 H)-one; (S)-6-ethoxy-1 -(1 -phenylethyl)- I H-imidazo[4 1 5-b]pyrazin-2(3 H)-one; (S)-6-ethyl-1 -(1 -phenylethyl)-1 H-imidazo[4, 5-bjpyrazin-2(3H)-cne; (S)-6-hexyl-1 -(1 -phenylethyl)-1 H-imidezo[4,5-bjpyrazin-2(3H)-one; (S)-6-isobutyl-1 -(1 -phenylethyi)-i H-imidazo(4,5-bjpyrazin-2(3H)-one; (S)-6-rnethoxy-1 -(1 -pheny lethy l)-1 H-4imid azo[4, 5-blpyrazin-2 (3H)-on e; (S)-methyl 2-oxo-3-( I-phenylethyo-2, 3-dihydro-1 H-iridazo(4,5-b]pyrezine-5 carboxylate; (S)-N, N-dliethyl-2-oxo-3-(1 -phenylethyl)-2,3-dhydro- I H-imidazo[4, 5 bjpyrazine-5-carboxamide; (8)-N, N-d imethyl-2-oxo-3-(l1-phenylethyl)-2,3-dihydro-1 H-iniidazo[4 .5 bjpyrazine-5-carboxarnide; (S)-N-benzyl-2-oxo-3-( 1-p henylethyl)-2.3-d ihydro-lIH-imidazof4 1 5-bjpyrazine 5-carboxamide; 34 (S)-N-methyl-2-oxo-3-(1 -pheriylethyl)-2, 3-dlhydro- I F--imidaza(4, 5-blpyrazine 5-carboxamide;, (S, E)-1 -(1 -phenytethyl)-6-(prop-1 -enyl)-1 H-imidazo[4, 5-bjpyrazin-2(3H)-one; (SZ)-I -(1 -phenylethyl)-6-(prop-1 -enyl)-1 H-i!mid azot4, 5-bjpyrazin-2 (3H)-o ne;
(S
1 Z)-6-(hex-2-enyl)-1 -(1 -phenylethyl)-1 H-imidazo[4,5-bjpyrazIn-2(3H)-ane; (Z)-1 -(pentan-3-y)-6-(prop-1 -enyl)-1 H-imidazo[4,5-b]pyrazin-2(SH)-one; (Z)-1 -cyclohexyl-6-(prop-1 -anyl)-1 H-imidazoj4 1 S-blpyrazin-2(3H)-one; (Z)-1 -cyctopropyt-6-(prop- I -enyl)-1 H-imidazo(4, 5-bjpyrazin-2(3H)-one; (Z)-1 -isopropyl-6-(prop-1 -enyl)-1 H-imidazo[4 1 5-bjpyrazin-2(3H)-one; (Z)-6-(prop-1 1-anyl)- I -(tetrahydro-2H-pyran-4-y)-1 H-imnidazo[4, 5-bjpyrazin 2(3H)-one; 1 -(1 -aminobutan-2-yI)-6-bromo-1 H-imidazo[4,5-b]pyrazin-2(3H)-ona; 1 -(1 -morp holinobutan-2-yl)-1 H-im idazc44,5-b]pyrazin-2(3H)-one; 1 -(pentan-3-yl)-1 H-imidazo[4, 5-blpyrazir-2(3H)-one; 1 -(pentan-3-yl)-1 H-imidazo[4,5-bjquinoxalin-2(3H)-one; 1 -(pentan-3-yl)-5-vinyl-lIH-imidazo[4 ,5-bjpyrazin-2(3H)-one; I -(pants n-3-yl)-6-(prop-1 -ynyl)-1 H-imidaza[4,5-bpyrazin-2 (3H )-one; 1 -(pentan-3-yI)-6-(trifluoromethyl)- I H-imidazof4, 5.blpyrazin-2(3H)-one; 1 -benzyl-6-(methylth io)-1 H-imidazo[4, 5-bjpyrazin-2(3H)-one; I -berizyr-6-bromo-1 H-imidazo(4,5-blpyrazin-2(3H}-one; 1 -cyclohexyl-6-(methylthio)-1 H-imidazoll4,5-blpyrazin-2(3H)-ona; 1 -oyclopropyr-6-(mnethylthio)- I H-iniidazo[4,5-b]pyrazin-2(3H)-ona;, 1 -isopropyl-6-(methylthio)-I H-imidazo(4.5-blpyrazin-2 (SH)-one; 2-(6-bromo-2-oxo-2,3-dihydro-lIH-imidazo[4, 5-b]pyrazin-I -yl)butanaic acid;, 2-oxo- I -(penta n-3-yI)-2, 3-dihydro- I H-imidazo(4.5-blpyrazine-5-carboxylic acid; 2-oxo-3-(pentan-3-yI)-2,3-dihydro-I H-imidazo(4,5-b~pyrazine-5-carbonitile; 5-(methylthio)-l1-(penta n-3-yl)-l H-imidazo[4, 5-blpyrazin-2 (3H) -one; 5-a catyl-lI-( pentanr-3-yl)- I H-imidazof4, 5-bjpyrazin-2(SH)-one; 5-bromno- I -(pentan-3-yl)-1 H-imidazo[4, 5-b]pyraziri-2(3H)-one; 5-ethyl-I -(pentan-3-y)-1 H-imidazo!4, 5-bjpyrazin-2(SH)-one; S35 6-(methylsulfinyl)-1 -((S)-1 -phenylethyl)-I H-imldezo[4,5-bjpyrazin-2(3H)-one; 8-(methylthio)-I -(pentan-3-yl)-I H-imidazo[4,6-b]pyrazi n-2(3H)-one; 6-(methylthio)-I -(tetra hyd ro-2 H-pyran-4-yi)-1I H-imidazo[4,5-b]pyrazin-2(3H) one; 6-bromo-I -(1 -(4-(methylsulfonyl)piperazin-1 -yl)butan-2-y)-1 H-Imidaza[4, 5 bipyrazin -2(3H)-one; 6-bromo-1 -(1 -(4-methylpiperazin-1 -yI)butari-2-yl)-1 H-im idazo[4, 5-bjpyrazin 2(SH)-one; 6-bromo- 1 -(1 -(d [methyl amino)butan-2-y)-1 H-imkiazo[4, 5-b)pyrazin-2(3H) one; 6-bromo-I -(l -(methylamino)butan-2-yI)-1 H-imidazot4,5-blpyrazi n-2(3H)-one; 6-bromo-1 -(I 1 3-dlhyd roxypropan-2-yl)-I H-imidazo[4,5-blpyrazln-2(3H)-one; 6-bromo- 1 -(l1-rnethoxybutan-2-y)-1 H-imidazo[4 ,5-b]pyrazin-2(3H)-one; 6-bromo- 1 -(1 -morpholino-1 -oxobutan-2-yl)-1 H-i midazo[4,5-bjpyrazin-2(38) one; 6-bromo-1 -(2-methyl-I -morpholinopropan-2-yl)-I H-iridazo[4 1 5-b]pyrazin 2 (3H)-one; 8-bromo- I -(2-rnorpholinoethy)- 1 H-imidazo[4 ,5-b]pyrazin-2(3H)-one; 6-bromo-1 -(pentan-3-yl)-1 H-imidazo[4 ,5-b]pyrazin-2(31-D-one; 6-broni -I -(tetrahydro-2 H-pytan-4-yI)-l I --imidazc[4, 5-blpyrazin-2(SH)-one; 6-bromo-I -cyclohexyl- I H-imidazoj4,5-bjpyrazin-2(SH)-one; 6-bromo- I-cyolopropyl-1 H-imidazo[4. 5-b~pyrazin-2(3H)-one; 6-bromo-I -isopropyl-I H-imidazo[4,5-blpyrazin-2(SH)-one; 6-bromo- i-tert-butyl-1 H-imidazo[4, 5-bjpyrazin-2(3 H)-one; 6-oyclopropyl-I -(pentan-3-yl)-1 H-imidazo[4, 5-b]pyrazin-2(3H)-one; 6-ethynyl-I -(pentan-3-yl)-1 H-imidazo[4, 5-frfpyrazin-2(3H)-one; 6-hydroxy-I -(pentan-3-yI)-I H-imidazo[4,5-bjpyrazin-2(3H )-one; 6-rnethoxy-I -(pentan-3-yl)-I H-imidazo[4, 5-blpyrazin-2(3H)-one; 6-methyl-i -(penten-3-yl)-1 H-imidazo[4, 5-.blpyrazin-2(3H)-one; methyl 2-oxo-I -(penta n-3-yl)-2,3-dihydro-I H-imidazo[4,5-blpyrazine-5 carboxylate; 36 methyl 4-(2-(6-bromo-2-oxo-2,3-dihydro-1H-imidazo[4,5-blpyrazin-1 yl)butyl)piperazine-1 -carboxylate; N,N-dimethyl-2-oxo-1 -(pentan-3-yl)-2,3-dihyd ro-1 H-imidazo[4,5-bjpyrazine-5 carboxamide; N-methyl-2-oxo-l-(pentan-3-y)-2,3-dihydro-1 H-imidazo[4,5-b]pyrazine-5 carboxamide; 6-(1-methyl-1 H-pyrazol-4-yl)-i -(pentan-3-yl)-1 H-imidao[4,5-b]pyrazin-2(3H) one; 6-bromo-1 -(heptan-4-yl)-1 H-imidazo[4,5-bjpyrazin-2(3H)-one; (R)-6-bromo-I -(4-methyl-1-morpholinopentan-2-yl)-1H-imidazo[4,5-bjpyrazin 2(3H)-one; 1-(pentan-3-yl)-6-vinyl-1 H-imidazo[4,5-b]pyrazin-2(3H)-one; 1-(pentan-3-yl)-6-(prop-I -en-2-yl)-I H-imidazo(4,5-blpyrazin-2(3H)-one; 6-isopropyl-1 -(pentan-3-yl)-1 H-imidazo[4,5-b]pyrazin-2(3H)-one 6-chloro-1-(pentan-3-yl)-11-imidazo[4,5-b]pyrazin-2(3H)-one; and 6- (dimethylamino)- 1 -(pentan-3-yI)- 1 H-imidazo[4,5-b]pyrazin-2(3H)-one. [098] The compounds of Formula I can be named and numbered (e.g., using NamExpert" available from Cheminnovation or the automatic naming feature of ChemDraw Ultra version 10.0 from Cambridge Soft Corporation) as described below. For example, the compound: N N -- OH i.e., the compound according to Formula I where R 1 is (E)-propen-Iyl, R 2 is (S)-sec phenethyl, and R 4 is H, can be named (S,E)-1-(1-phenylethyl)-6-(prop-I-enyl)-1H imidazo[4,5-b]pyrazin-2-ol. [099] Likewise the compound: NI N N 37 i.e., the compound according to Formula I where R 1 is (Z)-propen-1-yi, R 2 is 3-pentyl, and R 4 is H, can be named (Z)-1-(pentan-3-yl)-6-(prop-1-enyl)-1 H-imidazo[4,5 b]pyrazin-2-ol. [0100] Similarly, the compounds of Formula Il can be named and numbered (e.g., using NamExpert"M available from Cheminnovation or the automatic naming feature of ChemDraw Ultra version 10.0 from Cambridge Soft Corporation) as described below. For example, the compound: H N N= N i.e., the compound according to Formula 11 where R 1 is (E)-propen-1-yl, R 2 is (S)-sec phenethyl, and R 4 is H, can be named (S,E)-1-(i-phenylethyl)-6-(prop-1-enyl)-IH imidazo[4,5-bjpyrazin-2(3H)-one. [01011 Likewise the compound: H i.e., the compound according to Formula II where R 1 is (Z)-propen-1-yl, R 2 is 3-pentyl, and R 4 is H, can be named (Z)-1-(pentan-3-y)-6-(prop-1-enyl)-1H-imidazo[4,5 bjpyrazin-2(3H)-one. [0102] The chemical entities described herein can be synthesized utilizing techniques well known in the art, e.g., as illustrated below with reference to the Reaction Schemes. [0103] Unless specified to the contrary, the reactions described herein take place at atmospheric pressure, generally within a temperature range from -10 *C to 200 *C. Further, except as employed in the Examples or as otherwise specified, reaction times and conditions are intended to be approximate, e.g., taking place at about atmospheric pressure within a.temperature range of about -10 *C to about 110 *C over a period of about I to about 24 hours; reactions left to run overnight average a period of about 16 38 hours. [0104] The terms "solvent," "organic solvent," and "inert solvent' each mean a solvent inert under the conditions of the reaction being described in conjunction therewith [including, for example, benzene, toluene, acetonitrile, tetrahydrofuran ("THF"), dimethylformamide ("DMF"), chloroform, methylene chloride (or dichloromethane), diethyl ether, methanol, N-methylpyrrolidone ("NMP"), pyridine and the like]. Unless specified to the contrary, the solvents used in the reactions described herein are inert organic solvents. Unless specified to the contrary, for each gram of the limiting reagent, one cc (or mL) of solvent constitutes a volume equivalent [0105] Isolation and purification of the chemical entities and intermediates described herein can be effected, if desired, by any suitable separation or purification procedure such as, for example, filtration, extraction, crystallization, column chromatography, thin layer chromatography or thick-layer chromatography, or a combination of these procedures. Specific illustrations of suitable separation and isolation procedures can be had by reference to the examples hereinbelow. However, other equivalent separation or isolation procedures can also be used. [0106] When desired, the (R)- and (S)-isomers may be resolved by methods known to those skilled in the art, for example by formation of diastereoisomeric salts or complexes which may be separated, for example, by crystallization; via formation of diastereolsomeric derivatives which may be separated, for example, by crystallization, gasliquid or liquid chromatography; selective reaction of one enantiomer with an enantiomer-specific reagent, for example enzymatic oxidation or reduction, followed by separation of the modified and unmodified enantiomers; or gas-liquid or liquid chromatography in a chiral environment, for example on a chiral support, such as silica with a bound chiral ligand or in the presence of a chiral solvent. Alternatively, a specific enantiomer may be synthesized by asymmetric synthesis using optically active reagents, substrates, catalysts or solvents, or by converting one enantiomer to the other by asymmetric transformation. [0107] Many of the optionally substituted starting compounds and other reactants are commercially available, e.g., from Aldrich Chemical Company (Milwaukee, WI) or can be readily prepared by those skilled in the art using commonly employed synthetic 39 methodology. REACTION SCHEME 1 R4 N NH 2
R
4 N NH 2 R4 N N A t R2-NHz A t)~~OH
R
1 N X step1 R 1 N NH Step2 R 1 N 101 102 R2 103 2 [0108] Referring to Reaction Scheme 1, Step 1, to a compound of Formula 101, wherein X is halo, is added an excess (such as about 2 to 20 equivalents) of a compound of formula R 2
-NH
2 . The reaction vessel is heated to about 110 "C to 190 *C over about 20 to 40 minutes, optionally with microwave irradiation. The product, a compound of Formula 102, is isolated and optionally purified. (0109] Referring to Reaction Scheme 1, Step 2, to a solution of a compound of Formula 102 in a suitable solvent (such as THF) is added a di-activated carbonyl equivalent such as carbonyl diimidazole (CDl), phospgene, or triphosgene. The product, a compound of Formula 103, is isolated and optionally purified. REACTION SCHEME 2 R4 N N R4 N N 0 X N N Step 3 (a-e) R 1 N 201 R2 104 R2 [01101 Reaction Scheme 2 illustrates reactions for further converting compounds of Formula 201, wherein X is a leaving group, to compounds of Formula 104 through one of Steps 3(a-e). In some embodiments, X is halo, for example, bromo. (01111 Referring to Reaction Scheme 2, Step 3(a), a compound of Formula 201 and about 0.05 to 0.15 equivalents of a suitable catalyst such as (Ph 3
P)
4 Pd in a suitable solvent such as NMP or dioxane, a suitable base, and an excess (such as about 1.5 to 32 molar equivalents) of a suitable tin reagent such as R1Sn(butyl)3 is mixed at from about 0 to about 200"C for about 6 to 48 hours. The product, a compound of Formula 104 wherein R 1 is selected from optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, and optionally substituted cycloalkyl, is isolated and optionally purified. [0112] Referring to Reaction Scheme 2, Step 3(b), a compound of Formula 201 and 40 an excess (such as about 4 to 5 equivalents) of a compound of the formula NaSRx where SR, is R 1 , and a suitable solvent (such as NMP) is heated to about 50 *C to 200 "C over about 10 min to 24 h, optionally with microwave irradiation. The product, a compound of Formula 104 wherein R 1 is sulfanyl, is isolated and optionally purified. [0113] Referring to Reaction Scheme 2, Step 3(c), a compound of Formula 201, an excess (such as about 1.9 to 2.3 equivalents) of a compound of the formula RB(OH) 2 , about 0.10 to 0.15 equivalents of (DPPF)Pdl 2 , a suitable solvent (such as dioxane) and about 2 to 3 equivalents of a suitable base (such as 2N K 2
CO
3 ) is heated to about 90 'C for about 6 to 24 hours. The product, a compound of Formula 104 wherein R 1 is selected from optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, and optionally substituted cycloalkyl, is isolated and optionally purified. [0114] Referring to Reaction Scheme 2, Step 3(d), about 2 equivalents of RkOH where OR, is R 1 and a suitable solvent (such as NMP), and about 2 equivalents of suitable base (such as NaH) is added followed by a compound of Formula 201. The mixture is heated to about 50 to about 200'C for about 10 minutes to about 48 hours. In some embodiments, the reaction is heated for about 30 minutes, optionally with microwave irradiation. The product, a compound of Formula 104 wherein R1 Is optionally substituted alkoxy, is isolated and optionally purified. [0115] Referring to Reaction Scheme 2, Step(e), a compound of Formula 201, an excess (such as about 2.0 equivalents) of a compound of the formula KR 1
BF
3 , an excess (such as about 3 equivalents) of a suitable base (such as Cs 2 C0 3 ), a suitable amount of (DPPF)PdC 2 (such as about 0.2 equivalents), a suitable solvent (such as dioxane and water) is mixed at about room termperature to about 100 "C for about 8 to 48 hours and the product, a compound of Formula 104 wherein R 1 is selected from optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, and optionally substituted cycloalkyl, is Isolated and optionally purified. [0116] A racemic mixture is optionally placed on a chromatography column and separated into (R)- and (S)-enantiomers. [01171 The compounds described herein are optionally contacted with a pharmaceutically acceptable acid to form the corresponding acid addition salts. 41 [0118] Pharmaceutically acceptable acid addition salts of compounds of Formula I or compounds of Formula i are optionally contacted with a base to form the corresponding free base. (0119] The chemical entities described herein modulate one or more of skeletal myosin, skeletal actin, skeletal tropomyosin, skeletal troponin C, skeletal troponin I, skeletal troponin T, and skeletal muscle, Including fragments and isoforms thereof, as well as the skeletal sarcomere, and are useful to bind to, inhibit and/or potentiate the activity thereof. As used in this context, "modulate" means either increasing or decreasing myosin activity, whereas "potentiate" means to increase activity and "inhibit" means to decrease activity. [0120] The chemical entities, pharmaceutical compositions and methods described herein are used to treat obesity, sercopenia, wasting syndrome, frailty, cachexia, muscle spasm, post-surgical and post-traumatic muscle weakness, neuromuscular disease, and other indications in a mammal. [0121] Methods to identify the chemcial entities as binding to a protein or as a modulator of the binding characteristics or biological activity of a protein are described in, for example, U.S. Patent No. 6,410,254 and U.S. Patent Application No. 10/987,165. [0122] For example, test compounds can be assayed in a highly parallel fashion by using multiwell plates by placing the compounds either individually in wells or testing them in mixtures. Assay components including the target protein complex, coupling enzymes and substrates, and ATP can then be added to the wells and the absorbance or fluorescence of each well of the plate can be measured with a plate reader. [0123] In some embodiments, the method uses a 384 well plate format and a 25 pL reaction volume. A pyruvate kinase/lactate dehydrogenase coupled enzyme system (Huang TG and Hackney D D. (1994) J Biol Chem 269(23):16493-501) can be used to measure the rate of ATP hydrolysis in each well. As will be appreciated by those in the art, the assay components are added in buffers and reagents. The incubation periods can be optimized to give adequate detection signals over the background. The assay can be done in real time giving the kinetics of ATP hydrolysis which. increases the signal to noise ratio of the assay. [0124] The compounds can be further tested using skinned muscle fiber 42 preparations. Such assays are known in the art, See, e.g., Cheung et al. (2002) Nature Cell Biol. 4:83 and U.S. Patent Publication No. 20020006962. [0125 The chemical entitles described herein are administered at a therapeutically effective dosage, e.g., a dosage sufficient to provide treatment for the disease states previously described. While human dosage levels have yet to be optimized for the chemical entitles described herein, generally, a daily dose ranges from about 0.05 to 100 mg/kg of body weight; in certain embodiments, from about 0.10 to 10.0 mg/kg of body weight, and in certain embodiments, from about 0.15 to 1.0 mg/kg of body weight. Thus, for administration to a 70 kg person, in certain embodiments, the dosage range would be about from 3.5 to 7000 mg per day; in certain embodiments, about from 7.0 to 700.0 mg per day, and in certain embodiments, about from 10.0 to 100.0 mg per day. The amount of the chemical entity administered will, of course, be dependent on the subject and disease state being treated, the severity of the affliction, the manner and schedule of administration and the judgment of the prescribing physician; for example, a likely dose range for oral administration would be from about 70 to 700 mg per day, whereas for intravenous administration a likely dose range would be from about 70 to 700 mg per day depending on compound pharmacokinetics. [0126] Administration of the chemical entities described herein can be via any of the accepted modes of administration for agents that serve similar utilities including, but not limited to, orally, sublingually, subcutaneously, intravenously, intranasally, topically, transdermally, intraperitonealy, intramuscularly, intrapulmonarilly, vaginally, rectally, or intraocularly. in some embodiments, oral or parenteral administration is used. {0127] Pharmaceutically acceptable compositions include solid, semi-solid, liquid and aerosol dosage forms, such as, e.g., tablets, capsules, powders, liquids, suspensions, suppositories, aerosols or the like. The chemical entities can'also be administered in sustained or controlled release dosage forms, including depot injections, osmotic pumps, pills, transdermal (including electrotransport) patches, and the like, for prolonged andlor timed, pulsed administration at a predetermined rate. In certain embodiments, the compositions are provided in unit dosage forms suitable for single administration of a precise dose. [0128) The chemical entities described herein can be administered either alone or 43 more typically in combination with a conventional pharmaceutical carrier, excipient or the like (e.g., mannitol, lactose, starch, magnesium stearate, sodium saccharine, talcum, cellulose, sodium crosscarmellose, glucose, gelatin, sucrose, magnesium carbonate, and the like). If desired, the pharmaceutical composition can also contain minor amounts of nontoxic auxiliary substances such as wetting agents, emulsifying agents, solubilizing agents, pH buffering agents and the like (e.g., sodium acetate, sodium citrate, cyclodextrine derivatives, sorbitan monolaurate, triethanolamine acetate, triethanolamine oleate, and the like). Generally, depending on the intended mode of administration, the pharmaceutical composition will contain about 0.005% to 95%; in certain embodiments, about 0.5% to 50% by weight of a chemical entity. Actual methods of preparing such dosage forms are known, or will be apparent, to those skilled in this art; for example, see Remington's Pharmaceutical Sciences, Mack Publishing Company, Easton, Pennsylvania. [0129] In addition, the chemical entities described herein can be co-administered with, and the pharmaceutical compositions can include, other medicinal agents, pharmaceutical agents, adjuvants, and the like. Suitable medicinal and pharmaceutical agents include modulators of one or more of skeletal myosin, skeletal actin, skeletal tropomyosin, skeletal troponin C, skeletal troponin I, skeletal troponin T, and skeletal muscle, including fragments and isoforms thereof, and the skeletal sarcomere and other suitable therapeutic agents useful in the treatment of the aforementioned disorders including: anti-obesity agents, anti-sarcopenia agents, anti-wasting syndrome agents, anti-frailty agents, anti-cachexia agents, anti-muscle spasm agents, agents against post-surgical and post-traumatic muscle weakness, and anti-neuromuscular disease agents, as well as the agents described in U.S. Patent Application No. 2005/0197367. [0130] Suitable additional medicinal and pharmaceutical agents include, for example: orlistat, sibramine, diethylpropion, phentermine, benzaphetamine, phendimetrazine, estrogen, estradiol, levonorgestrel, norethindrone acetate, estradiol valerate, ethinyl estradiol, norgestirnate, conjugated estrogens, esterified estrogens, medroxyprogesterone acetate, testosterone, insulin-derived growth factor, human growth hormone, riluzole, cannabidiol, prednisone, albuterol, non-steroidal anti 44 inflammatory drugs, and botulinum toxin. [0131] Other suitable medicinal and pharmaceutical agents include TRH, diethylstilbesterol, theophylline, enkephalins, E series prostaglandins, compounds disclosed in U.S. Patent No. 3,239,345 (e.g., zeranol), compounds disclosed in U.S. Patent No. 4,036,979 (e.g., sulbenox), peptides disclosed in U.S. Patent No. 4,411,890 growth hormone secretagogues such as GHRP-6, GHRP-1 (disclosed in U.S. Patent No. 4,411,890 and publications WO 89107110 and WO 891D7111), GHRP-2 (disclosed in WO 93/04081), NN703 (Novo Nordisk), LY444711 (Lilly), MK-677 (Merck), CP424391 (Pfizer) and B-HT920, growth hormone releasing factor and its analogs, growth hormone and its analogs and somatomedins including IGF-1 and IGF-2, alpha adrenergic agonists, such as clonidine or serotonin 5-HT agonists, such as sumatriptan, agents which inhibit somatostatin or its release, such as physostigmine, pyridostigmine, parathyroid hormone, PTH(1-34), and bisphosphonates, such as MK 217 (alendronate). [0132] Still other suitable medicinal and pharmaceutical agents include estrogen, testosterone, selective estrogen receptor modulators, such as tamoxifen or raloxifene, other androgen receptor modulators, such as those disclosed in Edwards, J. P. et. al., Bho. Med. Chem. Let., 9, 1003-1008 (1999) and Hamann, L. G. et. al., J. Med. Chem., 42, 210-212 (1999), and progesterone receptor agonists ("PRA"), such as levonorgestrel, medroxyprogesterone acetate (MPA). [0133] Still other suitable medicinal and pharmaceutical agents include aP2 inhibitors, such as those disclosed in U.S. Ser. No. 09/519,079 filed Mar. 6, 2000, PPAR gamma antagonists, PPAR delta agonists, beta 3 adrenergic agonists, such as AJ9677 (Takeda/Dainippon), L750355 (Merck), or CP331648 (Pfizer), other beta 3 agonists as disclosed in U.S. Patent Nos. 5,541,204, 5,770,615, 5,491,134, 5,776,983 and 5,488,064, a lipase inhibitor, such as orlistat or ATL-962 (Alizyme), a serotonin (and dopamine) reuptake inhibitor, such as sibutramine, topiramate (Johnson & Johnson) or axokine (Regeneron), a thyroid receptor beta drug, such as a thyroid receptor ligand as disclosed in WO 97/21993, WO 99/00353, and GB98/284425, and anorectic agents, such as dexamphetamine, phentermine, phenylpropanolamine or mazindol. 45 [0134] Still other suitable medicinal and pharmaceutical agents include HIV and AIDS therapies, such as indinavir sulfate, saquinavir, saquinavir mesylate, ritonavir, lamivudine, zidovudine, lamivudine/zidovudine combinations, zalcitabine, didanosine, stavudine, and megestrol acetate. [0135] Still other suitable medicinal and pharmaceutical agents include antiresorptive agents, hormone replacement therapies, vitamin D analogues, elemental calcium and calcium supplements, cathepsin K inhibitors, MMP inhibitors, vitronectin receptor antagonists, Src SH.sub.2 antagonists, vacular -HltATPase inhibitors, ipriflavone, fluoride, Tibo lone, pro stanoids, 17-beta hydroxysteroid dehydrogenase inhibitors and Src kinase inhibitors. {0136] The above other therapeutic agents, when employed in combination with the chemical entities described herein, may be used, for example, in those amounts indicated in the Physicians' Desk Reference (PDR) or as otherwise determined by one of ordinary skill in the art. (0137] In certain embodiments, the compositions will take the form of a pill or tablet and thus the composition will contain, along with the active ingredient, a diluent such as lactose, sucrose, dicalcium phosphate, or the like; a lubricant such as magnesium stearate or the like; and a binder such as starch, gum acacia, polyvinylpyrrolidine, gelatin, cellulose, cellulose derivatives or the like. In another solid dosage form, a powder, marume, solution or suspension (e.g., in propylene carbonate, vegetable oils or triglycerides) is encapsulated in a gelatin capsule. [0138] Liquid pharmaceutically administrable compositions can, for example, be prepared by dissolving, dispersing, etc. at least one chemical entity and optional pharmaceutical adjuvants in a carrier (e.g., water, saline, aqueous dextrose, glycerol, glycols, ethanol or the like) to form a solution or suspension. Injectables can be prepared in conventional forms, either as liquid solutions or suspensions, as emulsions, or in solid forms suitable for dissolution or suspension in liquid prior to injection. The percentage of chemical entities contained in such parenteral compositions is highly dependent on the specific nature thereof, as well as the activity of the chemical entities and the needs of the subject. However, percentages of active ingredient of 0.01% to 10% in solution are employable, and will be higher if the composition is a solid which 46 will be subsequently diluted to the above percentages. In certain embodiments, the composition will comprise from about 0.2 to 2% of the active agent in solution. 10139] Pharmaceutical compositions of the chemical entities described herein may also be administered to the respiratory tract as an aerosol or solution for a nebulizer, or as a microfine powder for insufflation, alone or in combination with an inert carrier such as lactose. In such a case, the particles of the pharmaceutical composition have diameters of less than 50 microns, in certain embodiments, less than 10 microns. [0140] The following examples serve to more fully describe the manner of using the above-described invention. It is understood that these examples in no way serve to limit the true scope of this invention, but rather are presented for illustrative purposes. Example I Synthesis of (S)-6-bromo-1-(1-phenylethyl)-1IH-imidazo[4,5-b]pyrazin-2-ol
NH
2 N NH 2
NH
2 Me" Ph ABr N NH Br Br MW, 180 C Me Ph [0141] Step 1: (S)--bromo-N 2 -(1-phenylethyl)pyrazine-2,3-diamine. A thick walled microwave bottle equipped with a stirbar was charged with 1.0 equiv of 3,5 dibromopyrazin-2-amine and 6.6 equiv of (S)-sec-phenethylamine. The bottle was fitted with a septum and cap and heated to 180 'C in a microwave for 30 min. The resulting solution was adsorbed onto 20 g of silica; flash chromatography (10% - 50% EtOAc/Hexanes) provided the title compound (60%) as an off-white foam. LCMS m/z (APCI) = 293.0, 295.0 (M+H). N j>NH2 excess CDI N Br N NH Br N N Me Ph THF, 67 0 C M>-Ph [0142] Step 2: (S)-6-bromo-1-(1-phenylethyl)-iH-imidazo[4,5-b]pyrazin-2-ol. To a 47 solution of (S)-6-bromo-N 2 -(1-phenylethyl)pyrazine-2b3-diamine (1.0 equiv) in refluxing anhydrous THF (5 volume equivalents) was added carbonyidlimidazote (CDI). Successive portions of CDI were added until the starting material was consumed (approx. 3.6 equiv total) as judged by TLC (50% EtOAclHexanes). After complete reaction, the mixture was cooled to room temperature and quenched by the careful addition of water until gas evolution had ceased. The mixture was diluted with 25 volume equivalents of EtOAc and washed with 3 x 7.5 volume equivalents of water and 1 x 7.5 volume equivalents of brine. The organic layer was dried over anhydrous sodium sulfate, filtered and concentrated in vacuo. Flash chromatography (Biotage MPLC 5% - 40% EtOAc/Hexanes) provided the title compound (66%) as a white solid. LCMS m/z (APCI) = 319.0, 321.0 (M+H). Example i(a) Br O ,Sn(n-Bu)3 ON N Ph Et 3 N, Dioxane Me MNPh m 80C Me [0143] (S)-1-(2-hydroxy-1 -(1 -phenylethyl)-1 H-imidazo[4,5-bjpyrazin-6 yl)ethanone. An oven-dried scintillation vial equipped with a stirbar was charged with (S)-6-bromo-1 -(1-phenylethyl)-1 H-imidazo[4,5-b]pyrazin-2-ol (1.0 equiv), and (Ph 3
P)
4 Pd (0.07 equiv). The bottle was covered with a sheet of Parafilm and purged with nitrogen for 5 min, and anhydous dioxane (13 volume equivalents), triethylamine (3.0 equiv), and tributyl(1-ethoxyvinyl)stannane (1.5 equiv) were added by syringe. The resulting mixture was heated to 80 'C overnight. The reaction was quenched with 1 N KHSO 4 and stirred for 30 min. The mixture was then diluted with EtOAc, washed twice with NaHCO 3 and once with brine. The organic layer was dried over sodium sulfate, filtered, and concentrated in vacuo. Flash chromatography (Biotage MPLC 10% - 66% EtOAc/Hexanes) provided the title compound (33%) as a white solid. LCMS m/z (APCI) = 283.1 (M+H). 48 Example I(b) >-OH Me Sn(n-Bu)3 OH Brl N N MeN Ne' N YPh Et 3 N, MW MePh Me NMP, 120 aC [01441 (S,E)-1-(1-phenylethyl)-6-(prop-1-enyl)-1H-imidazo[4,5-b]pyrazin-2-ol. A thick-walled microwave bottle equipped with a stirbar was charged with (S)-6-bromo-1 (1-phenylethyl)-1 H-imidazo[4,5-bjpyrazin-2-oI (1.0 equiv), and (PhaP) 4 Pd (0.12 equiv). The bottle was covered with a sheet of Parafilm and purged with nitrogen for 5 min, and N-methylpyrrolidone (14 volume equivalents), triethyl amine (2.0 equiv), and (E) tributyl(prop-1-enyl)stannane (3.0 equiv) were added by syringe. The resulting mixture was immediately fitted with a septum and cap and heated to 120 *C in a microwave for 20 min. The reaction was then diluted with EtOAc, washed four times with saturated aq. NaHCO 3 and once with brine. The organic layer was dried over sodium sulfate, filtered, and concentrated in vacuo. Reverse-phase preparative HPLC provided the title compound (54%) as a foam. LCMS m/z (APCI) = 281.1 (M-H). Example 1(c) 5TOH NaSMe ,MeS N OH M Ph MW, NMP, 180 0 [0145] (S)-6-(methylthio)-I-(1 -phenylethyl)-1 H-imidazo[4,5-b]pyrazin-2-ol. A thick-walled microwave bottle equipped with a stirbar was charged with (S)-6-bromo-1 (1-phenylethyl)-1 H-imidazo[4,5--bjpyrazin-2-ol (1.0 equiv), sodium thiomethoxide (4.5 equiv), and N-methylpyrrolidone (10 volume equivalents). The bottle was fitted with a septum and cap and heated to 180 'C in a microwave for 30 min. The reaction mixture was then diluted with 100 volume equivalents of EtOAc and washed with 4 x 100 volume equivalents of water and I x 100 volume equivalents of brine. The organic layer 49 was dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo. Reverse phase preparative HPLC (20% - 80% MeCN/H 2 O) provided the title compound (24%) as a white solid. LCMS mlz (APCI) = 287.1 (M+H). Example 1(d) BrOH B(OH)2 OH BrSN:CN Kax KA N Ph DPPFPdC 2 , aq. K2CO 3 Ph Me Dioxane, 90 00 [01461 (S,Z)-1-(1-phenylethyl)-6-(prop-1-enyl)-1H-imidazo[4,5-b]pyrazin-2-ol. A scintillation vial equipped with a stirbar was charged with (S)-6-bromo-1-(1-phenylethyl) 1 H-imidazo[4,5-blpyrazin-2-ol (1.0 equiv), (Z)-prop-1-enyl boronic acid (2.0 equiv) and (DPPF)PdCIl (0.10 equiv). The vial was fitted with a septum-lined cap and purged with nitrogen for 5-10 min. To this mixture was added dioxane (16.6 volume equivalents) and degassed 2 N K2C03 (4.2 volume equivalents) by syringe. The resulting mixture was heated to 90 *C overnight. The mixture was cooled to room temperature, diluted with EtOAc, washed with twice with saturated aq. NaHCO3, and once with brine. The organic layer was dried over sodium sulfate, filtered, and concentrated in vacuo. Flash chromatography (Biotage MPLC 5% - 40% EtOAc/Hexanes) provided the title compound (63%) as an off-white foam. LCMS m/z (APCI) = 281.1 (M+H). Example 1(e) N N N__ _ _ _ _ NN Br OH MB3(OH)2 O Ph aq. K2C03 Ph Me Dioanne, 90 0 C Me [0147] (S)-1-(1-phenylethyl)-6-vinyl-1H-imidazo[4,6-b]pyrazin-2-ol. A scintillation vial equipped with a stirbar-was charged with (S)-6-bromo-1 -(1-phenylethyl)-1 H imidazo[4,5-bjpyrazin-2-ol (1.0 equiv), vinyl boronic acid (2,2 equiv), and (DPPF)PdC 2 50 (0.10 equiv). The vial was fitted with a septum-lined cap and purged with nitrogen for.5 10 min. To this mixture was added dioxane (16.6 volume equivalents) and degassed 2 N K2C0 3 (4.2 volume equivalents) by syringe. The resulting mixture was heated to 90 'C overnight. The mixture was cooled to room temperature, diluted with 12 volume equivalents EtOAc, washed with twice with saturated aq. NaHCO 3 , and once with brine. The organic layer was dried over sodium sulfate, filtered, and concentrated in vacuo. Flash chromatography (Blotage MPLC 5% - 40% EtOAc/Hexanes) provided the title compound as an off-white solid (54%). LCMS m/z (APC) = 267.0 (M+H). Example 1(f) Br NX OH NaH, MeOH, MW. MeO N N MSE Ph NMP, 200 *C me( Ph [0148] (S)-6-methoxy-1 -(1 -phenylethyl)-IH-imidazo[4,5-b]pyrazin-2-ol. A thick walled microwave bottle equipped with a stirbar was charged with MeOH (2.0 equiv) and NMP (20 volume equivalents). To the resulting solution was added NaH (2.0 equiv), resulting in gas evolution. (S)-6-Bromo-1-(1-phenylethy)-1 H-imidazo[4,5-b]pyrazin-2-ol (1.0 equiv) was then added to the reaction, and the resulting mixture was immediately fitted with a septum and cap and heated to 200 'C in a microwave for 30 min. The reaction was then diluted with EtOAc, washed twice with saturated aq. NaHCO 3 and once with brine. The organic layer was dried over sodium sulfate, filtered, and concentrated in vacuo. Reverse-phase preparative HPLC provided the title compound (29%) as a white solid. LCMS m/z (APCI) = 271.1 (M+H). 51 Example 1(g) NXN Pd/ N N --- OH H2(1 atm), Pd/C Et N N Me, Ph MeOH, 23CC M -Ph [0149] (S)-I-(1-phenylethyl)-6-ethyl-1H-imidazo[4,5-b]pyrazin-2-ol. A scintillation vial equipped with a stirbar was charged with (S)-6-vinyl-1-(1-phenylethyl)-1Himidazo[4,5-bjpyrazin-2-ol (1.0 equiv), methanol (280 volurne equivalents), and catalytic Pd/C. The resulting mixture was purged with hydrogen for 45 minutes; the reaction was complete as judged my LCMS. The mixture was then filtered through a pad of diatomaceous earth and the pad of diatomaceous earth was washed twice with MeOH. The solution was concentrated in vacuo. Flash chromatography (Biotage MPLC 5% 40% EtOAc/Hexanes) provided the title compound (86%) as a foam. LCMS m/z (APCI) 269.1 (M+H). Example 2 Synthesis of 6-bromo-1-(pentan-3-yl)-1H-imidazo[4,5-b]pyrazin-2-ol
NH
2 N NH 2 N H Et Et Br N NH Br Br MW, 150 "C Et Et [0150] Step 1: 6-bromo-N 2 -(pentan-3-yl)pyrazine-2,3-diamine. The title compound was prepared in a manner analogous to Example I Step 1 except that 3-aminopentane (2.6 volume equivalents) was substituted for (S)-sec-phenethylamine. LCMS m/z (APCI) = 259.0, 260.0 (M+H). Br H excess CDI .
OH Br NXNH Br \NN Et Et THF, 67 C Et )Et 52 [01511 Step 2: 6-bromo-1-(pentan-3-yl)-lH-imidazo[4,5-b]pyrazin-2-ol. The title compound was prepared by treating 6-bromo-N 2 -(pentan-3-yl)pyrazine-2,3-diamine in a manner analogous to Example I Step 2 LCMS m/z (APCI) = 285.0, 287.0 (M+H). Example 2(a) r N> OH Me Sn(n-Bu)3 MeOH Br N ~ ____ Et 3Et1N, MW Et Et NMP, 120 "C Et [01521 (E)-1-(pentan-3-yl)-6-(prop-1-enyl)-1H-imidazo[4,5-blpyrazin-2-ol. A thick walled microwave bottle equipped with a stirbar was charged with 6-bromo-1 -(pentan-3 yl)-1 H-imidazo[4,5-bjpyrazin-2-ol (1.0 equiv) and (Ph 3
P)
4 Pd (0.15 equiv). The bottle was covered with a sheet of Parafilm and purged with nitrogen for 5-10 min, and N methylpyrrolidone (11.7 volume equivalents), triethyl amine (2.0 equiv), and (E) tributyl(prop-i-enyl)stannane (2.0 equiv) were added by syringe. The resulting mixture was immediately fitted with a septum and cap and heated to 120 'C in a microwave for 20 min. The reaction was then diluted with EtOAc, washed with three times with water and once with brine. The organic layer was dried over sodium sulfate, filtered, and concentrated in vacuo. Reverse-phase preparative HPLC provided the title compound (15%) as a foam. LCMS m/z (APCI) = 247.1 (M+H). Example 2(b) Br NH NaSMe , eS N OH EtXEt MW, NMP, 180 0C Et Et [0153] 6-(methylthio)-1-(pentan-3-yl)-1H-imidazo[4,5-bjpyrazin-2-ol. The title compound was prepared by reacting 6-bromo-1-(pentan-3-yi)-1lH-imidazoj4,5-blpyrazin 2-ol (1.0 equiv), sodium thiomethoxide (1.4 equiv), and N-methylpyrrolidone (5.9 volume 53 equivalents) in a manner analagous to Example 1(c). LCMS m/z (APCI) = 253.0 (M+H). Example 2(c) ~NyN me Me NXN Br NOH <,B(OH)2 \-OH E>Et aq. K2CO3 Et Dioxane, 90 *C 10154] (Z)-1 -(pentan-3-yl)-6-(prop-1 -enyl)-1 H-imidazo(4,5-bpyrazin-2-ol. The title compound was prepared by reacting 6-bromo-1 -(pentan-3-y)-1 H-imidazo[4,5-blpyrazin 2-ol (1.0 equiv), (Z)-prop-i-enyl boronic acid (1.5 equiv) and (DPPF)PdCl 2 (0.15 equiv) in a manner analagous to Exmple 1(d). LCMS m/z (APCI) = 247.0 (M+H). Example 3 Synthesis of i-(pentan-3-y)-1H-imidazo[4,5-bjquinoxalin-2-aI NH2 N NH2 N N H 2 E t E t , I N N H CI MW, 120 "C Et Et [0155] Step 1: N 2 -(pentan-3-yi)quinoxaline-2,3-diamine. A thick-walled microwave bottle equipped with a stirbar was charged with 3-chloroquinoxalin-2-amine (1.0 etjuiv) and 20 volume equivalents of 3-aminopentane. The bottle was fitted with a septum and cap and heated to 120 *C in a microwave for 30 min. The resulting solution was concentrated in vacuo. Flash chromatography (20% - 60% EtOAc/Hexanes) provided the title compound (78%) as a yellow solid. LCMS m/z (APCI) = 231.1 (M+H). 54 excess CDI OH Et THF, 67 0 C Et Et Et El E [0156] Step 2: 1 -(pentan-3-yl)-1 H-imidazo[4,5-b]quinoxalin-2-ol. The title compound was prepared by treating N 2 -(pentan-3-yl)quinoxaline-2,3-diamine in a manner analogous to Example I Step 2 LCMS m/z (APCI) = 257.2 (M+H). Example 3(a) <N N KMeBF 3 NXN Br N NCDbxan e Me N N Et Ft Et> Et [0157] Synthesis of (Z)-1-(pentan-3-yl)-6-(prop-1-enyl)-1IH-imidazo[4,5-b)pyrazin 2-ol. A scintillation vial equipped with a stirbar was charged with 6-bromo-1-(pentan-3 yl)-1H-imidazo[4,5-blpyrazin-2-ol (1.0 equiv), KF 3 BMe (2.0 equiv), Cs 2 00 3 (3.0 equiv) and (DPPF)PdC 2 (0.20 equiv). The vial was fitted with a septum-lined cap and purged with nitrogen for 5-10 min. To this mixture was added dioxane (25 volume equivalents) and degassed water (5 volume equivalents) by syringe. The resulting mixture was heated to 90 'C overnight. The mixture was cooled to room temperature, diluted with 15 mL EtOAc, washed twice with saturated aq. NaHCO 3 and once with brine. The organic layer was dried over sodium sulfate, filtered, and concentrated in vacuo. Flash chromatography (Biotage MPLC 5% - 40% EtOAc/Hexanes) provided the title compound (53%) as a white solid. LCMS m/z (APCI) = 221.1 (M+H). Example 4 Synthesis of 6-ethynyl-1-(pentan-3-yl)-1H-imidazo[4,5-b]pyrazin-2-oI Example 4(a) 55 B H PdC1 2 (PPh 3
)
2 NN Br N NCul, NEt 3 , DMF, 80 *C N N TMS 1.(pentan-3-yI)-6-((trimethylsilyl)ethynyl)-1H-imidazo[4,5-b]pyrazin-2-ol. A mixture of 6-bromo-1-(pentan-3-y)-1H-imidazo[4,5-b]pyrazin-2-ol (3.75 9 13.2 mmol)), trimethylsilylacetylene (2.8 mL, 19.8 mmol), PdC1 2 (PPh) 2 (0.93g, 1.32 mmol), Cul (0.5 g, 2.64 mmol) and triethylamine (5.5 mL, 39.5 mmol) in DMF (50 mL) was purged with N 2 for 30 seconds followed by stirring at 80 *C. After 3 hours the reaction mixture was diluted with EtOAc, washed with NH 4 CI solution, dried over Na 2
SO
4 , and concentrated in vacuo. Purification with over silica gel (Biotage MPLC 10 - 80% EtOAc/hexanes) provided the title compound (3.2 g, 80%) as a brown solid. Example 4(b) OH KF I N -OH TMS MeOHIfHFIH 2 O 6-ethynyl-1 -(pentan-3-yl)-1 H-imidazo[4,5-bjpyrazin-2-ol. A mixture of I -(pentan-3-yl) 6-((trimethylsilyl)ethyny)-1 H-imidazo[4,5-b]pyrazin-2-ol (3.2 g, 10.6 mmol), KF (1.6 g, 27.5 mmol) in MeOHITHF/H2O (50 mL, 2/2/1) was stirred at room temperature. Upon complete conversion by LCMS, the solution was concentrated in vacuo, diluted with EtOAc, washed with NH 4 C solution, dried over Na 2
SO
4 , and concentrated in vacuo. Purification over silica gel (Biotage MPLC 10 - 80% EtOAc/Heaxanes) gave a brown solid, which was washed with 15% EtOAc/hexanes to give product the title compound as a white solid (0.9 g, 37%). Example 5 56 Synthesis of 6-(dimethylamino)-1-(pentan-3-y)-1H-imidazo[4,5-bjpyrazin-2-ol Example 6(a) Boc Br HcN Br OI
NE
3 , DCM tert-butyl 5-bromo-2-oxo-3-(pentan-3-yI)-2,3-dihydroimidazo[4,5-blpyrazine-1 carboxylate. To a solution of 6-bromo-1-(pentan-3-yl)-1H-imidazo[4,5-b)pyrazin-2-ol (5.0 g, 17.6 mmol) in DCM (80 mL) containing triethylamine (7.34 mL, 52.8 mmol) was added Boc 2 O (7.0 g, 35 mmol). The reaction mixture was stirred at room temperature overnight, washed with NaHC0 3 solution, dried over Na 2
SO
4 and concentrated in vacuo. Purification over silica gel (Biotage MPLC 10 - 50% EtOAc/hexanes) gave the desired product as a white solid (1.7 g. 25%). Example 5(b) Boc rH Pda(dba)2, NaOtBu HcI N H Or~N N +' I,2 BNPhP(cy) 2 , Toluene, 120 *C 6 -(dimethylami no)-1 -(pentan-3-yl).1 H-imldazo[4,5-b]pyrazin-2-ol. A mixture of tert butyl 5-bromo-2-oxo-3-(pentan-3-yl)-2,3-dihydroimidazo[4,5-bjpyrazine-1-carboxylate (200 mg, 0.52 mmol), dimethylamine (0.5 mL, 2M in THF, 1.0 mmol), Pd 3 (dba) 2 (48 mg, 0.052 mmol), BPhP(Cy) 2 (37 mg, 0.10 mmol) and NaOtBu (150 mg, 1.56 mmol) in anhydrous toluene (4 mL) was purged with N 2 for 15 second and then stirred at 120 *C for 20 minutes in microwave. The mixture was diluted with EtOAc, washed with NaHCO 3 solution, dried over Na 2
SO
4 , and then concentrated in vacuo to give a dark muddy residue. The residue was dissolved in MeOH (10 mL) and treated with 1 mL 4M HCI in dioxane. After one hour, the reaction was concentrated, diluted with EtOAc, 57 washed with NaHCO 3 , dried over Na 2
SO
4 , and concentrated in vacuo. Purification over silica gel (Biotage MPLC 10 - 70% EtOAc/hexanes) gave the title compound as a light yellow solid (42 mg, 32%). Example 6 Preparation of Sarcomeric Proteins from Skeletal Muscle [0158] Actin was purified by first preparing an ether powder of cardiac muscle (Zot HG and Potter J D. (1981) Preparative Biochemistry 11:381-395) as described below. Subsequently, actin was cycled between the filamentous and soluble state through rounds of centrifugation and dialysis (Spudich J A and Watt S. (1971) J. Biol. Chem. 246:4666-4871). It was stored in the filamentous state at 4 'C. [0159 Tropomyosin was extracted from the ether powder and separated from the other proteins based on pH dependent precipitations followed by successive ammonium sulfate cuts at 53% and 65% (Smillie LB. (1981) Methods Enzymol 85 Pt B:234-41). The troponins were isolated as an intact complex of TnC, TnT, and Tnl. Ether powder is extracted in a high salt buffer. Successive ammonium sulfate cuts of 30% and 45% were done; the precipitate was solubilized by dialysis into a low salt buffer and then further purified on a DEAE Toyopearl column with a 25-350 mM KCI gradient. There was no measurable ATPase in any of the components except for myosin which naturally had a very low basal ATPase in the absence of actin. [0160] Just prior to screening, the actin, tropomyosin, and troponin complex are mixed together in the desired ratio (e.g., 7:1:1) to achieve maximal calcium regulation of the actin filament. The screen is conducted at a pCa=6.5. This calcium concentration is in the physiological range during muscle contraction. [0161] To measure the generation of ADP during the reaction, a pyruvate kinase/lactate dehydrogenase/NADH coupled enzyme system (PK/LDH) is added to the actin. The myosin is kept separately. The plates are read in real time so that kinetic curves are obtained. These compounds are in DMSO and were already spotted onto the bottoms of 384 well plates at 10 to 40 pg/ml final concentration. 58 Example 7 Actin Preparation 1. Extract powder (as prepared in Example 6 or 7 below) with 20 ml buffer A (see below, add BME and ATP just prior to use in each of the following steps) per gram of powder (200 ml per 10 g). Use a large 4 L beaker for 150 g of powder. Mix vigorously to dissolve powder. Stir at 4 *C. for 30 min. 2. Separate extract from the hydrated powder by squeezing through several layers of cheesecloth. Cheesecloth should be pre-sterilized by microwaving damp for 1-2 min. 3. Re-extract the residue with the same volume of buffer A and combine extracts. 4. Spin in JLAI0 rotor(s) for 1 hr at 10K rpm (4 "C.). Collect supernatant through 2 layers of cheesecloth. 5. Add ATP to 0.2 mM and MgCI 2 to 50 mM. Stir on stir plate at 4 "C for 60 minutes to allow actin to polymerize/form para-cryslals. 6. Slowly add solid KOI to 0.6 M (45 g/l). Stir at 4 *C for 30 min. 7. Spin in JLA10 rotor(s) at 10K rpm for 1 hr. 8. Depolymerization: Quickly rinse surface of pellets with buffer A and dispose of wash. Soften the pellets by pre-incubation on ice with small amount of buffer A in each tube (use less than half of final resuspension volume total in all tubes). Resuspend by hand first with cell scraper and combine pellets. Wash tubes with extra buffer using a 25 ml pipette and motorized pipettor, aggressively removing actin from sides of tubes. Homogenize in large dounce in cold buffer A on ice. Use 3 ml per gram of powder originally extracted. 9. Dialyze against buffer A with 4 changes over 48 hour period. 10. Collect dialyzed actin and spin in the 45Ti rotor at 40K rpm for 1.5 hr (4 "C.). 11. Collect supernatant (G-Actin). Save a sample for gel analysis and determination of protein concentration. [0162] To polymerize G-actin for storage add KCI to 50 mM (from 3 M stock), MgCl 2 to 1 mM, and NaN 3 to 0.02% (from 10% stock). Store at 4 *C. Do not freeze. 59 E0163] Buffer A: 2 mM tris/HC, 0.2 mM CaCl 2 , 0.5 mM (36 pl/L) 2-mercaptoethanol, 0.2 mM Na 2 ATP (added fresh), and 0.005% Na-azide; pH 8.0. Example 8 Powder Preparation 1, Volumes are given per about 1000 g of the minced muscle. 2. Pre-cut and boil cheesecloth for 10 min in water. Drain and dry. 3. Mince chicken breast in a prechilled meat grinder. 4. Extract with stirring in 2 L of 0.1 M KCI, 0.15 M K-phosphate, pH 6.5 for 10 min at 4 "C. Spin 5000 rpm, 10 min, 4 "C in JLA. Collect the pellet, 5. Extract pellets with stirring with 2 L of 0.05 M NaHCO 3 for 5 min. Spin 5000 rpm, 1 0min, 4 "C in JLA. Collect the pellet. Repeat the extraction once more. 6. Extract the filtered residue with 2 L of 1 mM EDTA, pH 7.0 for 10 min with stirring. 7. Extract with 2 L of H 2 0 for 5 min with stirring. Spin 10000 rpm, 15min, 4 "C in JLA. Carefully collect the pellet, part of which will be loose and gelatinous. 8. Extract 5 times with acetone (2 L of acetone for 10 min each with stirring). Squeeze through cheesecloth gently. All acetone extractions are performed at room temperature. Acetone should be prechilled to 4 "C. 9. Drying: Place the filtered residue spread on a cheesecloth in a large glass tray and leave in a hood overnight. When the residue is dry, put in a wide mouth plastic bottle and store at 20 "C. Example 9 Alternate Powder Preparation Based on Zot & Potter (1981) Prep. Biochem. 11(4) pp.381-395. 1. Dissect left ventricles of the cardiac muscle. Remove as much of the pericardial tissue and fat as possible. Grind in a prechilled meat grinder. 60 Weigh. 2. Prepare 5 volumes of Extract buffer (see below). Be sure the pH=8.0. Then, homogenize the meat in a blender, 4 times 15 sec on blend with 15 secs in between. Do this with 1 volume weight/volume) of buffer taken from the 5 volumes already prepared. Add the homogenate back to the extract buffer and stir until well mixed (5 minutes). 3. Filter through one layer of cheesecloth in large polypropylene strainer. Resuspend back into 5 volumes of extract buffer as above. 4. Repeat Step 3 four more times. At the end, do not resuspend in extraction buffer but proceed to Step 5. The pellets should be yellow white. 5. Resuspend in 3 volumes (according to original weight) of 95% cold ethanol. Stir for 5 min and squeeze through cheesecloth as above, repeat two more times. 6. Weigh squeezed residue and then resuspend in 3 volumes (new weight/volume) of cold diethyl ether. 7. Repeat Step 6 a total of three times. 8. Leave ovemight in a single layer on a cheesecloth in a glass tray. 9. When dry, collect the powder, weigh and store in a wide-mouth jar at 4 *C, EXTRACT BUFFER: 50 mM KCI, 5 mM Tris pH 8.0 Prepare as 50 times concentrate: For 2L 250 mM Tris pH 8.0. Tris Base (121.14 g/mol, 60.6 g) pH to 8.0 with cono. HCI, then add: 2.5 M KCI (74.55 g/mol, 372 g) Example 10 Purification of Skeletal Muscle Myosin [01641 See, Margossian, S.S. and Lowey, S. (1982) Methods Enzymol. 85, 55-123 and Goldmann, W.H. and Geeves, M.A. (1991) Anal. Biochem. 192, 55-58. 61 Solution A: 0.3 M KCI, 0.15 M potassium phosphate, 0.02 M EDTA, 0.005 M MgC2. 0.001 M ATP, pH 6.5. Solution B: 1 M KC, 0.025 M EDTA, 0.06 M potassium phosphate, pH 6.5. Solution C: 0.6 M KCI, 0.025 M potassium phosphate, pH 6.5. Solution D: 0.6 M KCI, 0.05 M potassium phosphate, pH 6.5. Solution E: 0.15 M potassium phosphate, 0.01 M EDTA, pH 7.5. Solution F: 0.04 M KCI, 0.01 M potassium phosphate, 0.001 M DTT, pH 6.5. Solution G: 3 M KCl, 0.01 M potassium phosphate, pH 6.5. All procedures are carried out at 4 *C. 1. Obtain -1000 g skeletal muscle, such as rabbit skeletal muscle. 2. Grind twice; extract with 2 L solution A for 15 min while stirring; add 4 L cold
H
2 0, filter through gauze; dilute with cold H 2 0 to ionic strength of 0.04, (about 10-fold); let settle for 3 h; collect precipitate at 7,000 rpm in GSA rotor for 15 min. 3. Disperse pellet in 220 ml solution B; dialyze overnight against 6 L solution C; slowly add -400 ml equal volume cold distilled H20; stir for 30 min; centrifuge at 10,000 rpm for 10 min in GSA rotor. 4. Centrifuge supernatant at 19,000 rpm for 1 h. 5. Dilute supernatant to ionic strength of 0.04 (-8-fold); let myosin settle overnight; collect about 5-6 L fluffy myosin precipitate by centrifuging at 10,000 rpm for 10 min in GSA rotor. 6. Resuspend pellet in minimal volume of solution G; dialyze overnight against 2 L solution D; centrifuge at 19,000 rpm for 2 h, in cellulose nitrate tubes; puncture tubes and separate myosin from fat and insoluble pellet. 7. Dilute supernatant to 5-10 mg/mI and dialyze against solution E extensively, load onto DEAE-sephaciex column. 8. Preequilibrate with solution E; apply 500-600 g myosin at 30 mil/h; wash with 350 ml solution E; elute with linear gradient of 0-0.5 M KCI in solution E (2 x 1 62 liter); collect 10 ml fractions; pool myosin fractions (>0.1 M KCI); concentrate by overnight dialysis against solution F; centrifuge at 25,000 rpm for 30 min; store as above, 9. The myosin is then cut with chymotrypsin or papain in the presence of EDTA to generate the SI fragment which is soluble at the low salt conditions optimal for ATPase activity (Margossian supra). Example 11 [0165] Using procedures similar to those described herein, the compounds in the following table were synthesized and tested. SKM MF Name m/z [on ACI4 (pM) (S)-6-bromo-1-(1-phenylethyl)-1H-imidazo[4,5- 319.0; [M+H]; 0.45 b~pyrazin-2-ol 321.0 (M+H]* (S)-6-bromo-1-(1-phenylethyl)-1H-imidazo[4,5- 319.0; [M+H]*; 0.45 blpyrazin-2(3H)-one 321.0 [M+H]* (R)-6-bromo-1-(1-phenylethyl)-1IH-imidazo[4,5- 319.0; [M+H}f; + 2.4 blpyrazin-2-ol 321.0 [M+H]* (R)-6-bromo-1-(1-phenylethyl)-1 H-imidazo[4,5- 319.0; [M+H}*; 24 blpyrazin-2(3H)-one 321.0 [M+H}* 1 -benzyl-6-bromo-1 H-imidazo[4,5-b]pyrazin-2-ol 305.1; [M+Hf; 23.5 307.1 [M+H] I -benzyl-6-bromo-1 H-imidazo(4,5-b]pyrazin- 305.1; [M+H] t ; 23.5 2(3H)-one 307.1 [M+H]* (S)-6-(methylthio)-1 -(1-phenylethyl)-1H imldazo(4,5-b]pyrazin-2-ol 63 SKM MF Name mlz ion ACI.4 (pM) (S)-6-(methylthio)-1-(1-phenylethyl)-1H-2 imidazo[4,5-b]pyrazin-2(3H)-one 1-benzyl-6-(methylthio)- I H-imIdazo[4,5-b]pyrazin- 273.0 [M+H] 4 22.6 2-ol 1-benzyl-6-(methylthio)-1 H-imidazo[4,5-b]pyrazin- 273.0 [M+H]* 22.6 2(3H)-one (R)-6-(methylthio)-1-(1-phenylethyl)-1 H imidazo(4,5-b]pyrazin-2-ol 287.0 LM+Hr 2.9 (R)-6-(methylthio)-1-(1 -phenylethyl)-1 H- 287.0 [M+H}* 2.9 imidazo[4,5-blpyrazin-2(3H)-one (S)-6-(2-methylprop-1 -enyl)-1-(1 -phenylethyl)-i H- 295A [M+H]* 2.7 imidazo[4,5-bjpyrazin-2-ol (S)-6-(2-methylprop-1 -enyl)- 1-(1 -phenylethyl)-1 H imidazo[4,5-blpyrazln-2(3H)-one (S)-6-cyclohexenyl-1-(1-phenylethyl)-1 H- 321.1 IM+H]* 31.0 imidazo[4,5-b]pyrazin-2-ol (S)-6-cyclohexenyl-1-(1-phenylethyl)-I H- 321.1 [M+H]* 31.0 imidazo[4,5-b]pyrazin-2(3H)-one (S,Z)-1 -(1 -phenylethyl)-6-(prop-1-enyl)-1 H- 281.1 [M+H]+ 1.0 imidazo[4,5-b]pyrazin-2-ol (S,Z)-1 -(1 -phenylethyl)-6-(prop-1-enyl)-1 H- 281.1 [M+Hl* 1.0 imidazo[4,5-b)pyrazln-2(3H)-one (S)-1 -(1-phenylethyl)-6-vinyl-1 H-imidazo(4,5- 267.0 [M+H]* 2.4 blpyrazin-2-ol (S)-1 -(1-phenylethyl)-6-vinyl-1 H-imidazo[4,5- 267.0 [M+H]* 2.4 bjpyrazin-2(3H)-one 64 SKM MF Name mlz Ion ACI.4 (pM) (S)-6-ethyl-1-(1-phenylethyl)-1 H-imidazo[4,5- 269.1 17.4 b]pyrazin-2-ol (S)-6-ethyl-1-(1-phenylethyl)-1 H-imidazo[4,5- 269.1 [M+Hf* 17.4 bjpyrazin-2(3H)-one (S)-1-(1-phenylethyl)-6-propyl-1 H-imidazo(4,5- 283.1 [M+Hl* 29.7 b]pyrazin-2-ol (S)-1 -(1 -phenylethyl)-6-propyl-1 H-imidazo[4,5- 283.1 [M+H]* 29.7 bjpyrazin-2(3H)-one (S)-6-methoxy-1 -(1 -phenylethyl)-1 H-imidazo[4,5- 271.1 [M+Hf* 8.8 bjpyrazin-2-ol (S)-6-methoxy-1-(1-phenylethyl)-1 H-imidazo[4,5- 271.1 [M+H] 4 8.8 b]pyrazin-2(3H)-one 6-bromo-1 -cyclohexyl-1 H-imidazo[4,5-b]pyrazin-2- 296.9; [M+H]*; 10.4 01 298.9 [M+H]* 6-bromo-1 -cyclohexyl-1 H-imidazo{4,5-b]pyrazin- 296.9; [M+H]f; 10.4 2(3H)-one 298.9 [M+H]* 1 -cyclohexyl-6-(methylthio)-1 H-imidazo[4,5- 265.1 [M+H* 13.9 b)pyrazin-2-ol 1 -cyclohexyl-6-(methylthio)-1 H-imidazot4,5- 265.1 [M+H]* 13.9 b]pyrazin-2(3H)-one (Z)- 1-cyclohexyl-6-(prop-1 -enyl)- H-imidazo[4,5- 259.1 (MH] 6.0 b]pyrazin-2-ol (Z)-1 -cyclohexyl-6-(prop- 1 -enyl)-1 H-imidazo[4,5 259.1 [M+H] 6.0 b]pyrazin-2(3H)-one (E)-1 -cyclohexyl-6-(prop-1 -enyl)-1 H-imidazo[4,5- 259.1 [M+H]* 6.1 b]pyrazin-2-ol 65 SKM MF Name mrz Ion ACI.4 (pM) (E)-1-cyclohexyl-6-(prop-1-enyl)-1 H-imidazo[4,5- 259.1 (M+H] 6.1 b]pyrazin-2(3H)-one (S,E)-1-(1-phenylethyl)-6-(prop-1-enyl)-1H imidazo(4,5-b]pyrazin-2-oI (S.E)-1-(1-phenylethyl)-6-(prop-1-enyl)-1 H- imidazo[4,5-b]pyrazin-2(3H)-one 6-bromo-1 -isopropyl-1 H-imidazo[4,5-b]pyrazin-2-oI 259.0 [M+H] t 6.0 6-bromo-1 -isopropyl-1 H-imidazo[4,5-bjpyrazin 2(SH)-one259.0 [M+H] t 6.0 2(3H)-one 1 -isopropyl-6-(methylthio)-1 H-midazo[4,5- 225.1 [M+Hj t 6.7 bjpyrazin-2-ol 1-lsop ropyl-6-(methylth io)- 1 H-imidazo[4,5- 225.1 (M+Hl+ 6.7 b]pyrazin-2(3H)-one (Z)- 1 -isopropyl-6-(prop- 1 -enyl)- 1 H-imid azo[4,5 219.2 [M+H-) 4.6 bjpyrazin-2-ol (Z)-1 -isopropyl-6-(prop-1 -enyl)- 1 H-im idazo[4,5 b]pyrazin-2(3H)-one (S)-6-ethoxy-1 -(1 -phenylethyl)-1 H-imidazo[4,5 b~pyazin2-oI285.2 [M+H] 10.6 b]pyrazin-2-ol (S)-6-ethoxy-1 -(1 -phenylethyl)-1 H-imidazo[4,5- 285.2 [M+H]+ 10.6 bjpyrazin-2(3H)-one 6-bromo-.'t-(pentan-3-yl)-1 H-imidazo[4,5-bjpyrazin- 286.0; [M+2H] ; 0.25 2-ol 288.0 [M+2H]2+ 6-bromo-1 -(pentan-3-yl)-1 H-imidazo[4,5-blpyrazin- 286.0; [M+2H]W; 2(3H)-one 288.0 [M+2H] 2 + 6-(methylthio)-1 -(pentan-3-yl)-1 H-imidazo[4, 5 253.1 [M+H]* 0.4 b]pyrazin-2-ol 66 SKM MF Name mlz Ion AC1.4 _________ (pM) 6-(methylthio)-1-(pentan-3-yl)-1 H-irnidazo(4,5 blpyrazin-2(3H)-one (E)-1-(pentan-3-yl)-6-(prop-1-enyl)-1
H
imidazo[4,5-blpyrazin-2-ol (E)-I-(pentan-3-yl)-6-(prop-1-enyl)-1
H
imidazo[4,5-b]pyrazin-2(3H)-one (Z)-I-(pentan-3-yl)-6-(prop-1-enyl)-IH imidato[4,5-bpyrazin-2-ol (Z)-1 -(pentan-3-yl)-6-(prop-1 -enyl)-1 H imidazo[4,5-b]pyrazin-2(3H)-one 6-methyl-1-(pentan-3-y)-IH-imidazo[4,5- 221.1 [M+H] 0.53 b]pyrazin-2-ol 6-methyl-1-(pentan-3-yl)-1H-imidazo[4,5- 221.1 jM+H)+ 0.53 b]pyrazin-2(3H)-one (SZ)-6-(hex-2-enyl)-1-(1-phenylethyl)-1
H
3.1 imidazo[4,5-b]pyrazin-2-ol 2-hydroxy-1-(pentan-3-yl)-1 H-imidazo[4,5- 232.1 EM+Hr 36.4 b]pyrazine-6-carbonitrile 2-oxo-3-(pentan-3-yl)-2,3-dihydro-1 H-imidazo[4,5- 232.1 IM+H1+ 36.4 b]pyrazine-5-carbonitrile (R)-6-brorno-1 -sec-butyl1 H-imidazo(4,5- 273.0 jM+H]+ 1.5 b]pyrazin-2-ol (R)-6-bromo- 1-sec-butyl- 1 H-imidazo[4,5- 273.0 (M+HJ+ 1.5 b]pyrazin-2(3H)-one (S)-6-bromo- 1 -sec-butyl-1 H-imidazo[4,5-b]pyrazin- 272.0 [M+2H] 2 + 0.8 2-ol 67 SKM MF Name mlz Ion ACI.4 (pM) (S)-6-bromo-1-sec-buty-1 H-imidazo[4,5-b]pyrazin 272.0 [M+2H)' 0.8 2(3H)-one 6-bromo-1-tert-butyl-1H-imidazo(4,5-b]pyrazin-2-ol 272.0 [M+2H]) 0.8 6-bromo-1-tert-butyl-1 H-imidazo[4,5-b]pyrazin- 272.0 [M+2H] 2 " 0.8 2(3H)-one 2-(6-bromo-2-hydroxy-1 H-imidazo[4,5-blpyrazin-1- 299.0 tM-1- 49 yl)butanoic acid 2-(6-bromo-2-oxo-2,3-dihydro-1 -imidazo[4,5- 299.0 [M-H 49 b]pyrazin-1-yI)butanoic acid 2-(6-bromo-2-hydroxy-1 H-imidazo[4,5-b]pyrazin-1- 370.0 [M+Nf >49 yl)-1 -morpholinobutan-1-one 6-bromo-1-(i-morpholino-i-oxobutan-2-yl)-1
H
370.0 [M+H} >49 imidazo[4,5-bjpyrazin-2(3H)-one (R)-6-bromo-1-(i-hydroxybutan-2-y)-1
H
imidazo[4,5-b]pyrazin-2-oI (R)-6-bromo-1-(1 -hydroxybutan-2-yl)-1 H imidazo(4,5-b]pyrazin-2(3H)-one (S)-6-bromo-1-(1 -hydroxybutan-2-yl)-1 H- 285.0 [M-HjT 19.1 imidazo(4,5-bjpyrazin-2-ol (S)-6-bromo-1-(1 -hydroxybutan-2-yl)-1 H imidazo[4,5-b]pyrazin-2(3H)-one 6-bromo-1 -(1 -methoxybutan-2-yl)-1 H-imidazo[4,5- 301.0 1M+H] 4.9 b]pyrazin-2-ol 6-bromo-1 -(1 -methoxybutan-2-yl)-IH-imidazol4,5 301.0 [M+H)* 4.9 b]pyrazin-2(3H)-one 1 -(1aminobutan-2-yl)-6-bromo-1H-imidazo[4,5- - [M+2H+ 1.1 287.0 [+H . b]pyrazin-2-oI 68 SKM MF Name mlz Ion ACI.4 (pM) 1-(1-aminobutan-2-yl)-6-bromo-1 -imidazo[4,5- 287.0 IM+2H1 2 + 1.1 blpyrazin-2(3H)-one 6-bromo-1-(1 -(methylamino)butan-2-yl)-1
H
300.0 [M+H] 45:7 imidazo(4,5-b]pyrazin-2-ol 6-bromo-1-(1 -(methylamino)butan-2-yl)-1H 300.0 [M+H]* 45.7 imidazo[4,5-bjpyrazin-2(3H)-one 6-bromo-1-(1 -(dimethylamino)butan-2-yl)-1
H
315.0 [M+2H]* 43.8 imldazo[4,5-b]pyrazn-2-ol 6-bromo-1 -(1 -(dimethylamino)butan-2-yl)-1 H 315.0 [M+2H3 2 * 43.8 imldazo[4,5-bjpyrazin-2(3H)-one 6-bromo-1 -(1 -(4-methy)piperazin-I -yl)butan-2-yl)- 369.0 (M+HJ t 14.9 1 H-imidazo[4,5-b]pyrazin-2-ol 6-bromo-1-(l -(4-methylpiperazin-1 -yl)butan-2-yl)- 369.0 [MiHf 14.9 1 H-imidazo[4,5-b]pyrazin-2(3H)-one (R)-6-bromo-1 -(1 -morpholinobutan-2-yl)-1 H- 356.0; [M+Hf; 0.3 imidazo[4,5-bjpyrazin-2-ol 358.0 [M+Hf (R)-6-bromo-1-(1-morpholinobutan-2-yl)-1 H- 356.0; [M+Hf; 0.3 imidazo[4,5-bjpyrazin-2(3H)-one 358.0 [M+H]* (S)-6-bromo-1-(1-morpholinobutan-2-y)-1 H- 356.0; [M+H]*; imidazo[4.5-bjpyrazin-2-ol 358.0 (M+Hf+ (S)-6-bromo-1 -(1 -morpholinobutan-2-yl)-1 H- 356.0; [M+Hf; imidazo[4,5-b)pyrazin-2(3H)-one 358.0 [M+H]' (E)-1-isopropyl-6-(prop-1-enyl)-1 H-imidazo[4,5- 219.1 [M+H]* 7.1 b]pyrazin-2-ol (E)-1-isopropyl-6-(prop-1-enyl)-1 H-Imidazo(4,5- 219.1 [M+H]* 7.1 bjpyrazin-2(3H)-one 1-(pentan-3-yl)-1H-imidazo[4,5-bjpyrazin-2-oI 207.1 [M+-Hf 16.0" 69 SKM MF Name mlz Ion ACI.4 (pM) 1-(pentan-3-yI)-IH-imidazo(4,5-b]pyrazin-2(3H)- 207.1 EM+Hf 1a.Ot one methyl 4-(2-(6-bromo-2-hydroxy-1H-imidazo[4,5 b]pyrazin-1 -yl)butyl)piperazne-1 -carboxylate methyl 4-(2-(6-bromo-2-oxo-2,3-dihydro-1 H imidazo[4,5-bjpyrazin-1-yl)butyl)piperazine-1 - 414.0 [M+2H]2+ 0.91 carboxylate 6-bromo-1 -(1 -(4-(methylsulfonyl)piperazin-1- 434.0 [M+2H] 2 3 2 t yl)butan-2-yI)-1 H-Ilmidazo[4,5-b]pyrazin-2-ol 6-bromo-1-(1-(4-(methylsulfonyl)piperazin-1- 434.0 (M+2H] 2 3 yl)butan-2-yl)-1 H-imidazo[4,5-b]pyrazin-2(3H)-one 5-bromo-1 -(pentan-3-yl)-1 H-imidazo[4,5-blpyrazin- 285.0; [M+H]f; 2-ol 287.0 [M+H]* 5-bromo-1 -(pentan-3-y)-1 H-irnidazo[4,5-b]pyrazln- 285.0; [M+H] t ; 11.5 2(3H)-one 287.0 [M+H]* 1-(pentan-3-y)-1 H-Cmidazo[4,5-b]qunoxalin-2-ol 257.1 [M+H]f 19.8 1-(pentan-3-yl)-1 H-imidazo[4,5-b]quinoxalin- 257.1 [N+H] 19.8 2(3H)-one 6-ethynyl-1-(pentan-3-yl)-1 H-imidazo[4,5- 231.2 0.1 b]pyrazin-2-ol 6-ethynyl-1-(pentan-3-yl)-1 H-imidazo[4, 5 b]pyrazin-2(3H)-one 1 -(pentan-3-yl)-6-(trifluoromethyl)-1 H-imidazo[4,5- 275.2 [M+H]* 10.
4 * b]pyrazin-2-oI I -(pentan-3-yI)-6-(trifluoromethyl)-i H-imidazo[4,5- 275.2 [M+H]* 10.4* b]pyrazin-2(3H)-one 70 SKM MF Name mlz [on ACI.4 (pM) 6-bromo-1 -(2-methyl-1-morpholinopropan-2-y)- 356.0; [M+H]r; 1 H-imidazo[4,5-b]pyrazin-2-ol 358.0 [M+H16 6-bromo-1 -(2-methyl-1 -morpholinopropan-2-yl)- 356.0; [M+H]*; 16A' 1H-imidazo[4,5-b]pyrazin-2(3H)-one 358.0 [M+Hr (S)-6-bromo-1-(1-morpholinopropan-2-y)-1 H- 342.0; [M+H]*; imidazo[4,5-blpyrazin-2-ol 344.0 [M+H]* (S)-6-bromo-1 -(I-morpholinopropan-2-yl)-1 H- 342.0; [M+H+; imidazo[4,5-bjpyrazin-2(3H)-one 344.0 [M+H)* 6-methoxy-1-(pentan-3-yl)- H-imidazo[4,5- 237.1 [M+H- 2.2t b]pyrazin-2-ol 6-methoxy-1-(pentan-3-y)-1 H-imidazo[4,5- 237.1 [M+H] 2.2 bjpyrazin-2(3H)-one (R)-6-bromo-1-(1-morpholinopropan-2-y)- 1H- 342.0; [M+H]*; imidazo[4,5-bpyrazin-2-ol 344.0 (M+H]+ (R)-6-bromo-1-(1-morpholinopropan-2-yl)-1 H- 342.0; [M+H]; imid azol4,5-blpyrazin-2(3H)-one 344.0 [M+H)* 1-(pentan-3-y)-1 H-imidazo[4,5-b]pyrazine-2,6-diol 223.2 [M+H) >49 6-hydroxy-1-(pentan-3-y)-1 H-imidazo[4,5- 223.2 jM+H] >49 blpyrazin-2(3H)-one 1-(pentan-3-yl)-6-(prop-1-ynyl)-1 H-imidazo[4,5 245.2 [M+H] >49 b]pyrazin-2-ol 1-(pentan-3-yl)-6-(prop-1-ynyl)-1 H-imidazo[4,5 245.2 [M+H] >49 b]pyrazin-2(3H)-one 1-(1 -morpholinobutan-2-yl)-I H-imidazo[4,5- 278.0 M+H]+ >49 bjpyrazin-2-ol 1-(1-morpholinobutan-2-yl)-1 H-imidazo[4,5 278.0 >49 b]pyrazin-2(3H)-one 71 SKM MF Name m/z Ion ACI.4 (pM) 1-(ethylpropyl)-6-(1-m.ethylpyrazolA- 287.1 [M+H] yl)imidazol4,5-b]pyrazin-2-ol 6-bromo-1-(propylbutyl)imidazo[4,5-blpyrazin-2-o 313.1 [M+H]' 0.7 1 -[(1 R)-3-methyl-1 -(morpholin-4-ylmethyl)butyl-6- 384 [M+HJ 4 0.5 bromoimidazo[4,5-blpyrazin-2-o 1-(ethylpropyl)-6-vinylimidazo[4,5-b]pyrazin-2-oI 2331 [M+H] 2.3 i -(ethylpropyl)-6-(1 -methylvinyl)imidazo[4,5- 247 [M+H1 0.6 bpyrazin-2-ol 1-(ethylpropyl)-6-(methylethyl)imidazo[4,5- 249 29.6 b]pyrazin-2-ol 6-chloro-1-(ethylpropyl)imidazo[4,5-b]pyrazin-2-oi 239.1 [M+H]* 0.7 6-(dimethylamino)- 1-(ethylpropyl)imidazo[4,5 250.1 [M+-H] 2.2 b]pyrazin-2-ol 1 -((1 R)-1 -methyl-2-morpholin-4-ylethyl)-6- 342, (M+H), 5.19 bromoimidazo[4,5-b]pyrazn-2-ol 344 (M+2+H) I -(ethylp ropyl)-6-ethynyi imidazo[4,5-blpyrazin-2-ol 229 (M-H) 0.15 1 -(ethylpropyl)-6-methoxyimidazo[4,5-blpyrazin-2 ol 237 (M-H) 2.20 0l 1-(1,1 -dimethyl-2-morpholin-4-ylethyl)-6- 355, (M+I), 19.11 bromoimidazo[4,5-bjpyrazin-2-o 358 (M+2+H) 6-(1 H- 1,2,3-triazol-4-yi)- 1- 274 (M+I)+ 46.64 (ethylpropyl)imidazo[4,5-bjpyrazin-2-ol I -(ethylp ropyl)-6-(trifluoromethyl)imidazo[4,5- 275 (M+H) 10.37 b]pyrazin-2-ol 1 -[(1 R)-1 -(morpholin-4-yimethyl)propyll-6- 302 (M+H) 0.13 ethynylimidazo[4,5-b]pyrazin-2-oI 72 SKM MF Name mlz Ion ACI.4 - (pM) 1-(ethylpropyl)-6-{2-[1--(ethylpropyl)-2 hydroxyimidazo[4,5-e]pyrazin-6- 435 (M+H) 19.32 yl]ethynyl)imidazo[4,5-b]pyrazin-2-ol 6-(dimethylamino)-I-(ethylpropyl)imidazo[4,5- 250 (M+H) 2.79 b]pyrazin-2-ol 6-ethyl-1-(ethylpropyl)imidazo[4,5-b]pyrazin-2-oI 235 [M+H] 8.58 T Mean value. * Median value. [0166] Using procedures similar to those described herein, the compounds in the following table were also synthesized and tested. Name (S)-1 -(2-hydroxy-1 -(1 -phenylethyl)-1 H-imidazo[4,5-b]pyrazin-6-yl)ethanone (S)-6-acetyl-1 -(1 -phenylethyl)-1 H-imidazo[4,5-b]pyrazin-2(3H)-one (S)-6-isobutyl-1-(1-phenylethyl)-1 H-irnidazo[4,5-b]pyrazn-2-o (S)-6-isobutyl-1-(1 -phenylethyl)-IH-imidazo[4,5-b]pyrazin-2(3H)-one (S)-6-hexyl-1-(1 -phenylethyl)-1 H-imidazo[4,5-bpyrazin-2-ol (S)-6-hexyl-1-(1-phenylethyl)-I H-imidazo[4,5-b]pyrazin-2(3H)-one (S)-6-cyclohexyl-1-(1 -phenylethyl)-1 H-im idazo[4,5-b]pyrazin-2-ol (S)-6-cyclohexyl-1-(1 -phenylethyl)-I H-imidazo[4,5-blpyrazin-2(3H)-one (S)-1 -(1 -phenylethyl)-I H-imidazo[4,5-bjpyrazn-2-ol (S)-1 -(1 -phenylethyl)-1 H-imidazo[4,5-b]pyrazin-2(3H)-one (S)-2-hydroxy-1-(1-phenylethyl)-1H-imidazo[4,5-bJpyrazine-6-carboxylic acid (S)-2-oxo-3-(1-phenylethyl)-2,3-dihydro-1H-imidazo[4,5-bjpyrazine-5-carboxylic acid (S)-methyl 2-hydroxy-1-(1-phenylethyl)-1H-imidazo[4,5-b]pyrazine-6-carboxylate (S)-methyl 2-oxo-3-(I-phenylethyl)-2,3-dihydro-1 H-imidazo[4, 5-b]pyrazine-5-carboxylate 73 (S)-2-hydroxy- 1 -(1 -phenylethyl)-1 H-imidazo[4, 5-bjpyrazlne-8-carbonitrile (S)-2-oxo-3-(1 -phenylethyQ-2 ,3-dihydro-1 H-irnidazoj4, 5-b]pyrezine-5-cerbonitrile (S)-2-hyd rowy-i -(1 -phenylethyl)-1 H-imidazo[4,5-bjpyrazin e-B-carboxa mid e (S)-2-oxo-3-(1 -phenylethyl)-2 ,3-dihydro-1 H-imidazo[4 1 5-b~pyrazine-5-ca rboxamide (S)-2-hydroxy-N-methyl-1 -(l -phenylethyl)-1 H-imidazo[4 1 5-bjpyrezine-6-csrboxamide (S)-N-methyl-2-oxo-3-(1 -phenylethy)-2,3-dihydro-1 H-imidazo[4, 5-blpyrezirie-5 carboxemide (S)-2-hydroxy-N, N-4iirilethyl-1 -(I -phertylethy)-1 H-imidazo[4,5-b~pyrazine-6-carboxa mide
(S)-N
1 N-dimethyl-2-oxo-3-( 1-ph enylethyl)-2,3-dihydro-i H-imidazo[4 1 5-b]pyrazine-5 carboxamide (S)-NN-diethyl-2-hydroxy-1 -(1 -phertylethyl)-1 )--imidazo[4, 5.bjpyrazine-G-c-arboxamide (S)-N,N-diethyl-2-oxo-3-(1 -ph enylethyl)-2,3-dihydro-1 H-imidazo[4 ,5-bjpyrazine-6 carboxamide (S)-(2-hydroxy- 1 -(1 -phenylethyl)- 1 H-imidazo[4,5-bjpyrazin-6-yI)(morpholino)metharione (S)-6-(morphollne-4-carbonyl)-1 -(l -phenylethyl) -1H-imidazoj4,5-bjpyrazin-2(3H)-one (S)-(2-hyd roxy-I -(1 -phenylethyl)-1 H--imid azo[4,5-blpyrazin-6-yl)(piperidin-1 yl)methanorie (8)-i -(1 -phenyrethyl)-6-(piperidine- 1 -carbonyl)-l I -- imidazo[4,5-b]pyrazin-2(3H)-one (S)-(2-hydroxy- 1 -(1 -phenylethyl)- IHI-imidazo[4 1 5-b)pyrazin-6-yIX(4-methylpiperazin-1 yI)methanone (S)-6-(4-methylpiperazine- I-carbonyl)-I -(I -phenylethyl)-1 H-iiidazo[4, 5-blpyrazin 2(3H)-one (8)-N-be nzyl-2-hyd roxy-1 -(I -phenylethyl)- 1 H-imidazo[4 ,6-bjpyrazine-6-carboxamide (S)-N-benzyl-2-oxo-3-( 1 -phenylethyl)-2, 3-dlhydro- 1 H-imidazo[4, 5-bjpyrazine-5 carboxam ide (S)-6-((d imethytamino)methyl)-1 -(1 -phenylethyl)- I Him ldazo[4,5-blpyrazin-2-o (S)-6-((d imethylamino)m ethyl)- 1 -(1 -phenylethyl)-i H-im idan4[4,5-blpyrazin-2(3H)-one (S)-6-(morpholinomethyl)-1 -(1 -phenylethyl)-1 H-imidazoj4, 5-bjpyrazin-2-ol (S)-6-(morpholinomethyi)- 1-(1 -phenylethyl)-1 H-im idazo(4,5-bjpyrazin-2(3H)-one 74 (S)-l1-(1 -phenylethyl)-6-(pipe rid in-I -ylmethyfl-1 H-imidazo[4,5-bjpyrazin-2-o (S)- 1-(1 -pheriylethyl)-6-(piperin-1 -ylmethyl)-1 K-imidazol4,5-blpyrazin-2 (31-)-one (S)-6-((4-methylpiperazii-1 -yI)methyl)-1 -(1 -phenylethyl)-1 H-midazo[4,5-blpyrazin-2-o (S)-6-((4-methylpiperarin-1 -yI)nmethyl)-1 -(1 -pheriylethyl)-1 H-imidazoj4, 5-b]pyrazin 2 (3H)-one (S)-6-(2-hydroxypropan-2-y)-1 -(1 -phenylethyl)-1 H-imidazot4, 5-b]pyrazln-2-ol (S)-6-(2-hydroxypropan-2-yI)- 1 -(1 -phenylethyl)-1 H--im idazo[4, 5-blpyrezin-2(SH)-one 6-(methylsulfinyl)-1 -((S)-1 -phenylethyl)-1 H-imidazo[4,5-b]pyrazin-2-oI 6-(methylsulfiny)-1 -((S)-1 -phenylethyl)-1 H-imidazot4, 5-bjpyrazin-2(3H)-one (S)-6-(methylsulfonyl)-1 -(1-p henylethyl)-I 1 --imidazol4.5-blpyrazin-2-oI (S)-6-(methylsulfonyl)-I -(1 -phenyiethyl)-1 H-imidazo[4 ,5-b]pyrazin-2(3H)-one 6-oyclopropyl-1 -(pentan-3-yl)- I H-imidazol4,5-bjpyrazln-2-o 6-cyolopropyl-i-(pentan-3-y)-1 H-imidazo[4, 5-b]pyrazin-2(3H)-one 6-(rmthto)- 1 -(tetrahyd ro-2H-pyri-4-yI)- H-imidazoj4 ,5-b]pyrazin-2-oI 6-(rmhlo)- -(tetrahydro-2 H-pyran-4-yI)- H-imidazoj4,5-b]pyrazin-2(3H)-one (I -cycopropyl-6-(prop-I -eny)-1 H-imidazo[4 1 5-bjpyrazin-2-oI IE- -yclopropyl-6-(prop-1-ey)- I H-imidazo[4, 5-b]pyrazln-2(3H)-one (E-(prop- I -eny1 -(tetrhydro-2 H-pyr n-4-yl)- H-imidazot4, 5-b]pyrazin-2-oI E6-(prhyo--enl) -(tetrahylro-2H-pyra n-4-yI)- H-imdazo[4,5-b]pyrazin-2(3H)-one (Z)-1-cyclopropyl-6-(p rop-1 -enyl)-1 H-im idazo[4,5-bjpyrazin-2-o (Z)- 1 -oyclopropyl-6-(prop-i -enyl)-1 H-imid azo[4, 5-b]pyrazin-2(3H)-ofle (Z)-6-(prop-l -enyl)- I -(tetrahiydro-2H-pyran-4-yl)-1 H-imidazc44, 5-b]pyrazin-2-oI (Z)-6-(prop-1 -enyl)-1 -(tetrahydro-2H-pyran-4-yI)- IH-imidazo[4, 5-b]pyrazin-2(3H)-one 5-bromo-l1-cyolopropyl-1 H-inidazo[4 .5-b]pyrain-2-oI 6-bromo-I -cyclopropyl-1 H-[midazojl4, 5-b]pyrazin-2(3H)-one 75 5-(methylthio)-1-(pentan-3-y)-1 H-imidazo[4,5-bpyrazin-2-ol 5-(methylthio)-1-(pentan-3-yl)- H-imidazo[4,5-blpyrazin-2(3H)-one 5-ethyl- -(pentan-3-y)-1 H-imidazo[4,5-bpyrazin-2-ol 5-ethyl--1-(pentan-3-yI)- H-imidazo[4,5-bppyrazin-2(3H)-one -h y--iyl-(pentan-3-yl) 1 Hmidazo[4,5-b]pyrazin-2-e b 1-(pentan-3-yl)-5-vinyl-1 H-imidazo[4,5-bpyrazein-2(3H)-one methyl 2-hydroxy-1 -(pentan-3-yl)-1 H-imidzo[4,5-b]pyrazine-5-carboxylate methyl 2-oxo-1-(pentn-3-yI)-2,3-dihydro-1 H-imidazo[4,5-b]pyrazine-5-carboxylate 2-hydroxy-N,N-dimethyl--(pentan-3-yl)-I 1 H-imidazo[4,5-b]pyrazine-5-carboxamide N,N-dimethyl-2-oxo-1-(pentan-3-yi)-2,3-dihydro-1H-imidazo[4,5-bpyrazine-5 carboxamide 2-hydroxy-N-nethyl-(pentan-3-y)-1 H-imidazo[4,5-b]pyrazine-5-carboxamide N-methyl-2-oxo-1 -(pentan-3-yi)-2,3-dihydro-HH-imidzo[4,5-b]pyrazine-5-carboxamide 12-(-bro--(pentan-3-yl)-1H-imidazo[4,5-bpyrazin-5-yl)etha none 5-acetyl-1 -(pentan-3-yl)- H-imidazo[4,5-b]pyraz -in-2(3H)-one (S)-1-(1-phenylethyl)-iH-imidazo[4,5-bquinoxalin-2-oI (S)-1 -(1-phenyiethyi)-1 H-imidazo[4,5-bjquinoxalin-2(3H)-one 2-(6-bromo-2-hydroxy-1 H-imidazo[4,5-blpyrazin-1-yl)propane-1,3-diol 6-bromo-1-(1,3-dihydroxypropan-2-yl) 1 H-imidazo[4,5-bjpyrazin-2(3H)-one 6-bromo-1-(2-morpholinoethyl)-1 H-imnidazo[4,5-bjpyrazin-2-ol 6-bromo-1-(2-morpholinoethyl)-1 H-imidazo{4,5-b]pyrazin-2(3H)-one 2-hydroxy-1-(pentan-3-yl)-IH-imidazot4,5-b]pyrazine-5-carboxylic acid 2-oxo-1-(pentan-3-yl)-2, 3-dihydro-1 H-imidazo[4,5-bjpyrazine-5-carboxylic acid [0167) While some embodiments have been shown and described, various modifications and substitutions may be made thereto without departing from the spirit and scope of the invention. For example, for claim construction purposes, it is not intended that the claims set forth hereinafter be construed in any way narrower than the literal language thereof, and it is thus not intended that exemplary embodiments from the specification be read into the claims. Accordingly, it is to be understood that the 76 present invention has been described by way of illustration and not limitations on the scope of the claims. [0168] The reference in this specification to any prior publication (or information derived from it), or to any matter which is known, is not, and should not be taken as an acknowledgment or admission or any form of suggestion that that prior publication (or information derived from it) or known matter forms part of the common general knowledge in the field of endeavour to which this specification relates. [0169] Throughout this specification and the claims which follow, unless the context requires otherwise, the word "comprise", and variations such as "comprises" and "comprising", will be understood to imply the inclusion of a stated integer or step or group of integers or steps but not the exclusion of any other integer or step or group of integers or steps. 77
Claims (16)
1. At least one chemical entity chosen from compounds of Formula I and compounds of Formula 11: R4)N H R4 N N CM OH '1 R N Ri N N R2 R2 Formula I Formula 11 and pharmaceutically acceptable salts thereof, wherein R 1 nd-R 4 are independently selected from hydrogen, halo, hydroxy, optionally substituted acyl, opt[0rally substituted alkyl, optionally substituted amino, optiomally substitutedalkenyl -optionally-stibstituted alkynyl, optionally substituted cycloalkyl, optionally substituted heteroaryl, optionally substituted alkoxy, optionally substituted aminocarbonyl, sulfonyl, sulfanyl, sulfinyl, carboxy, optionally substituted alkoxycarbonyl, and cyano; and in the alternative, R 4 and R1, taken together with any intervening atoms, form a fused ring system selected from optionally substituted fused aryl, optionally substituted fused heteroaryl, optionally substituted fused cycloalkyl, and optionally substituted fused heterocycloalkyl; and R 2 is is selected fromoptionatly substituted alkyl, optionally substituted cycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, and optionally substituted heterocycloalkyl; provided that R 1 is not hex-1-enyl; and further provided that the compound, of Formula I or the compound of Formula i is not z (S)-6-bromo-1-(1-phenylethyl)-1H-imidazo[4,5-b]pyrazin-2(3H)-one; 1.5,6-trimethyl-1 H-imidazo4,5-blpyrazin-2(3H)-one; 1-methyl-1- H-imid azo(4, 5-b]pyrazin-2(3H)-one; 78
6-bromo-1 -(3-nitrobenzyl)-1 H-imidazo[4,5-bpyrazin-2(3H)-one; 5-(hydroxymethyl)-1,6-dimethyl-1H-imidazo[4,5-b]pyrazin-2(3H)-one; or 1 -(piperidin-4-yl)-1 H-imidazo[4,5-b]pyrazin-2(3H)-one. 2. At least one chemical entity of claim 1 wherein R 2 is selected from optionally substituted lower alkyl, optionally substituted cycloalkyl, optionally substituted alkoxy, and optionally substituted heterocycloalkyl. 3. At least one chemical entity of claim 2 wherein R 2 is selected from heterocycloalkyl, cycloalkyl, lower alkyl, and lower alkyl substituted with optionally substituted phenyl, hydroxy, optionally substituted alkoxy, optionally substituted amino and optionally substituted heterocycloalkyl. 4. At least one chemical entity of claim 3 wherein R 2 is selected from 1-(R) phenylethyl, 1-(S)-phenylethyl, benzyl, 3-pentyl, 4-heptyl, 4-methyl-1-morpholinopentan 2-yl isobutyl, cyclohexyl, cyclopropyl, sec-butyl, tert-butyl, isopropyl, 1-hydroxybutan-2 yl, tetrahydro-2 H-pyran-4-yl, 1-methoxybutan-2-yl, I-aminobutan-2-yl, and 1 morpholinobutan-2-y. 5. At least one chemical entity of any one of claims I to 4 wherein R, is selected from hydrogen, halo, acyl, optionally substituted lower alkyl, optionally substituted alkenyl, optionally substituted alkynyl, dialkylamino, amino substituted with an alkyl group and with a group chosen from acyl, aminocarbonyl, alkoxycarbonyl, and sulfonyl; optionally substituted lower alkoxy, and -S-(optionally substituted lower alkyl). 6. At least one chemical entity of claim 5 wherein R 1 is selected from hydrogen, halo, acyl, alkenyl, alkynyl, lower alkoxy, dialkylamino, amino substituted with an alkyl group and with a group chosen from acyl, aminocarbonyl, alkoxycarbonyl, and sulfonyl, pyrazolyl substituted with lower alkyl, -S-(optionally substituted lower alkyl), lower alkyl, and lower alkyl substituted with halo. 79
7. At least one chemical entity of claim 6 wherein R 1 is selectedfrom hydrogen, bromo, chloro, fluoro, methyl, ethyl, propyl, hexenyl, butenyl, propenyl, vinyl, ethynyl, methoxy, ethoxy, methylsulfanyl, dimethylamino, and methyl substituted with up to three fluoro groups.
8. At least one chemical entity of claim 7 wherein R 1 is selected from hydrogen, bromo, chloro, fluoro, methyl, ethyl, n-propyl, Isopropyl, dimethylamino, isobuten-1-yl, (Z)-propen-1-yl, (E)-propen-1-yi, propen-2-yl, vinyl, ethynyl, methoxy, ethoxy, methylsulfany, and trifluoromethyl.
9. At least one chemical entity of any one of claims 1 to 8 wherein R4 is selected from hydrogen, halo, acyl, optionally substituted alkyl, alkenyl, optionally substituted cycloalkyl, optionally substituted aminocarbonyl, sulfanyl, optionally substituted amino, and optionally substituted alkoxycarbonyl.
10. At least one chemical entity of claim 9 wherein R 4 is selected from hydrogen, halo, acyl, optionally substituted lower alkyl, lower alkenyl, optionally substituted cycloalkyl, optionally substituted aminocarbonyl, sulfanyl, optionally substituted amino, and optionally substituted lower alkoxycarbonyl.
11. At least one chemical entity of claim 10 wherein R 4 is selected from hydrogen, halo, acyl, lower alkyl, lower alkenyl, cycloalkyl, optionally substituted aminocarbonyl, sulfanyl, and lower alkoxycarbonyl.
12. At least one chemical entity of claim 11 wherein R 4 is selected from hydrogen, bromo, chloro, fluoro, acetyl, methyl, ethyl, vinyl, cyclohexen-1-yl, methylcarbamoyl, dimethylcarbamoyl, methylsulfanyl, and methoxycarbonyl.
13. At least one chemical entity of any one of claims 1 to 4 wherein R 4 and R 1 , taken together with any intervening atoms, form a fused ring system selected from optionally substituted fused aryl, optionally substituted fused cycloalkyl, and optionally 80 substituted fused heterocycloalkyl.
14. At least one chemical entity of claim 13 wherein R4 and R 1 are taken together to form an optionally substituted benzo group.
15. At least one chemical entity of claim 14 wherein R 4 and R 1 are taken together to form a benzo group.
16. At least one chemical entity of claim 1 wherein the compound of Formula I is chosen from 1-((1 R)-1-methyl-2-morpholin-4-ylethyl)-6-bromomidazo[4,5-b]pyrazin-2-ol; I-(ethylpropyl)-6-ethynylimidazo[4,5-blpyrazin-2-ol; 1-(ethylpropyl)-6-methoxyimidazo[4,5-b]pyrazin-2-ol; 1-(1,I-dimethyl-2-morpholin-4-ylethyl)-6-bromoimidazo[4,5-blpyrazin-2-ol; 6-(1 H-1,2,3-triazol-4-yi)-1-(ethylpropyl)imidazo[4,5-b]pyrazin-2-ol; 1-(ethylpropyl)-6-(trifluoromethyl)imidazo[4,5-b)pyrazin-2-ol; 1-[(1R)-1-(morpholin-4-ylmethyl)propyl]-6-ethynylimidazo[4,5-b]pyrazin-2-ol; 1-(ethylpropyl)-6-(2-[1-(ethylpropyl)-2-hydroxyimidazo[4,5-epyrazin-6 yl]ethynyl}imidazo[4,5-b]pyrazin-2-ol; 6-(dimethylamino)-I -(ethylpropyl)imidazo[4,5-bpyrazin-2-ol; 6-ethyl-1 -(ethylpropyl)imidazo[4,5-b]pyrazin-2-ol; (E)-i-(pentan-3-yl)-6-(prop-1-enyl)-I H-imidazo[4,5-bjpyrazin-2-ol; (E)-1-(pentan-3-y)-6-(prop-1-enyl)-1 H-imidazo[4,5-b)pyrazin-2-ol; (E)-1-cyclohexyl-6-(prop-1-enyl)-1H-imidazo[4, 5-bjpyrazin-2-ol; (E)-1-cyclopropyl-6-(prop-1 -enyl)-1 H-imidazo[4,5-blpyrazin-2-ol; (E)-1 -isopropyl-6-(prop-1-enyl)-1 H-imidazo(4,5-b]pyrazin-2-ol; (E)-6-(prop-1 -enyl)-1 -(tetrahydro-2H-pyran-4-yl)- 1 H-imidazo(4, 5-bjpyrazin-2 01; (R)-6-(methylthio)-1-(1 -phenylethyl)-1 H-imidazo[4,5-b]pyrazin-2-ol; (R)-6-bromo-I -(1-hydroxybutan-2-yl)-iH-imidazo[4,5-b]pyrazin-2-ol; (R)-6-bromo-1 -(1 -morpholinobutan-2-yl)-1 H-imidazo[4,5-b]pyrazin-2-o; 81 (R)-6-bromo-1 -(1 -morpholinopropan-2-yI)- H-irnidazo[4,5-blpyrazin-2-cI; (R)-6-bromo-1-(1 -phenylethyl)-1H-imidazo[4,5-bpyrazin-2-ol; (R)-6-bromo-1 -sec-butyl-1 H-imidazo[4,5-bjpyrazn-2-ol; (S)-(2-hydroxy-i-(1-phenylethyl)-i H-imidazo[4,5-b]pyrazln-6-yl)(4 methylpiperazin-1 -yl)methanone; (S)-(2-hydroxy-1-(1-phenylethyl)-1 H-imidazo[4,5-blpyrazin-6 yl)(morpholino)methanone; (S)-(2-hydroxy-1-(1 -phenylethyl)-1 H-imidazot4,5-blpyrazin-6-yi)(piperdin-1 yl)methanone; (S)-1-(1-phenylethyl)-1 H-imidazo{4,5-b]pyrazin-2-ol; (S)-1 -(1-phenylethyl)-1 H-imidazo[4,5-bquinoxalin-2-ol; (S)-1-(1-phenylethyl)-6-(piperidin-1-ylmethyl)-1 H-imidazo[4,5-bpyrazin-2-ol; (S)-1-(1-phenylethyl)-6-propyl-1 H-imidazo[4,5-blpyrazin-2-ol; (S)-I-(1-phenylethyl)-6-vinyl-1 H-midazo[4,5-b]pyrazin-2-ol; (S)-1 -(2-hyd roxy- 1 -(1 -p henylethyl)- 1 H-imidazo[4,5-bjpyrazn-6-yl) ethanone; (S)-2-hydroxy-1 -(1 -phenyiethyl)-1 H-imidazo[4,5-b]pyrazine-6-carbonitrile; (S)-2-hydroxy-1 -(1 -phenylethyl)-1 H-imid azo[4,5-b]pyrazine-6-carboxamide; (S)-2-hydroxy-1 -(1 -phenylethyl)-1 H-imidazo[4,5-b]pyrazine-6-carboxylic acid; (S)-2-hyd roxy-N, N-dimethyl-1 -(1 -phenylethyl)-I H-imidazo[4,5-b]pyrazine-6 carboxamide; (S)-2-hyd roxy-N-methyl-1 -(1 -phenylethyl)-1 H-imidazo[4, 5-b]pyrazine-6 carboxamide; (S)-6-((4-methylpiperazin-1 -yl)melhyl)-1 -(1 -phenylethyl)-1 H-imidazo[4,5 b]pyrazin-2-ol; (S)-6-((dimethylami no)methy)-1 -(1 -phenylethy)-1 H-imidazo[4,5-b]pyrazin-2 ol; (S)-6-(2-hyd roxypropan-2-yl)-1 -(1 -phenylethyl)-1 H-imidazo[4,5-blpyrazin-2-ol; (S)-6-(2-methylprop- I -enyl)- 1-(1 -phenylethyl)- 1 -irnidazo[4, 5-b]pyrazin-2-ol; (S)-6-(methylsulfonyl)- 1 -(1 -phenylethyl)-1 H-imidazo[4,5-blpyrazin-2-ol; (S)-6-(methylthio)-1 -(1 -phenylethyl)-1 H-imidazo[4,5-b)pyrazin-2-ol; (S)-6-(morp holinomethyl)-1 -(1 -phenylethyl)- 1 H-imida zo [4,5-b]pyrazin-2-ol; 82 (S)-6-bromo-l1-(1 -hydroxybutan-2-y)-1 I--imidazo[4, 5-b] pyrazin-2-ol; (S)-6-bromo- 1 -(1 -morp holinobutan-2-yI)-1 H-imidaza[4, 5-b)pyrazin-2-ol; (S)-6-bromo-1 -(1 -morp holi nopropan-2-y)-1 H-imidazo[4 .5-blpyrazin-2-oI; (S)-6-bromo- 1 -(1 -phenylethyl)- i H-imidazo[4 ,5-blpyrezin-2-o; (S)-6-bromo-i -sec-butyl-1 H-inmidazot4,5-blpyrezin-2-ol; (S)-6-cycrohexenyl-1 -(1 -phenylethyl)-1 H-imidazo[4,5-bjpyrezn-2-ol;, (S)-6-o~yclohexyl-1 -(i-p heriylethyl)-1 H-i mid azo[4, 5-blpyrazin-2-ol; (S)-6-ethoxy- 1-(lI-phenylethy)-1 H-imidaza(4, 5-bjpyrazin-2-o;, (8)-S-ethyl-I -(l -phenylethyl)-i H-imidazoj4 ,5-bjpyrazin-2-oI; (S)-6-bexyl-i -(1 -phenylethyl)-1 H-imidazo[4, 5-b]pyrazin-2-ol; (S)-6-isobutyl-1 -(1 -phe nylethyl)- I H-imidazol4,6-blpyrazin-2-ol; (S)-6-methoxy-1 -(l -phenylethyl)- 1 H-imidazol4,5-b~pyrazin-2-ol; (8)-methyl 2-hydroxy- 1-(1 -phenylethyl)-I H-imidazo[4, 5-b]pyrazine-6 carboxylate; (8)-N, N-diethyl-2-hyd roxy-l1-(1 -phenylethyl)-1 H-imnidazo[4,5-bjpyrazine-6 carboxamide; (S)-N-benzyl-2-hydroxy-l1-(1 -phenylethyl)-1 H-imidaro[4,5-bjpyrazine-6 ca rboxamide; (S, E)- I -(1 -phenylethyl)-S- (prop- I -eny9)- 1 H-mid azof4, 5-bjpyrazin-2-o; (S,Z)-1 -(1 -phenylethyl)-6-(prop-I-enyl)-I H-imcdazo[4, 5-blpyrazin-2-o; (S, Z)-6-(hex-2-enyl)-1I -(I -phe nylethyl)-1 H-i mid azot4, 5-b] pyrazin-2-oI;, (Z)-1 -(pentan-3-yl)-6-( prop-i -enyl)- 1 H-imidazo[4 1 5-bjpyrazin-2-o; (Z)-1 -cyclohexyl-6-(prop-I -eriyl)-I H-imidazol4. 5-bjpyrazin-2-ol; (Z)-1 -cyctopropyl-6-(prop-1 -enyI)-1 H-imidaza(4, 5-b~pyrazin-2-o; (Z)-lI-isopropyl-6-(prop- I-eriyl)-I H-imildazof4, 5-bjpyrazin-2-ol; (Z)-6-(prop-1 -enyl)- 1-(tetrahydro-2H-pyran-4-yI)-I H-imidazo[4,5-b]pyrazin-2 ol; 1 -(1 -aminobutan -2-yl)-6-bromo-1 H--imidazc44, 5-b]pyrazin-2-ol; 1 -(1 -morph oli nobuta n -2-yl)-1 H-l mid azo[4,5-bpyrazi n-2-o;, I -(2-hydroxy- I-(pentan-3 -yI)- I H-imidazol4, 5-blpyrazin-5-yI)ethanone; 1 -(penta n-3-yl)- I H-imidazo[4,5-b]pyrazin-2-o; 83 1-(pentan-3-yI)- I H-imidazo(4, 5-blpyrazine-2, 6-dial; i-(pentan-3-yl)-1 I--imIdazo[4,5-blquinoxalin-2-o; l-(pentan-3-yl)-5-vinyl-1 H-imidazo[4,5-blpyrazn-2-ol; i -(pentan-3-yl)-6-(p rap-i -ynyl)-1 H-imidazol4 ,5-bjpyrazin-2-ol; 1 -. (pe ntan-3-yl)-6-(trifluorom ethyl)- 1 H-imidaza(4, 5-b~pyrarin-2-o; 1 -benzyl-6-(methylthio,)-1 H-imnidazof4,5-bjpyrazin-2-ol; 1-benzyl-6-bromo-1 H-imidazoJ4,5-b)pyrazin-2-o; 1 -cyclohexyl-6-(methylttiio,)-1 H-imidazo[4 ,5-blpyrazin-2-ol; 1-cyclopropyl-6-(methythio)-1 H-imidazo[4,5-bjpyrazin-2-ol; 1 -isopropyl-6-(methylthio)- 1 H-irnidaza[4, 5-bjpyrazin-2-ol; 2-(6-bromo-2-hydraxy-1 H-imldazol4, 5-b~pyrazin-1 -yip- -m orpholinobutan-1 one; 2-(6-bromno-2-hydroxy-1 H-imidaza(4, 5-bjpyrazin-1 -yl)butanoic acid; 2-(6-brono-2-hydroxy-1 H-1imid azo!4, 5-b]pyrazn- 1 -yI)propane-1 1 3-dol; 2-hydroxy-1 -(pentan-3-yl)-i H-imidazol4, 5-bjpyrazine-5-carboxylic acid; 2-hydroxy-i -(pentari-3-yl)-1 H-imiclazo[4, 5-blpyrazine-6-carbonitriie; 2-hydroxy-N, N-dimnethyl-i -(pentan-3-yl)-1 H-imidazo[4 1 5-blpyrazine-5 carboxamide; 2-hyd roxy-N-methyl-1 -(pentan-3-yl)-1 H-imnidazo[4, 5-bjpyrazine-5 carboxamide; 5-(methylthio)-1 -(pentan-3-yI)-i H-imidazo[4 .5-b~pyrazin-2-oI; 5-bromo-1-(pentan-3-yl)-l H-imidazo[4,5-blpyrazin-2-ol; 5-ethyl-i -(pentan-3-yl)-i H-imidazol4,5-blpyrazin-2-ol; 6-(methylsufi nyl)-1 -((S)-lI-phenylethyl)-1 H-irnidazo[4, 5-bjpyrazin-2-oI; 6-(methylthio)- I -(penta n-3-yl)-i H-midazol4, 5-b~pyrazin-2-o; 6-(methylthic)-I -(tetra hyd ro-2 H-pyra n-4-yI)-i H-imn idazo[4, 5-b~pyrazin-2-ol; 6-bromno- 1 -(I -(4-(methyisulfcnyl)pipe razin- 1-yl)butan-2-yl)-i H-imidazo[4, 5 blpyrazin-2-ol; 6-bromo~ 1-(1- (4-methylpiperazin- I-yI) butan-2-yl)-lIH- imidazo(4, 5-b]pyrazin-2 al; 6-bromo-1- (1 -(dimethylamino)butan-2-y)-lIH-imidaro[4, 5-bipy razin-2-ol; 84 6-bromo-1 -(1 -(methylamIno)butan-2-yI)-1 H-imidazo[4,5-bjpyrazn-2-ol; 6-bromo-1-(1 -methoxybutan-2-y)-1 H--imidazo[4,5-b]pyrazin-2-oI; 6-bromo-I-(2-methyl-1-morpholinopropan-2-y)-1H-imidazo[4,5-bjpyrazin-2-ol; 6-bromo-1-(2-morpholinoethyl)-1 H-imidazo[4,5-bjpyrazin-2-ol; 6-bromo-1-(pentan-3-yl)-1 H-imidazo[4,5-b]pyrazin-2-ol; 6-bromo-1 -(tetrahydro-2H-pyran-4-yl)-1 H-imidazo[4,5-b]pyrazin-2-ol; 6-bromo-1-cyclohexyl-1H-imidazo[4,5-bjpyrazin-2-ol; 6-bromo-1-cyclopropyl-1 H-imidazo[4,5-b]pyrazin-2-ol; 6-bromo-1-isopropyl-1 H-imidazo4,5-b]pyrazin-2-ol; 6-bromo-1 -tert-butyl-1 H-I midazo[4,5-bjpyrazin-2-ol; 6-cyclopropyl- 1 -(pentan-3-yl)-1 H-imidazo[4,5-b]pyrazin-2-ol; 6-ethynyl-1 -(pentan-3-yl)-1H-imidazo[4,5-b]pyrazin-2-ol; 6-methoxy-1 -(pentan-3-yl)-1 H-imidazo[4,5-b]pyrazin-2-ol; 6-methyl-I -(pentan-3-yl)-1 H-imidazo[4,5-blpyrazin-2-ol; methyl 2-hydroxy-1-(pentan-3-yI)-iH-imidazo[4,5-bjpyrazine-5-carboxylate; methyl 4-(2-(6-bromo-2-hydroxy-1H-imidazo[4,5-b]pyrazin-1 yl)butyl)piperazine- 1-carboxylate; 1-(ethylpropyl)-6-(1 -methylpyrazol-4-y)irnidazo[4,5-b]pyrazin-2-ol; 6-bromo-1 -(propylbutyl)imidazo[4,5-b]pyrazin-2-ol; 1-[(1 R)-3-methyl-1 -(morpholin-4-ylmethyl)butyll-6-bromoimid azo[4,5 blpyrazin-2-ol: 1-(ethylpropyl)-6-vinylimidazo[4,5-b]pyrazin-2-ol; i-(ethylpropyl)-6-(1 -methylvinyl)imidazo[4,5-bpyrazin-2-ol; 1 -(ethylpropyl)-6-(methylethyl)imidazo[4,5-bjpyrazin-2-ol; 6-chloro-1-(ethylpropyl)imidazo4,5-blpyrazin-2-ol; and 6-(dimethylamino)-I-(ethylpropyl)imidazo[4,5-bpyrazin-2-ol.
17. At least one chemical entity of claim 1 wherein the compound of Formula II is chosen from (R)-6-bromo-1-(1-morpholinopropan-2-y)-1lH-irnidazo[4,5-bjpyrazin-2(3H) one; 85 6-ethynyl-l -(penta n-3-yl)-1 H-imkazo[4, 5-b]pyrazin-2(3 H)-one; 6-mnetlioxy-1 -(pentan-3-yI)-l H-imidazo(4,6-blpyrazin-2(3H)-one; 6-bromno-I -(2-methyl-I -morpholinopropan-2-yi)-I H-imidazo[4 1 5-blpyrazin 2(3H)-one; i-(pentan-3-yl)-6-(i H-i ,2, 3-triazol-4-yI)-1 H-imidazc44, 5-b]pyrazin-2(3H)-one; I -(pentan-3-yI)-6-(trifluoromethyl)- I H-imidazo[4, 5.bjpyrazin-2(3H)-one; (R)-6-ethynyl-I -(I-morpholinobutan-2-y)-lIH-imldazo[4, 5-blpyrazin-2(3H) one; 6-((2-hydroxy- i-(pentan-3-yl)-1 H-imidazo(4,5-b jpyrazin-6.-yl)ethynyl)- 1 (pentan-3-yI)-I H-imidezol4)5-blpyrazin-2(3H)-ona; 6-(dimnethylam ino)-i -(pentan-3-yt)-I H-imidazo[4,5-blpyrazin-2(3H)-one; 6-ethyl-i -(pentan-3-yI)-I l--imidazo[4 1 5-blpyrazin-2(3H)-one; (E)-I -(pentan-3-yl)-6-(prop-I -enyl)-I H-Imidazo[4,5-blpyrazin-2(3H)-one:, (E)-1 -cyolohexyl-6-(prop-i -enyl)-1 H-imidazo[4,5-b]pyrazin-2(3H)-one; (E)-i -cyolopropyl-6-(prop-1 -enyl)-i H-imidazo[4,5-blpyrazin-2(3H)-one;, (E)- I -sopropyl-6-(prop-I -enyl)-1 t--imidazo(4 1 5-b]pyrazin-2(SH)-one; (E)-6-(prop-i -enyl)-1 -(tetrahydro-2H-pyran-4-yl)-1 H-kuidazo[4, 5-b~pyrazin 2(3H)-one;, (R)-6-(mnethylthio)-1 -(I -phenylethyl)- i H-imidazo[4, 5-blpyrazin-2G3H)-one; (R)-6-bromo-lI-(I -hydroxybutan-2-yl)-I H-imidazo[4,5-blpyrain-2(3H)-one; (R)-6-bromno-I-(i -mnorpholinobutan-2-yI}-i H-imidazot4,5-blpyrazin-2(3I-)-one; (jR)-6-bromo- i -(I -morpholinopropa n-2-yI)-i H-imidazo[4,5-b]pyrazirt-2(3 H) one: (R)-6-bromno'-I-(I -phenylethyl)- IH-imidazot4 5-bjpyrazi n-2(3H)-one; (R)-6-bromo- I -sec-butyl- I H-imidazo[4, 5-blpyrazin-2(3H)-one; (S)-I -(I -phenylethyl)-I H-imidazol4 ,5-b]pyrazin-2(3H) -one; (S)-l1-(1 -phenylethyl)-I H-imid azo[4 ,5-bjquinoxal in-2(3 H)-one; (S)-i -(I -phenylethyl)-6-(piperdin-1I-ylmethyl)-I H-lrnid azo[4,5-b)pyrazin-2(3H) one; (S)-l -(1 -phenylethyl )-6-(piperidine-I -carbonyl)- I H-imidaro[4, 5-blpyrazin 2(3H)-One;, 86 (S)-1 -(1 -phenylethyl)-6-propyl-1 H-imidazo[4,5-b]pyrazin-2(3H)-one; (S)-1-(1 -phenylethyl)-6-vinyl-1 H-imidazo[4,5-b]pyrazin-2(3H)-one; (S)-2-oxo-3-(1-phenylethyl)-2,3-dhydro-1 H-imidazo[4,5-blpyrazine-5 carbonitrile; (S)-2-oxo-3-(1 -phenylethyl)-2,3-dihydro-1 H-imidazo[4,5-b]pyrazine-5 carboxamide; (S)-2-oxo-3-(1-phenylethyl)-2,3-dihydro-1 H-imidazo[4,5-b]pyrazine-5 carboxylic acid; (S)-6-((4-methylpiperazin-1-yl)methyl)-1-(1-phenylethyl)-iH-imidazo[4,5 bjpyrazin-2(3H)-one; (S)-6-((dimethylamino)methyl)-1-(1-phenylethyl)-1H-imidazo[4,5-b]pyrazin 2(3H)-one; (S)-6-(2-hydroxypropan-2-yl)-1-(1-phenylethyl)-1 H-imidazo[4,5-b]pyrazin 2(3H)-one; (S)-6-(2-methylprop-1 -enyl)-1 -(1 -phenylethyl)-1 H-imidazo[4,5-b]pyrazin 2(3H)-one; (S)-6-(4-methylpiperazine-1 -carbony)-1 -(1 -phenylethyl)-i H-imidazo[4,5 b)pyrazin-2(3H)-one; (S)-6-(methylsulfonyl)-1-(1 -phenylethy)-1 H-imidazo[4,5-b]pyrazin-2(3H)-one; (S)-6-(methylthio)-1 -(1-phenylethyl)-1 H-imidazo[4,5-b]pyrazin-2(3H)-one; (S)-6-(morpholine-4-carbonyl)-1 -(1-phenylethyl)-1 H-imidazo[4,5-b]pyrazin 2(3H)-one; (S)-6-(morpholinomethyl)-1-(1-phenylethyl)-1 H-imidazo[4,5-blpyrazin-2(3H) one; (S)-6-acetyl-1 -(1 -phenylethyl)-1 H-imidazo[4,5-b]pyrazin-2(3H)-one; (S)-6-bromo-1-(1-hydroxybutan-2-yI)-1 H-imidazo{4,5-b]pyrazin-2(3H)-one; (S)-6-bromo-1-(1-morpholinobutan-2-yl)-1 H-imidazo[4,5-b]pyrazin-2(3H)-one; (S)-6-brorio-1-(1-morpholinopropan-2-yl)-1 H-imidazo[4,5-b]pyrazin-2(3H) one; (S)-6-bromo-1 -(1 -phenylethyl)-i H-imidazo[4,5-b]pyrazin-2(3H)-one; (S)-6-bromo-1-sec-butyl-I H-im idazo[4,5-b]pyrazin-2(3H)-one; 87 (S-6-ocyclohexenyl- 1 -(l -phenylethyl)-1 H-imidazo[4 ,5-blpyrazin-2(3 H)-one; (S)-6-cyclohexyl-1 -(I -phenylethyl)-1 H-imidazo(4,5-blpyrazin-2(3H)-one;, (S)-6-ethoxy-1 -(1 -phenylethyl)-1 H-imidazo[4 ,5-b~pyrazin-2(3H)-one; (S)-6-ethyl-1 -(1 -phenylethyl)- 1 H-Fmidazof4, 5-blpwrazin-2(3H)-one; (S)-6-hexyl-1 -(1 -phenylethyl)-1 H-imid azo[4,5-b~pyrazi n-2(3H)-vne; (S)-6-isobutyl-1 -(1 -phenylethyl)-I H-imidazof4 1 5-bjpyrazin-2(3H)-one, (S)-6-methoxy-I -(I -phenyethyl)-I H-imidazoj4,5-b)pyrazin-2(3H)-one; (S)-methyl 2-oxo-3-(1 -phenylethyl)-2 1 3-d ihydro-I H-im idazo[4 1 5-bjpyrazine-5 carboxylate; (S)-N ,N-diethyl-2-oxo-3-( I -phenylethyl)-2, 3-dihyciro-I I-I-midazo[4,5 blpyrazine-5-carboxamide; (S)-N, N-dimethyl-2-oxo-3-(1 -phenylethyl)-2 1 3-dihydro-1 H-imidazo[4, 5 b]pyrazine-5-carboxamide; (S)-N-be nzyl-2-oxo-3-( 1-phenylethyl)-2 1 3-dihydro-1 H- iridazot4, 5-bjpyrazine 5-carboxamide, (S)-N-methyl-2-oxo-3-(I -pheriylethyl)-2 .3-dihydro-1 H-irnidazo[4, 5-bjpyrazine 5-carboxamide; (S, E)-I -(1 -phenylethyl)-6-(prop-I -anyO)-I H-imidaro(4, 5-b]pyrazin-2(3H)-one; (S,Z)-1- (1 -phenylethy I)-6-(prop-1 -enyl)- 1 H-imidazot4, 5-b]pyrazin-2(3H)-one; (S.Z)-6-(hex-2-enyl)- 1 -(1 -phenylethyl)-I H-imidazo[4,5-b]pyrazin-2(3 H)-one; (Z)-1 -(pentan-3-yI)-6-(p rop-I -enyl)-1 H-imidazoE4,5-b]pyrazln-2(3H)-one; (Z)-I -cyctohexyl-6-(p rap-I -enyl)-I H-imidazo[4,5-b]pyrazin-2(3H)-one; (Z)-1 -cyclopropyl-6- (prop-1I -e nyl)-1 H-imidazo[4 ,5-b~pyrazin-2(3F9)-one; (Z)-I-isopropyl-6-(prap-1 -enyl)- I H-imnidazo[4, 5-b]pyrazin-2 (3 H)- one; (Z)-6-(prop-I -enyl)-1 -(tetrahydro-2H-pyran-4-y)-1 H-imidazo(4,5-b]pyrazin 2(3H)-one; I-(I -aminobutan-2-yF)-6-bromo-I H-imidazo[4, 5-bjpyrazin-2(3H)-one; 1 -(1 -morphotinobutan-2-yI)-I H-imidazo[4,5-bjpyrazin-2(3H)-one; I -(pentan-3-yI)-l-I im idazo [4, 5-b pyrazin-2(3H)-one; I -(pentan-3-yI)-I H-im idazo[4, 5-bjqui noxalin-2(3H)-one; 1 -(pentan-3-yI)-5-vinyl-I H-imidazo[4,5-blpyrazin-2(3H)-one; 88 1 -(pentan-3-yQ)-6-(p rop-1 -ynyl)- I H-imidazo[4 1 5-b]pyrazin-2 (3H)-one; 1 -(pentan-3-yl)-6-(trifluoromethyl)-1 H-imidazo(4,5-b]pyrazin-2(3H)-one; I -benzyl-6-(methylthio)-1 H-imidazo[4,5-b]pyrazin-2(3H-)-one; I -benzyl-6-bromo-1 H-imidazol4,5-blpyrazin-2(3H)-o ne; I -oyclohexyl-6-(methylthio)-1 H-imidazo[4, 5-b]pyrezin-2(3 H)-one; 1 -oyclopropyl-6-(methylthio)- I H-imidazo[4, 5-b]pyrazin-2(3H)-one; I -isopropyl-6-(rnethyltlo)-I H-imidazol4 1 5-blpyrazin-2(3H )-one; 2-(6-bromo-2-oxo-2 ,3-dihydro-1 H-imidazof4, 5-blpyrezin-1I-yl)buta nob Bold; 2-oxo-lI-(pentan-3-yI)-2 ,3-dihyd ro-1 H-imidazo[4,5-blpyrazine-5-carboxylio acid; 2-oxo-3-(pentan-3-yI)-2,3-dihydro-1 H-imidazo [4,5-bjpyrazine-5-oa rbonitrile; 5-(methylthio)-I -(pentsn-3-yl)-I H-imidszo[4,5-b]pyrazin-2(3H)-one; 5-acetyl- I -(pentan-3-yl)- I H-imidazo[4, 5-b]pyrazin-2(3H)-one; 5-bromo-lI-(pentan-3-yI)-1 H-imidazo[4,5-b]pyrazin-2(3H)-one; 5-ethyl-i -(penta n-3-yI)-lIH-Imidazo[4,5--b]pyrazin-2(3H)-one; 6-(methylsulflnyl)-I -((6)-I -phenylethyl)-I H-imidazo(4, 5-b~pyrezin-2 (3H)-one; 6-(methylthio)-I -(pentsn-3-yI)-I H-imidezot4,5-blpyrazin-2(3H)-one: 6-(mnethylthio)-l -(tetrahydro-2H-pyrert-4-yl)- I H-imidazo[4, 5-bjpyrszin-2(3H) one; 6-bromo-I -(I -(4- (methylaulfonyl)plperazin-l -yI~butan-2-y)- I H-irnid azo[4 1 5 blpyrazin-2(SH)-one; 6-bromo-1 -(l -(4-methylpiperazin-1I-yI)butan-2-yI)- IH-imidazof4,5-b]pyrazi n 2(3H)-one; 6-bromo-I -(I -(dimethylamino)butan-2-y)- I H-imidazo[4, 5-bjpyrazin-2(3H) one; 6-bromo-I -(l -(methylamino)butan-2-yI-1 H -imidazol4, 5-b]pyrazin-2(3H)-one: 6-brom o-I -(1, 3-dihydroxypropa n-2-yl)-I H-imidazo[4, 5-b] pyrazin-2(3H)-one; 6-bromo- 1 -(1 -meth oxybutan-2-yl)-I H-imid azo[4, 5-b~pyrezin-2(3H)-one; 6-bromo- 1 -(I -morpholino-l -axobutan-2-yl)-l H-binidazo[4,.5-bjpyrazin-2 (3H), one; 6-bromo-I -(2-methyl-I -morpholinopropan-2-yi)-1 H-imnidazo[4, 5-bJpyrazin 89 2(3H-)-one; 6-bromo-1 -(2-morpholinoethyl)- 1 H-imidazo[4 ,5-b]pyrazin-2(3H)-one; 6-bromo-1 -(pentan-3-yl)-lIH-irnidazof4,5-b]pyrazin-2(3H)-one; 6-bromo-1 -(tetra hydro-2 H-pyra n-4-yl)-1 H-imicfazc44, 6-b]pyrazin-2(SH)-one; 6-bromo-1 -oyclohexyl-1 H-imidazaf4 1 5-blpyrezin-2(3H)-one; 6-bromo-1 -oyclopropyl-1 H-imidazo[4 1 -b]pyrazin-2(3H)-one; 6-brorno-I -isopropyl- I H-imidezo[4, 5-bjpyrazin-2(3 H)-one; 6-bromo-I -tert-butyl- I H-imidazo[4 ,5-bjpyrazin-2(SH)-one; 6-cyolopropyl-i -(pentan-3-yl)- I H-imidazol4,5-b]pyrazin-2(SH)-one: 6-ethynyl-I -(pentan-3-yI)-1 H-imidazo[4 ,5-b]pyrazin-2(3H)-one; 6-hyd roxy- 1 -(pen tan-3-yl)-1 H-imidazo[4,5-b]pyrazin-2 (3H)-one; 6-methoxy- I -(pentan-3-yl)-I H-imidazo(4,5-b]pyrazin-2(3H)-one; 6-methyl-I -(pentan-3-yl)- I H-irnicfazo[4, 5-blpyrazin-2(3H)-one; methyl 2-oxo-1 -(pentan-3-yl) -2,3-dihydro-1 H-imidaro(4, 5-bjpyrazine-5 carboxylate; methyl 4-(2-(6-bromo-2-oxo-2 ,3-dihydro-1 H-imidazo[4 ,5-blpyrazin- 1 yl)butyl)piperazine-i -carboxylate; N,WNd imethyl-2-oxo-l -(pentan-3-yl)-2,3-dihyd ro-i H-imidazo[4,5-b]pyrazi ne-5 carboxamide; N-methyl-2-oxo-I -(penta n-3-yI)-2 ,3-dihydro-1 H-imidazo(4, 5-b]pyrazine-5 carboxanhide; 6-(1 -methyl-I I--pyrazol-4-yl)-1 -(pentan-3-yI)-I H-imicfazo[4,5-b]pyrazin-2 (3H) one; 6-bromo-I -(heptan-4-yi)- I H-imidazo(4, 5-blpyrazin-2(3-)-one; (R)-6-bromo- I -(4-methyl-I -morph olinopentan-2-yl)-I H-imidazo[4. 5-bjpyrazin 2(3H)-one; 1 -(pentan-3-yl)-6-vinyl-1 H-lmidazo[4,5-b~pyrazin-2 (3H)-one: 1 -(pentan-3-yl)-6-(prop- I -en-2-yl)-I H-imidazo[4,5-bjpyrazin-2(3H)-o ne; 6-isopropyr-I -(pentan-3-yl)-1 H-imidazo[4,5-b~pyrazin-2(3H)-one; 6-chloro-I-(pentan-3-yI)-I H-imidazo[4,5-h]pyrazin-2(3H )-one; and 6-(dimethylaniino)-1 -(pa ntan-3-yI)-l H-Th'idazo[4,5-b]pyr~zih-2(3H)-one. 90 16. A pharmaceutically acceptable composition comprising a pharmaceutically acceptable carrier and at least one chemical entity of any one of claims 1 to 17. 14. A pharmaceutical composition df claim 18, wherein the composition is formulated in a form chosen from tablets, capsule, powders, liquid, suspension , suppositories and aerosols.
20. A packaged pharmaceutical composition, comprising a pharmaceutical composition of claim 18 or 19 and instructions for using the composition to treat a patient suffering from a disease chosen from obesity, sarcopenia, wasting syndrome, frailty, cachexia, muscle spasm, post-surgical and post-traumatic muscle weakness, and a neuromuscular disease.
21. A packaged pharmaceutical composition, comprising a pharmaceutical composition of claim 18 or 19 and instructions for using the composition to treat a patrient suffering from a disease responsive to modulation of one or more of skeletal myosin, skeletal actin, skeletal tropomyosin, skeletal troponin C, skeletal troponin I, skeletal troponin T, skeletal muscle, and skeletal sarcomere.
22. A method for treating a patient having a disease chosen from obesity, sarcopenia, wasting syndrome, frailty, cachexia, muscle spasm, post-surgical and post traumatic muscle weakness, and a neuromuscular disease comprising administering to the patient a therapeutically effective amount of at least one chemical entity of any one of claims 1 to 17. 2/3. A method for treating a patient having a disease responsive to modulation of one or more of skeletal myosin, skeletal actin, skeletal tropomyosin, skeletal troponin C, skeletal troponin I, skeletal troponin T, skeletal muscle, and skeletal sarcomere, comprising administering to the patient an effective amount of at least one chemical entity of any one of claims I to 1'7. 91
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2016202040A AU2016202040B2 (en) | 2006-08-02 | 2016-04-01 | Certain medical entities, compositions, and methods |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US60/835,272 | 2006-08-02 | ||
US60/921,054 | 2007-03-30 | ||
AU2007281468A AU2007281468B2 (en) | 2006-08-02 | 2007-08-01 | Certain chemical entities, compositions and methods |
AU2012258383A AU2012258383B9 (en) | 2006-08-02 | 2012-11-26 | Certain medical entities, compositions, and methods |
AU2016202040A AU2016202040B2 (en) | 2006-08-02 | 2016-04-01 | Certain medical entities, compositions, and methods |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2012258383A Division AU2012258383B9 (en) | 2006-08-02 | 2012-11-26 | Certain medical entities, compositions, and methods |
Publications (2)
Publication Number | Publication Date |
---|---|
AU2016202040A1 true AU2016202040A1 (en) | 2016-04-21 |
AU2016202040B2 AU2016202040B2 (en) | 2018-08-16 |
Family
ID=55807248
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2016202040A Ceased AU2016202040B2 (en) | 2006-08-02 | 2016-04-01 | Certain medical entities, compositions, and methods |
Country Status (1)
Country | Link |
---|---|
AU (1) | AU2016202040B2 (en) |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1796467A4 (en) * | 2004-09-24 | 2009-07-01 | Janssen Pharmaceutica Nv | Imidazo{4,5-b}pyrazinone inhibitors of protein kinases |
-
2016
- 2016-04-01 AU AU2016202040A patent/AU2016202040B2/en not_active Ceased
Also Published As
Publication number | Publication date |
---|---|
AU2016202040B2 (en) | 2018-08-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2007281468B2 (en) | Certain chemical entities, compositions and methods | |
US20100173930A1 (en) | Certain Chemical Entities, Compositions and Methods | |
WO2008121333A1 (en) | Certain chemical entities, compositions and methods | |
US10766899B2 (en) | Methods for preparing substituted imidazo[4,5-b]pyrazines | |
CN101522681A (en) | Certain chemical entities, compositions and methods | |
AU2012258383B2 (en) | Certain medical entities, compositions, and methods | |
AU2016202040A1 (en) | Certain medical entities, compositions, and methods |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MK4 | Application lapsed section 142(2)(d) - no continuation fee paid for the application | ||
NA | Applications received for extensions of time, section 223 |
Free format text: AN APPLICATION TO EXTEND THE TIME FROM 01 AUG 2016 TO 01 MAR 2017 IN WHICH TO PAY A CONTINUATION FEE HAS BEEN FILED |
|
NB | Applications allowed - extensions of time section 223(2) |
Free format text: THE TIME IN WHICH TO PAY A CONTINUATION FEE HAS BEEN EXTENDED TO 01 MAR 2017 |
|
FGA | Letters patent sealed or granted (standard patent) | ||
MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |